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Bryostatin 1 is a large macrocyclic polyketide natural product that was isolated 
from the marine bryozoan Bugula neritina. Bryostatin was found to have many interesting 
biological properties stemming from its extremely high affinity for protein kinase C (PKC) 
isozymes. Bryostatin 1 has attracted increased attention due to its anticancer and immune 
system stimulating properties. In recent years, bryostatin 1 has been found to have 
properties that may lead to effective treatments for Alzheimer’s disease and HIV.  Several 
high affinity PKC ligands are potent tumor promoters; however, bryostatin 1 does not 
display any of these properties and even antagonizes the effects of phorbol esters, which 
are potent tumor promoters.  
Due to the continued interest in bryostatin 1, attention has been focused on the 
synthesis of simplified analogs in order to study structure-function relationships. Most of 
this work has focused on the synthesis of analogs with simplified AB top-halfs, while very 
little attention has been applied towards the synthesis of analogs with simplified C-ring 
binding domains. Extensive work has been conducted on the synthesis of diacylglycerol 
(DAG) lactone analogs, which are simple high affinity PKC ligands. The focus of this work 
involves the substitution of a DAG lactone for the C-ring in a bryostatin analog, resulting 
in the synthesis of 3 bryostatin analogs. Biological evaluation indicates that significant 
binding affinity in the first analog was lost as compared to the natural product even though 
all structural elements were present that are thought to be required for good affinity. 
	  	  
	  
Molecular modeling studies indicate that the planer conformation of the top-half of the 
natural product was lost in these new analogs, resulting in a conformation unfavorable for 
effective binding. The binding domain orientation of the analog was reversed, resulting in a 
slight increase in affinity, but at the cost of lower stability under biological conditions, due 
to the diester linkage used to assemble the first two analogs. Building upon these results, a 
third-generation analog with increased lipophilicity and lacking the diester linker was 
synthesized. The third-generation analog had a much higher affinity for PKC as well as an 
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SYNTHESIS OF A VERSATILE DIACYLGLYCEROL LACTONE MOTIF  




 Bryostatin 1 is a macrocyclic marine natural product isolated from the marine 
bryozoan Bugula neritina in the search for antineoplastic natural products. Since its 
isolation, Bryostatin 1 has been in over 80 clinical trials for the treatment of various 
cancers. More recently, bryostatin has shown promise in the treatment of HIV-AIDS, 
stroke, and Alzheimer’s disease. The impressive biological properties of bryostatin 1 
stem from its nanomolar affinity for protein kinase C (PKC). Unlike many PKC 
activators, bryostatin 1 is not a tumor promoter and even reverses the effects of certain 
tumor promoters. In the search for potent bryostatin analogs, many modifications of the 
natural product have been made, but few have focused on the simplification of the 
binding domain. Diacylglycerols (DAGs) are the endogenous ligand for PKC. Building 
upon the structure of DAGs, Marquez and Coworkers produced a series of high affinity 
DAG lactones. The results section of this chapter describes the synthesis of a DAG 
lactone binding domain amenable to the synthesis of bryostatin analogs bearing this 




The Bryostatins and Related Natural Products 
The bryostatins are a series of 20 macrolactone natural products that were first 
discovered in 1970 by Pettit and coworkers while screening marine organisms for 
antineoplastic compounds.1 The bryostatins were isolated from the marine bryozoan 
Bugula neritina, a sessile marine animal, which commonly attaches itself to the hulls of 
ships and docks.2 Further studies of extracts from this organism indicated considerable 
activity against murine p388 lymphocytic leukemia as well as activity against 60 other 
NCI cancer cells.3 The active component of these extracts, bryostatin 1, was isolated and 
fully characterized in 1982.2 The bryostatin family of natural products is characterized by 
the presence of a 20-membered macrolactone with 3 pyran rings, which are situated 
within it (Figure 1.1). The 3 pyran rings are named A, B, and C; the natural products 
differ at C7 (R1) and C20 (R2) with various esters connected to these points.4 Three 
members of the bryostatin family (3, 19, and 20) have an additional oxygenation at C22, 
which is esterified with the C21 enoate to form a fused butyrolactone with the C-ring.4 
The C20 ester substituent and C19 hemi-ketal are both missing in bryostatins 16 and l7 
while bryostatin 18 only lacks the C20 ester.4 Neristatin is a bryostatin type of natural 
product with a highly modified C-ring consisting of a [3.3.2] fused bicyclofuranone 
scaffold.5 The complexity and the wide range of biological effects of these natural 
products have produced much interest in the isolation of the natural product and the 
preparation of simplified analogs that retain the biological activity of the natural product.  
Bugula neritina was initially thought to produce bryostatin. However, later work 
determined that the endosymbiotic bacterium Candidus endobugula sertula secretes this 
product.6 Bryostatin is thought to discourage predation of the larvae of the host organism 
	  	  
3	  





B. neritina.7 The bryostatin content of B. neritina was found to be extremely low, with 
isolation yields typically around 10-6 percent.3 Isolation of relevant quantities of 
bryostatin is rendered difficult due to the miniscule amount that is found in the organism. 
Extraction of 10000 gallons of wet B. neritina yielded 18 g of bryostatin 1 after extensive 
purification8; this relatively small amount of bryostatin has enabled over 80 clinical trials 
of bryostatin against various cancers as a single agent and in combination with other 
chemotherapeutic agents3 due to its extremely high affinity for PKC.  
However, continued isolation of bryostatin from wild B. neritina is not feasible 
for continued studies. In order to overcome these supply issues, studies of aquaculture of 
B.  neritina were initiated by the now defunct CalBioMarine Technologies9; these studies 
appeared to be successful, but were never commercially used. Another interesting result 
is the identification of the bryA gene cluster, which is believed to be responsible for the 
biosynthesis of the bryostatins.10 Further work in this area has been hampered by the 
large size of the gene cluster and uncertainties in the regulation of gene expression 
making expression and biosynthesis in a suitable host organism difficult. Even if 
successful, however, this biosynthetic approach would produce “bryostatin 0”, a 
bryostatin with considerably less oxidation than the flagship compound bryostatin 1.10 
 
Bryostatin 1 and Its Anticancer Properties 
Bryostatin was initially found to have a high activity against murine p388 
lymphocytic leukemia cells; this activity has resulted in many in vitro and in vivo studies 
as summarized by Pettit.3 Bryostatin 1 was found to double the life expectancy of mice 
with p388 leukemia, and caused remission in mice with B16 melanoma and M5 ovary 
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carcinoma.11 As a single agent, bryostatin has not proven to be an effective drug in 
clinical trials, in contrast to its potent effects in cell culture and murine cancer models. 
On the other hand, studies using bryostatin in combination with other chemotherapeutic 
drugs have shown promise. Studies conducted with vincristine,12 paclitaxel,13 
cytarabine,14 dolastatin,15 and others are among the over 80 clinical trials to date.3 
Bryostatin is an extremely potent drug; only 1 mg is needed for 6 weeks of treatment.12 
During these studies, bryostatin was found to be relatively nontoxic; the only dose-
limiting side effect attributed to bryostatin itself was severe myalgia (muscle pain).16 
Injection site reactions were also a considerable problem, but this was a result of the 
ethanol formulations required to solubilize it, and not bryostatin itself.17 Contributing to 
bryostatin’s appeal as a chemotherapeutic is that it has demonstrated immunostimulatory 
properties such as promoting the production of proinflammatory cytokines.18 Bryostatin 
was also shown to promote the growth of normal bone marrow progenitor cells,19 and the 
activation of neutrophils, platelets,20 and T-lymphocytes.21 These properties are a stark 
contrast to most chemotherapeutic agents, which are generally highly toxic, and indicate 
that bryostatin may be a useful drug when used in combination with other therapeutics to 
support natural immune response during chemotherapy.  
 
Bryostatin 1 and Neurodegenerative Conditions 
 Bryostatin has been shown to have impressive effects upon several neurological 
conditions. Dr. Daniel Alkon of the Banchette Rockefeller Institute of Neuroscience has 
conducted many studies of PKC activators, most especially bryostatin 1 on murine 
models of stroke22 and Alzheimer’s disease.23 Bryostatin treatment improves the 
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cognitive ability of rats.24 Bryostatin treatment of aged ischemic rats promotes 
synaptogenesis, neurogenesis, reduces apoptosis, and improves cognitive abilities of the 
treated animals.25 Bryostatin treatment is thought to cause activation of protein kinase C 
(PKC), its subsequent downregulation, and resultant de-novo synthesis of PKC, along 
with attenuation of the inflammatory response; this may account for the results observed 
in rats.26  
 Alzheimer’s Disease (AD) is thought to be the result of the accumulation of 
amyloid plaques in brain tissue with resulting neuronal death.27 These plaques result from 
an abnormal degradation pathway of amyloid precursor protein (APP) to form the toxic 
amyloid β.28 Protein kinase signaling is believed to be crucial for the normal degradation 
of APP into sAPP-α.29 In a transgenic murine model of AD, bryostatin and other PKC 
activators are known to increase the production of α-secretase, which is responsible for 
the production of sAPP-α from APP.30  Bryostatin has also demonstrated the ability to 
reduce the formation of amyloid plaques in a mouse model of AD.30 Based on these 
preclinical results,  the FDA approved a phase II clinical trial in 2009 to evaluate the 
effectiveness of bryostatin in treating AD. The results of this work have not been 
published to date. Recently, treatment of a patient with severe early onset AD with 
bryostatin resulted in improvement of speech, limb spasticity, attentional focus, and 
swallowing.31  
 
Bryostatin 1 and HIV Activation 
 Current treatments for HIV-AIDs reduce the viral load to undetectable levels and 
allow for the management of the disease.32 Drugs used in highly active antiretroviral 
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therapy (HAART) have many long-term side effects and compliance with such a 
treatment regime can be problematic.32 HAART kills the active virus, but dormant viral 
DNA remains incorporated in CD4+ T-cells, resulting in a latent viral reservoir that 
results in the return of the disease if therapy is discontinued.33 Discovery of drugs that 
activate the dormant virus, thus allowing current treatment options to clear the patient of 
the disease, are a current area of HIV research.33 Bryostatin treatment of cultured latent 
infected lymphocytic cells resulted in viral activation via PKC, MAPK, and NF-κB 
pathways.34 The HIV receptors CD4 and CXCR4 are downregulated by bryostatin 
treatment, preventing infection of new cells.34 Recently, Wender35 has reported the 
synthesis of structurally simplified bryostatin analogs that are potent activators of HIV in 
cell culture. Bryostatin 1 could be effectively used with current HAART therapy in a 
strategy known as “shock and kill” to effectively cure HIV infection.32  
 
Bryostatin 1 and PKC Activation 
 The multitude of biological effects of bryostatin 1 stem from its nanomolar 
binding affinity towards the cell signaling enzyme protein kinase C (PKC). Dysfunction 
of PKC is implicated in many disease processes such as cancer,36 and neurological 
conditions.37  PKC enzymes, when suitably activated, serve to phosphorylate the amino 
acid residues serine and threonine in other proteins. PKCs are involved in cellular 
signaling cascades, differentiation, apoptosis, and proliferation.38  
The PKC family of kinases consists of at least 10 different isozymes that are 
divided into three classes based upon regulatory domain structure and the requirement for 
a cofactor.39 The three classes consist of classical (cPKC), novel (nPKC), and atypical 
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(aPKC). These isozymes are present in differing amounts depending on cellular or tissue 
types.40 The phospholipid, phosphotidyl-L-serine is required by all PKCs.41 Classical 
PKCs (α, βI, βII, γ) also require endogenous 1,2-diacylglycerol (DAG) and calcium. 
Novel PKCs (δ, ε, η, θ) are only DAG dependent, while atypical PKCs (ξ, τ) require 
neither.  
The PKCs are enzymes that are composed of a regulatory domain and a catalytic 
domain (Figure 1.2). The C-terminal catalytic domain is highly conserved amongst 
isozymes,42 while the N-terminal (regulatory) domain is highly variable dependent on 
isozyme type.39 A pseudo-substrate is bound to the catalytic site when the enzyme is in its 
resting state; this motif is present at the N-terminus43. The cysteine-rich regulartory 
domains termed C1 and C2 are involved with ligand binding and interaction with cellular 
membranes.44 The C1 domain of PKC’s binds to secondary messenger ligands such as 
diacylglycerols or phobol esters. The C1 domain can be expressed as a single domain or a 
pair of domains usually labled C1a and C1b, depending on the isozyme. The C1 domain 
consists of approximately 50 amino acids and has 4 cysteine residues which coordinate 2 
zinc cations45. The C1 domains of aPKC’s do not bind phorbol esters due to structural  
modifications. Classical PKCs and novel PKCs also have a C2 domain which is thought 
to be involved in binding calcium and anionic phospholipids. The C3 domain is involved 
in binding ATP, while the C4 domain is the catalytic site of the enzyme. The V domains 
are variable sequences depending on isozyme type.  
Diacylglycerols or DAGs are endogenous intercellular messengers that are 
produced upstream by hydrolysis of phosphatidylinositol 2,5-bisphosphate by phosphor- 









Figure 1.2 Protein Kinase C Structure and Activation  






the DAG-dependent cPKCs, and nPKCs, DAG binds to the C1b domain, resulting in a 
conformational change, thereby removing the pseudo substrate from the active site. The 
activated PKC translocates from the cytosol to cellular membranes. ATP and calcium 
bind, and the holoenzyme phosphorylates its specific protein substrates, continuing the 
signaling cascade. The activated enzyme is then subject to downregulation by several 
different pathways, including ubiquitinylation and caveolae-dependent degradation.47  
 
PKC Binding Hypotheses  
Initial studies into the mode of ligand binding to the C1 domain of PKC were 
undertaken by the Wender group. Through computer modeling, Wender reasoned that the 
C1 ester, C19 ketal, and C26 alcohol were involved in binding to the C1 domain of PKC 
(Figure 1.3).48 A crystal structure of the C1 domain of PKC δ bound to phorbol 12-
myristrate 13-acetate (PMA) demonstrated that threonine 242, leucine 251, and glycine 
253 are involved in binding to the PKC ligand.49 Building upon these results, Keck 
embarked in another modeling study based upon experimental results gleaned from 
previous analog work and docking of the ligand to the C1b domain (Figure 1.4).50 This 
study showed that the C21 enoate and not the C19 ketal is involved in binding. 
The C19 ketal was found to be involved in an intramolecular hydrogen bonding 
network between the C3 alcohol and A and B ring pyran oxygens. The network holds the 
pharmacophore elements of bryostatin 1 in proper position for binding to the C1 domain 
of PKC. The C1 ester is bound to glutamine 257, the C21 enoate carbonyl is bound to 
glycine 253, while the C26 alcohol is bound to leucine 251 and threonine 242. The C9 







Figure 1.3 Wender’s Binding Hypothesis (Adapted from ref 60b). 
 





Tumor Promoting and Nontumor Promoting PKC Ligands 
The resin obtained from the shrub Croton tiglium has long been recognized as a 
potent irritant and poison.51 Early studies into the composition of this substance yielded a 
complex mixture of esters of the terpene phorbol. Animal studies of mixtures of these 
esters determined that these compounds sensitized mice towards carcinogens applied to 
the skin. The most studied member of the phorbol ester family is phorbol-12-myristate-
13-acetate (PMA) (Figure 1.5). PMA is a very potent activator of PKC with nanomolar 
(Ki = 0.55 nM) binding affinity to the C1 domain of PKC.52  
Several other natural products that are tumor-promoting PKC activators have been 
isolated from diverse sources (Figure 1.5). Teleocidin was isolated from Streptomyces 
mediocidicus.53 Aplysitoxin, isolated from the sea hare Stylocheilus longicauda, is a 
spiroketal natural product that also binds PKC (3.0 nM for PKCδ) and is highly tumor 
promoting.54 Aplysiatoxin is a tumor promoter with a very high affinity for PKCδ (3.0 
nM). 
Several compounds with high affinity for PKC isozymes, but which lack the 
tumor promoting properties of the phorbol esters and related natural products, are in 
clinical trials (Figure 1.6). The phorbol type terpene 12-deoxyphorbol 13-acetate 
(prostratin) was isolated from the mamala tree, Homalanthus nutans.55 The bark of the 
tree was used by Samoan natives to treat hepatitis, and further studies of this compound 
indicated that it has a high affinity for PKC (12.5 nM). Prostratin has been experimentally 




    Figure 1.5 Tumor Promoters 
 
 




tricyclic structure as PMA, but lacks functionality at C12, and is nontumor promoting.  
The natural product PEP005, isolated from the petty spurge, Euphorbia peplus, is 
a member of the ingenol family of terpenes, which are structurally related to the phorbol 
esters.57 PEP005 is a very potent PKC ligand with sub nanomolar affinity for PKC. 
PEP005 is not a tumor promoter and was approved for the treatment of actinic keratosis 
by the FDA. Bryostatin 1, the most studied member of the bryostatin family, is a potent 
PKC ligand and is nontumor promoting. Bryostatin when given in the presence of PMA 
antagonizes and reverses the effects of PMA in a dose-dependent manner.58  
The difference between tumor promoting and nonpromoting ligands is believed to 
be dependent upon differences in polarity of side chains attached to the top section of the 
PKC ligand.  Ligands with nonpolar, long side chains, like those attached to PMA, tend 
to be tumor promoting. Ligands with no side chain or very short side chains tend to be 
nontumor promotors like prostratin. Interestingly, the binding constant to PKC has little 
correlation to tumor promotion properties. Bryostatin, a nontumor promoter, has a single 
digit nanomolar affinity for PKC, while PMA, a high affinity ligand, is a tumor promoter. 
The crystal structure of PMA bound to PKC49 indicates that the most polar 
portion of the ligand binds to the C1 domain. The rest of the ligand rests on top of the C1 
domain, forming a hydrophobic surface on the enzyme. This lipophilic ligand/ enzyme 
complex then interacts with internal cellular membranes. These interactions are thought 






Early Structural Modifications of Bryostatin 	   Early studies on the structure-activity relationships of the bryostatins focused 
upon making derivatives of the natural product to determine which structural elements 
are important for PKC binding. Upon comparing the natural bryostatins, it was noticed 
that the various ester groups at C7 and C20 had minor effects on binding. The lack of the 
C19 acetal and C20 ester in bryostatins 16 and 17 resulted in a large decrease in affinity. 
In a collaboration between Blumberg, Pettit, and Wender, bryostatin 2, which lacks the 
C7 ester, was successively hydrogenated to determine if any of the unsaturations were 
important for binding (Figure 1.7).59  
Hydrogenation of the C20 side chain as well as the C13 enoate slightly decreased 
the affinity for PKC. However, further hydrogenation reduced the C21 enoate, and the 
resulting compound had a binding affinity for PKC 3 orders of magnitude lower than that 
of the natural product. Inversion or acylation of the C26 alcohol produced analogs with a 
low binding affinity. Finally, epoxidation of the C13 enoate on bryostatin 4 did not 
significantly alter binding affinity.  
From these studies, it was determined that alteration of the A- and B-ring 
functionality of bryostatin had minimal effects on binding. On the other hand, changes of 
hydrogen bonding groups on the C-ring were very detrimental to binding. The only 
variability on the C-ring that did not significantly affect the binding was the nature of the 
C20 ester. A computer modeling study was conducted by Wender and coworkers, which 
showed homology between several PKC ligands; this work demonstrated that 1,2-
diacylglycerols, PMA, and bryostatin all have hydrogen bonding domains which interact 








oxygenated functionalities, which were proposed to interact with the C1 domain (Figure 
1.8).48 The upper portions of these molecules were hypothesized to serve as spacer 
domains that interact with cellular membranes and influence the biological activities of 
these ligands and position the C-ring pharmacophores into position for binding.  
 
Wender’s Analog Work 
 Paul Wender hypothesized that the C-ring of bryostatin, which he termed the 
“recognition domain”, is the key portion of the molecule in relation to its binding  affinity 
for PKC.49, 60 The top portion of the molecule served as a spacer domain to position the 
pertinent hydrogen bonding pharmacophores in the C-ring into position to bind with 
PKC.Wender incorporated this idea into his synthesis of highly potent bryostatin analogs, 
with a fully functionalized C-ring and simplified A- and B-rings (Figure 1.9).60 The 
synthesis of these provided much information on structure-activity relationships of the 
bryostatins.  
Analog 1.1 retained much of the affinity for PKC, but had a drastically simplified 
AB top-half for ease of synthesis. Elimination of the C3 alcohol in 1.2 resulted in the 
decrease of binding affinity by several orders of magnitude. Elimination of the A- ring in 
1.3 and attachment of a tert-butyl group at C9 resulted in a compound that still retained 
high affinity for PKC. Complete elimination of the macrocyclic lactone in 1.4 resulted in 
almost complete loss of activity, demonstrating that the macrolactone is a requirement for 
PKC affinity.Analog 1.5, lacks the C27 methyl group and retains high binding affinity. 
This analog, 1.5, was called “picolog” due to its subnanomolar affinity for PKC61; upon 




Figure 1.8 PKC Ligand Pharmacophores 
 




evaluated in the NCI 60 tumor cell panel and was generally found to be as potent as 
bryostatin 1. This indicates that removal of the C26 methyl group has little effect on 
binding. 
 
Keck’s Analog Work 
 The key reaction in the Keck lab bryostatin program is the pyran annulation, 
which was developed by Dr. Covel for the synthesis of 2,6-disubstituted tetrahydropyrans 
in the context of complex polyketide natural product synthesis.63 The substrate for this 
reaction can be prepared in a single step by catalytic asymmetric allylation of an aldehyde 
1.6 with a bifunctional stannane 1.7 to produce a β-hydroxyallylsilane 1.864 (Figure 
1.10). Pyran annulation of 1.8 with a second aldehyde 1.9 is carried out under Lewis 
acidic conditions (TMSOTf at –78 oC) to yield a tetrahydropyran 1.10 as a single 
diastereomer. The pyran annulation is a powerful method for the rapid synthesis of 
bryostatin like compounds. For example, removal of TBDPS group of 1.10 and 
subsequent oxidation of the primary alcohol provides an aldehyde 1.11, which is suitable 
for a second pyran annulation with another β-hydroxyallylsilane 1.12. Using this method, 
a simplified bryostatin spacer domain 1.13 was prepared in only 8 steps from 
commercially available compounds. 
 
Early Keck Group Analogs 
 The Keck group has directed much effort towards the synthesis of bryostatin 1 
and simplified analogs. The development of the pyran annulation enabled the 














first bryostatin analog was synthesized by Dr. Ahn Truong.65At that time, the function of 
the C20 ester and enoate remained unknown, so the C21 enoate was omitted and C20 was 
left at the ketone oxidation state. This analog was designed so that further 
functionalization would allow for the installation of all elements of the natural 
bryostatinC-ring at a late stage. The retrosynthesis of this analog is shown in Figure 1.11.  
 The synthesis began with the BOM protection of commercially available (R)-(+)-
isobutyl lactate 1.20, followed by partial reduction to aldehyde 1.21 (Figure 1.12). 1, 2-
Chelation controlled allylation of aldehyde 1.21 provided alcohol 1.22 as a single 
diastereomer via 1HNMR.66 PMB ether formation followed by ozonolysis provided 
aldehyde 1.23. 1,3-Chelation controlled allylation67 and subsequent protection of the 
newly formed alcohol as the TBS ether provided olefin 1.24 as a 5:1 mixture of 
diastereomers. Hydroformylation of 1.24 using Buchwald’s conditions68 provided the 
homoelongated aldehyde 1.25 in high yield. Prenyl indium addition69 followed by 
oxidation with PCC70 gave ketone 1.19 in an overall yield of 46% over 3 steps.  
The completion of the C-ring fragment (Figure 1.13) was achieved by ozonolysis 
of 1.19 and olefination to form thiol ester 1.28.71 TBS deprotection and dehydration of 
the resulting hemiketal yielded glycal 1.29. Selective reduction yielded aldehyde 1.17. 
Pyran annulation with β-hydroxyallylsilane 1.18, afforded pyran 1.31. TBDPS 
deprotection and oxidation under Ley conditions72 afforded aldehyde 1.16 (Figure 1.14). 
Pyran annulation with β-hydroxyallylsilane 1.15 yielded tricycle 1.32 bearing all of the 
carbons of the target compound. 
Functionalization of the C-ring was accomplished first by epoxidation and in-situ 




Figure 1.11 Retrosynthesis of Ahn’s Analog 
 






















acid, and finally PMB deprotection produced seco-acid 1.33 in 31% yield over 5 steps. 
Completion of the analog 1.14 was achieved via Yamaguchi macrolactonization74 and 
subsequent BOM and methyl ketal deprotection using Lipshutz’s conditions.75 Even 
though the analog contains the 3 crucial pharmacophores as determined by Wender, the 
analog demonstrated low binding affinity for PKC α, 546 nM. This compound 
demonstrates the requirement of the C20 ester and C21 enoate for high binding affinity. 
Dr. Carina Sanchez finished the functionalization of Ahn’s analog via attachment 
of the C21 enoate and C20 ester (Figure 1.15). Protection of C3 of 1.34 as a TBS ether 
followed by an aldol reaction with methyl glyoxylate and subsequent dehydration with 
Burgess reagent76 produced enoate 1.35. Luche reduction77 of the C20 ketone followed 
by acylation gave C20 ester 1.36. Deprotection of the C26 BOM ether and C20 ketal was 
once again accomplished with Lipshutz’s conditions (LiBF4, MeCN/ H2O)75 yielding 
analog 1.37. Analog 1.37 has a high affinity for PKC α, 0.7 nM, indicating that the C20 
ester and C21 enoate are required for high affinity. 
 
Merle 23, a Highly Potent PKC Activator 
Graduate students Matt Kraft and Wei Li developed a more convergent route for 
the assembly of bryostatin analogs, resulting in the synthesis of Merles 21, 22, 23, which 
only differed with respect to the C20 ester. All showed similar binding affinities for 
PKCα which were essentially identical to that of bryostatin 1. Merle 23, which bears the 
natural C-ring of bryostatin 1, was found to be the most active of this series with a Ki of 
0.7 nM.  Further improvements to the route were made by Tom Cummins and Mark 















compound as well as many other analogs. The final route is considerably more 
convergent and efficient; the retrosynthesis is shown in Figure 1.16.  
Synthesis of the fully functionalized C-ring fragment began with the alkylation of 
the enolate of methyl isobutyrate 1.44 with allyl bromide, followed by Wohl-Zeigler 
bromination (Figure 1.17).78 Displacement of the bromide of 1.46 with potassium acetate 
followed by transesterification and protection of the free alcohol with a TBS ether gave 
ester 1.47. Hydrolysis of 1.47 afforded carboxylic acid 1.40. Even though this route was 
low yielding, large quantities of carboxylic acid 1.40 could be produced inexpensively. 
Alcohol 1.41 was produced via the same allylation procedure as described in Figure 1.12. 
Union of the two pieces was accomplished via Keck-Boden modified Steglich 
esterification conditions79 to produce ester 1.48. Homoelongation of 1.48 began with 
hydroboration/ oxidation80 to produce alcohol 1.49. Parikh-Doering oxidation81 followed 
by Wittig olefination82 afforded olefin 1.39 in good overall yield. The Rainier metathesis 
reaction83 was then used to cyclize olefin 1.39 to glycal 1.50, allowing for the production 
of gram quantities of this intermediate. 
Functionalization of glycal 1.50 proceeded via epoxidation with magnesium 
monoperoxy phthalate, followed by in-situ epoxide opening with methanol (Figure 1.18). 
Oxidation of the intermediate alcohol via Ley conditions72 gave C20 ketone 1.51. Aldol 
reaction of 1.51 with methyl glyoxylate under mild conditions produced enoate 1.52 with 
good selectivity.76 Luche reduction77 of enoate 1.52 proceeded with high selectivity due 
to the bulky substituent at C19. Esterification of the intermediate alcohol gave ketal 1.53. 
Deprotection of the C15 TBS followed by subsequent oxidation72 provided aldehyde 

























yield to give the fully functionalized C-ring fragment 1.38. 
The synthesis of A-ring fragment 1.42 began with mono protection of 1,3-
propanediol as the TBDPS ether, followed by oxidation of the free alcohol to the 
aldehyde (Figure 1.19). Catalytic asymmetric allylation of aldehyde 1.9 with 
allylstannane using (R)-BITIP catalyst afforded homoallylic alcohol 1.56 in excellent 
yield and a 97% ee.64  
Protection of the free hydroxyl group of alcohol 1.56 as the PMB ether, followed 
by ozonolysis, produced aldehyde 1.57 in moderate yield. 1,3-chelation controlled 
allylation of aldehyde 1.57 with stannane 1.7 gave β-hydroxyallylsilane 1.15 as a single 
diastereomer in moderate yield.84 Synthesis of the functionalized aldehyde for the pyran 
annulation began with the Michael addition of benzyl alcohol into acrylonitrile 1.58 
(Figure 1.20). Blaise reaction85 of the resulting nitrile with ethyl bromoacetate gave keto-
ester 1.59. Noyori hydrogenation86 produced the β-hydroxy ester 1.60 in excellent yield 
with a 99% ee. TBS protection of the free alcohol, removal of the benzyl ether via 
hydrogenolysis, and Parikh-Doering81 oxidation produced aldehyde 1.43. 
Finally, pyran annulation of aldehyde 1.43 with β-hydroxyallylsilane 1.15 gave 
pyran 1.62 in good yield and as a single diastereomer.87 Removal of the C11 TBS group 
in the presence of the C1 TBDPS group of 1.62 was not selective enough for producing 
large quantities of advanced intermediates. However, deprotection of both silyl groups 
followed by selective re-protection of C1 provided access to secondary alcohol 1.63 
(Figure 1.21). Protection of the free alcohol in 1.64 as the TMS ether, followed by a 
Bunnelle reaction,88 provided β-hydroxyallylsilane 1.42 in good overall yield. Union of 




























Figure 1.21 Completion of β-hydroxyallylsilane 1.42 
 
1.65 in good yield and as a single diastereomer (Figure 1.22).87 
Functionalization of C1 was achieved by selective deprotection of the C1 TBDPS 
in the presence of the C25 secondary TBS with AcOH/ TBAF, affording alcohol 1.66 
(Figure 1.23).89 Parikh-Doering81 and Pinnick73 oxidations produced the C1 carboxylic 
acid 1.67. Deprotection of the C25 TBS group was accomplished with HF•pyridine and 
Yamaguchi macrolactonization74 was used to cyclize the seco-acid to give macrolactone 
1.68 in moderate yield. Deprotection of the C3 PMB group was accomplished with 
buffered DDQ and both the C19 methyl ketal and C26 BOM groups were cleanly 




























Biology of Merle 23 
 An assumption was made that Merle 23 and similar compounds would exhibit 
similar biological activity to that of bryostatin 1 since all C-ring pharmacophores are held 
into the same position in Merle 23 by the spacer domain as in bryostatin 1. In Merle 23, 
the C8 gem-dimethyl and C9 ketal are deleted, and the C7 acetate and C13 enoate are 
replaced by methylene groups (Figure 1.24). Up until this point, biological evaluation of 
bryostatin analogs had solely focused on PKC binding affinity and activity in cancer cell 
lines. Could deletion of substituents on the spacer domain dramatically change a PKC 
ligands biological activity? 
Both Merle 23 and bryostatin 1 are high affinity ligands for PKC, Ki = 0.70 nM,90 
and Ki = 1.35 nM, respectively; however, binding affinity for PKC does not correlate 
with tumor promoting ability. Bryostatin 1 does not cause tumor promotion and 
counteracts the effects of PMA, a potent tumor promoter. Would simplified bryostatin 
analogs act like bryostatin or would they simply act like PMA and cause tumor 
promotion? A vital collaboration with Dr. Peter Blumberg at the NIH was formed with 
the Keck group to investigate this biological question and facilitate the rational design of 




Figure 1.24 Bryostatin 1 and Merle 23 Top Halves. 
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 The response of U937 leukemia cells towards PKC ligands has been used to 
differentiate between tumor promoting and nonpromoting ligands (Figure 1.25).91 
Phorbol esters such as PMA induce attachment of U937 cells and inhibit proliferation. 
Bryostatin 1 has a much less dramatic effect. Bryostatin 1 also antagonizes and reverses 
the effects of PMA in a dose-dependent manner. Merle 23 was shown to exhibit identical 
effects as those of PMA in the proliferation and attachment assays.90 Results in K562 
leukemia cells are similar to those seen in the U937 cells.  
 Results with Merle 23 in the LNCaP human prostate cancer cell line were 
different from those of PMA.92 PMA induces apoptosis, TNF α secretion, and inhibits 
proliferation, while bryostatin 1 and Merle 23 failed to illicit these responses (Figure 
1.26). Upon further examination, the effects of Merle 23 in LNCaP cells were found to be 
very complex depending on the PKC isozyme and experimental conditions (Figure 1.26). 
It was found that PMA causes translocation of PKC δ to the cell membrane, but Merle 23 
and bryostatin 1 tended to cause translocation to internal membranes. In the presence of 
the protease inhibitor MG-132, Merle 23 displays PMA-like behavior in LNCaP cells, 
whereas bryostatin 1 behavior is unaffected. Differential effects were also seen with 
respect to activation, translocation, and downregulation of specific PKC isozymes. From 
these studies, it is apparent that Merle 23 is a distinct compound from either bryostatin 1 
or PMA in its biological effects in LNCAP cells.  
 
The Polarity Hypothesis 
 After the biological evaluation of Merle 23, the Keck group turned its attention 










LNCaP Proliferation Assay 
 
LNCaP Apoptosis Assay 
Figure 1.26 Effects of PKC Ligands in LNCaP Prostate Cancer Cells 
 	  
PMA: 0.1, 1, 10, 100, 1000 nM 
Bryostatin 1: 0.1, 1, 10, 100, 1000 nM 
Merle 23: 0.1, 1, 10, 100, 1000, 10000 nM 
PMA: 0.1, 1, 10, 100, 1000 nM 
Bryostatin 1: 0.1, 1, 10, 100, 1000 nM 
Merle 23: 1, 10, 100, 1000 nM 
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attempt to define what characteristics influence if a PKC ligand behaves like bryostatin or 
PMA. A series of analogs were synthesized wherein the A- and B-ring substituents were 
systematically removed from bryostatin 1 or introduced in Merle 23, and the response in 
U937 leukemia cells measured (Figure 1.27).93 From this study, it was determined that no 
single substituent acted as a ‘switch’ that would determine if an analog would behave like 
PMA or Bryostatin. However, it was observed that analogs that bore two or more polar 
groups on the top-half tend to behave more “bryo-like” in assays, but the more lipophilic 
analogs tend to act more PMA-like. From these studies, it is clear that the top-half of 
bryostatin does not merely serve as a “spacer domain”, but has dramatic influences upon 
the biology of these compounds. The C-ring of bryostatin is thought to interact with the 
binding domain of PKC, while the top-half is thought to produce a hydrophobic surface 
on top of the C1 domain. The ligand-enzyme complex then translocates to cellular 
membranes. Interaction of the hydrophobic surface of the PKC-ligand complex with 
these membranes is thought to dictate biological activity. The C-ring motif in bryostatin 1 
is very complex, requiring 20 linear steps to synthesize it. Substitution of a suitable 
surrogate for the C-ring that is less complicated to synthesize would be highly desirable 
for the synthesis of new PKC activators.  
 
Diacylglycerols and Marquez Lactones 
 1,2-Diacyl glycerols (DAG) are the endogeneous ligands for PKC signaling. 
Binding of extracellular ligands to G-coupled protein receptors initiates signaling 
cascades that result in phospholipase C (PLC) hydrolyzing membrane bound 

























(IP3). IP3 causes the release of Ca+2, then DAG, in combination with Ca+2, activates PKC, 
which then phosphorylates threonine or serine residues of target proteins. 
 In order to study structure-activity relationships, Victor Marquez and coworkers 
at the NCI chose to study DAG analogs since synthesis of large numbers of these 
compounds was much more feasible than modifying potent PKC ligands such as 
bryostatins or phorbol esters. Early models60 of PKC-ligand interactions identified a three 
point pharmacophore domain on the ligand that was responsible for binding (Figure 
1.28). Despite the similarities of the pharmacophores, PMA is 1000 times more potent 
than DAG.  
 In order to increase the binding affinity of DAGs, Marquez reasoned that 
constraining the DAG pharmacophore into a 5-membered ring would reduce the entropic 
penalty for ligand binding.94 In order to accomplish this, an extra carbon was added to the 
DAG scaffold. The preferred configuration of natural DAGs is (S); the (R) enantiomer is 
basically inactive (Figure 1.29). Cyclization of (S) DAG results in the orientation of the 
lactone carbonyl, which is crucial to binding, changing to an inactive configuration. 
Cyclization of (R) DAG results in a lactone with the carbonyl in the proper orientation for  
 
 






Figure 1.29 DAG Lactone Configuration Rational (used with permission from ref 89a). 
 Evaluation of simple DAG lactones revealed that they are fairly potent PKC  
 
effective binding with PKC. Evaluation of simple DAG lactones revealed that they are 
fairly potent PKC ligands.95 It was observed that the pure (R)-enantiomers were twice as 
potent as the racemic compounds; the racemate was used for expediency of synthesis in 
many cases (Figure 1.30).95 Addition of an enoate side chain to the α-postion of the 
lactone increased the binding affinity by an order of magnitude.95 Modification of the 










acetate for a pivalate group at the esterified hydroxymethyl group, increased binding by 
another order of magnitude.96 It was also found that the Z-enoate was more potent than 
the E-enoate by a factor of 2.  
A short asymmetric synthesis of the most potent DAG analog was developed by 
Marquez and Coworkers97; this route is shown in Figure 1.31. Mono protection of 
commercially available diol 1.69 gave alcohol 1.70 in moderate yield. Sharpless 
asymmetric epoxidation of allylic alcohol 1.71 gave the desired epoxide in high yield 
with an ee of 96%.  Protection of the free alcohol as a benzyl ether followed by addition 
of lithium acetylide and Lindlar reduction gave allylic alcohol 1.73 in high overall yield. 
Hydroboration, and oxidation of the intermediate organoborane with PCC, gave lactone 
1.74 in moderate yield. 
Aldol reaction of 1.74 with 5-methyl-3-(2-methylpropyl)hexanal, followed by 
mesylation-elimination gave a nearly 50:50 mixture of E/Z isomers. Removal of the trityl 
group, acylation with pivaloyl chloride, and removal of the benzyl group gave DAG 
lactone 1.76. Biological evaluation of DAG lactones indicates that they have potent 
anticancer properties against leukemia and colon cancer cell lines.98 DAG lactone 1.76  
induces apoptosis in LNCaP cells, but is selective towards PKCα, unlike PMA, which 
activates both PKCα and PKCδ.99 1.76 also selectively translocates PKCδ to nuclear 
membranes, unlike PMA, while PKCα is exclusively translocated to the plasma 
membrane.  Lactone 1.76 has also demonstrated considerable activity towards the K562 
leukemia and colo205 colon cancer cell lines.100 These studies potentially indicate that 
DAG lactones are not mimics of PMA in-vitro. Synthesis of hybrid DAG lactones 















functionality relationships to be determined. 
 
Results and Discussion 
Synthesis of a Diacylglycerol Lactone C-ring  
 In the search for simplified bryostatin analogs that retain the high binding affinity 
of the natural compound, it was decided to substitute the C-ring binding motif of the 
simplified analog Merle 23 for a scaffold that retained the high binding affinity of the 
original compound. The diacylglycerol lactones, extensively studied by Marquez and 
coworkers, were chosen to be the C-ring surrogate due to their high affinity for PKC and 
simplicity of construction. The retrosynthesis for the first- generation analog is shown in 
Figure 1.32. The synthesis of the C-ring domain was based upon modifications of the 
optimized Marquez route97 (Figure 1.31) to allow for late stage alteration and 
functionalization.  
Commencement of the synthesis of the functionalized C-ring surrogate began 
with a tandem aldol reaction-Horner-Wadsworth Emmons olefination of diethyl 
phosphonoacetate to yield acrylate 1.84 (Figure 1.33).101 Since acrylate 1.84 is readily 
polymerizable, it was immediately protected as the trityl ether, yielding protected acrylate 
ester 1.82 in 97% yield on a 35g scale.102 Reduction of ester 1.82 to the corresponding 
alcohol 1.81 was conducted with DiBAL-H. Sharpless epoxidation103 with L-(+)-diethyl 
tartrate and Ti(i-OPr)4 produced epoxy alcohol 1.85 with an ee of 90% on a gram scale. 
Protection of the free hydroxy group as the benzyloxy methyl (BOM) ether yielded 
epoxide 1.80. Nucleophilic ring opening of the epoxide using a lithium acetylide 




Figure 1.32 C-Ring Retrosynthesis 
 
hydrogenation104 of propargylic alcohol afforded allylic alcohol 1.87.  
Hydroboration-oxidation of the allylic alcohol produced diol 1.88. Diol 1.88 was 
then oxidized to the corresponding hydroxy acid via sequential Parikh-Doering and 
Pinnick oxidations. Cyclization of hydroxy acid was achieved by formation of the mixed 
anhydride with benzoyl chloride, followed by spontaneous cyclization to produce lactone 
1.89.105 
This route was successful; however, we realized that lactone 1.89 could be 
produced by a much shorter route commencing with the nucleophilic ring opening of 
protected epoxide 1.80 with the enolate of diethyl malonate, followed by spontaneous 
ring closure to produce diester 1.90 (Figure 1.34).106 Diester 1.90 can be hydrolyzed to 
the corresponding β-keto acid which was decarboxylated at 80 oC in toluene in the 
presence of quinoline.107 This route shortens the synthesis of lactone 1.89 by 3 steps and 
provides lactone in 85% yield overall from epoxide 1.80 The functionalization of the 
alpha position of lactone 1.89 proved difficult to accomplish in a selective manner.97 
Enolization of lactone 1.89 with LDA at –78 oC followed by the aldol reaction with 














Figure 1.34 Second-Generation C-ring Lactone Synthesis 
 
were not further characterized (Figure 1.35). One-pot mesylation yield and elimination 
with DBU yielded a 1.2:1 mixture of Z/ E enoate products in 55%, separable viacolumn 
chromatography.  
In order to improve selectivity for the desired Z-enoate, another approach for 
olefination was evaluated (Figure 1.36). Lactone 1.89 was deprotonated with LDA at –78 
oC to form the enolate and then reacted with diethyl chlorophosphate to form the enol 
phosphate which was exposed to LDA to cause rearrangement to the C- phosphonate 
1.91.108 This phosphonate was not readily isolated as a pure compound and was therefore  
used without characterization.  
To further advance phosphonate 1.91, we sought to use a Z-selective Horner-
Wadsworth-Emmons type olefination for which examples have been reported in the 
literature. The results of a screen of conditions for selective olefination are reported in 
Figure 1.36. Deprotonation of phosphonate 1.91 with LDA at –78 oC in the presence of 









Conditions  Result 
LDA, 18-crown-6, THF, –78 oC 1:2 Z/ E 
KHMDS, 18-crown-6, THF, –78 oC Decomposition 
LiCl, DBU, MeCN, r.t. 1:3 Z/ E 
K2CO3, 18-crown-6, THF 10:1 Z/ E 40% yield, 31% elimination 
 





enoates.109 A Z- selective olefination using KHMDS and 18-crown-6 was evaluated in 
this context.110 These conditions lead to the decomposition of the starting phosphonate 
1.91.  
Roush conditions111 using LiCl, DBU in MeCN, lead to a 1:3 Z/ E mixture of  
enoates. The best conditions that we identified were K2CO3, and 18-crown-6 in THF,112  
which produced a 10:1 mixture of Z/ E products. The desired Z-enoate was obtained in 
40% yield with a 31% yield of the C3 TBS eliminated product. However, these 
conditions were not found to be acceptable to produce the desired Z-enoate product on a 
preparative scale. The only Z-selective conditions that were found caused much 
elimination of the terminal OTBS group of the olefinated product. The previously 
mentioned aldol/ dehydration sequence (Figure 1.35) was found to be more scalable and 
therefore was used to produce gram quantities of the desired enoate 1.77 after 
chromatographic separation.  
In order to couple the lactone fragment with the AB-ring system of Merle 23, the 
trityl group of enoate 1.77 needed to be selectively removed in the presence of a primary 
BOM ether and a primary homoallylic TBS ether.  The results of the deprotection 
campaign are shown in Figure 1.37. Formic acid in ether113 resulted in TBS deprotection, 
but not the desired trityl deprotection. Use of Me2AlCl in CH2Cl2114 resulted in cleavage 
of both the trityl and BOM groups. Reaction with BF3•Et2O in CH2Cl2115 resulted in 
cleavage of both the trityl and TBS groups. Exposure to triethylsilane and TMSOTf in 
CH2Cl2116 afforded the desired trityl deprotected compound 1.93, but in low yield. It was 
found that a 50:50 mixture of TFA/ TFAA in CH2Cl2117 removed the trityl group at 0 oC 





HCOOH, Et2O, rt TBS deprotection 
Me2AlCl, CH2Cl2, rt Trityl and BOM deprotection 
BF3•Et2O, CH2Cl2, rt TBS and trityl deprotection 
Et3SiH, TMSOTf, CH2Cl2, rt Trityl deprotection, 49% yield 
TFA/TFAA, CH2Cl2, 0 oC Trityl deprotection, 81% yield 
 
Figure 1.37 Trityl Deprotection 
 
Conclusions 
The scale up synthesis of the A-ring hydroxyallylsilane 1.42, based upon 
improvements of the previous route developed for the synthesis of Merle 23 allowed for 
the synthesis of many bryostatin analogs. Several improvements were made to the 
Marquez route for the synthesis of DAG lactones, including starting from low cost 
precursor, and an efficient malonic ester addition-cyclization route to form the lactone 
skeleton from a chiral epoxide. Attempts were made at selective Z-olefination of the 
lactone; however, these were unsuccessful due to facile elimination of the γ-alkoxy group 
of the enoate after formation. The efficient synthesis of the DAG lactone core was used to 





General Experimental Procedures 
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, and 
CH2Cl2, were distilled from CaH2. Reagent grade DMF, DMSO, and acetone were 
purchased, stored over 4Å molecular sieves, and used without further purification. Et2O, 
THF, and toluene were distilled from Na under an atmosphere of N2. MeOH was distilled 
from dry Mg turnings. The titer of n-BuLi was determined by the method of Baclawski 
and Kofron.118 Ti(i-OPr)4 was distilled prior to use. All other reagents were used without 
further purification. Yields were calculated for material judged homogenous by thin layer 
chromatography and nuclear magnetic resonance (NMR). Thin layer chromatography 
was performed on Merck Kieselgel 60Å F254 plates or Silicycle 60Å F254 eluting with 
the solvent indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic 
solution of 12-molybdophosphoric acid, a solution of ninhydrin in 1-butanol, a solution 
of p-anisaldehyde in ethanol acidified with sulfuric acid, an aqueous potassium 
permanganate solution, or a solution of ceric ammonium molybdate, acidified with 
sulfuric acid. Flash column chromatography was performed with Silicycle Flash Silica 
Gel 40 – 63 µm or Silicycle Flash Silica Gel 60 – 200 µm, slurry packed with hexanes in 
glass columns. Glassware for reactions was oven dried at 125 °C and cooled under a dry 
atmosphere prior to use. Liquid reagents and solvents were introduced by oven-dried 
syringes through septum-sealed flasks under a nitrogen atmosphere. Enantiomeric excess 
(ee) were determined using a Rainin Dynamax HPLC with a Knauer variable wavelength 
detector set at 254 nm, using a Chiracel OD-H column. Nuclear magnetic resonance 
spectra were acquired at 300, 500 MHz for 1H and 75, 125 MHz for 13C. Chemical shifts 
	  	  
56	  
for proton nuclear magnetic resonance (1H NMR) spectra are reported in parts per 
million relative to the signal of residual CDCl3 at 7.27 ppm or (CH3)4Si at 0.00 ppm. 
Chemicals shifts for carbon nuclear magnetic resonance (13C NMR and DEPT) spectra 
are reported in parts per million relative to the centerline of the CDCl3 triplet at 77.23 
ppm. Chemical shifts of the unprotonated carbons (‘C’) for DEPT spectra were obtained 
by comparison with the 13C NMR spectrum. The abbreviations s, d, dd, ddd, dddd, 
ddddd dt, quint, t, and m stand for the resonance multiplicity singlet, doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, 
doublet of doublet of doublet of doublet of doublets, doublet of triplets, quintet, triplet, 
and multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell 
with a 1 dm path length. Specific rotations ([α], Unit: °cm2/g) are based on the equation α 
= (100·α)/(l·c) and are reported as unit-less numbers where the concentration c is in g/l00 
mL and the path length l is in decimeters. Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a time 
of flight (TOF) high-resolution mass spectrometer. Compounds were named using 
ChemBioDraw 14.0.0. 
 
Synthesis of Reagents 
Preparation of allyltributylstannane: To a 2000 mL 3-neck round 
bottomed flask was added magnesium turnings (19.3 g, 792 mmol, 1.25 equiv); a 
magnetic stir bar, reflux condenser, and addition funnel were then attached. The system 
was put under vacuum and flame dried. Nitrogen was admitted after cooling to rt. THF 
(500 mL) was added to the flask followed by several I2 crystals. The mixture was stirred 
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and heated to reflux. A solution of allyl bromide (66 mL, 760 mmol, 1.2 equiv) and 
chlorotributyltin (172 mL, 634 mmol, 1.0 equiv) in THF (100 mL) was added dropwise 
over 1.5 h to the stirred mixture. The solution turned to a cloudy gray color and most of 
the magnesium had dissolved after 2 h. The mixture was then heated at reflux for 20 h. 
After cooling, the mixture was filtered and the filter cake was washed with 9:1 hexanes/ 
EtOAc (400 mL). The combined organic phase was then washed with saturated aqueous 
NaHCO3 solution (200 mL) and brine (100 mL). The organic phase was dried over 
Na2SO4, filtered, and concentrated. The product was distilled under vacuum, collecting 
between 105 oC –	   120 oC at 0.35 mmHg. The resulting allyltributylstannane was 
transferred to 2 Aldrich Sure-Seal bottles for storage (205g, 98%). 300 MHz 1HNMR 
(CDCl3) δ 6.03–5.86 (m, 1H), 4.79 (d, J = 16.9 Hz, 1H), 4.65 (d, J = 9.5 Hz, 1H), 1.79 (d, 
J = 8.8 Hz, 2H), 1.57–1.43 (m, 6H), 1.49–1.24 (m, 6H), 0.91 (t, J = 7.2 Hz, 9H), 0.90 (q, 
J =7.2 Hz, 6H). 
Bu3SnH Preparation of tributyltin hydride: A 2000 mL 3-neck flask was fitted 
with a reflux condenser, addition funnel, and stir bar. The flask was flame dried under 
vacuum and cooled to rt. LiAlH4 (28.0 g, 737 mmol, 2.0 equiv) was added under a stream 
of N2. Et2O (1000 mL) was then added and the mixture was heated to reflux. 
Chlorotributyltin (100 mL, 367 mmol, 1.0 equiv) was added dropwise through the 
addition funnel to the mixture over 30 min. The mixture was heated at reflux for 1.5 h 
and then cooled in an ice bath. Crystals of Na2SO4•10H2O were added slowly until the 
exothermic reaction had subsided; a substantial excess of the salt was then added. The 
mixture was filtered through a 6 × 3 cm bed of Celite™ and the Celite™ was washed 
with Et2O (100 mL). The solvent was evaporated and the crude product was distilled 
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under reduced pressure, collecting the fraction boiling between 70 oC –	  90 oC at 1.0 mm 
Hg. The tributyltin hydride was stored in an Aldrich Sure-Seal bottle (101 g, 94%). 300 
MHz 1HNMR (CDCl3) δ 5.30 (s, 1H), 1.70–1.60 (m, 6H), 1.43–1.30 (m, 12H), 0.93 (t, J 
= 12.5 Hz, 9H).  
Preparation of benzyloxymethyl chloride (BOMCl): A dry 250 
mL flask was fitted with a stir bar and addition funnel. Paraformaldehyde (8.26 g, 275 
mmol, 1.0 equiv) and benzyl alcohol (28.5 mL, 275 mmol, 1.0 equiv) were added to the 
flask. After cooling to 0 oC, SOCl2 (20 mL, 275 mmol, 1.0 equiv) was added through the 
addition funnel dropwise over 25 min to the stirred mixture. The mixture was then 
warmed to rt and stirred for 1 h. The reaction mixture was quenched with pentane (200 
mL) and extracted with brine (2 × 100 mL). After drying over MgSO4, the solution was 
filtered and concentrated to yield the product as a colorless oil (40.2 g, 94%). 300 MHz 
1HNMR (CDCl3) δ 7.40 (s, 5H), 5.57 (s, 2H), 4.78 (s, 2H).  
Preparation of magnesium bromide diethyletherate: A modified 1000 mL 3-
neck flask bearing a fritted filter fused to one of the necks was fitted with a reflux 
condenser and addition funnel. The filter had a ground glass joint and a vacuum adaptor, 
which was sealed off respectively with a 1000 mL flask and rubber septum. The 
apparatus was flame dried under vacuum after adding magnesium (15.5 g, 638 mmol, 1.1 
equiv). After cooling to rt, Et2O (600 mL) was added and the mixture was heated to 
reflux. To the stirred mixture was added 1,2-dibromoethane (50 mL, 580 mmol, 1.0 
equiv) dropwise over 3 h. The mixture was refluxed for 2 h and filtered through the side 
arm under positive pressure while still hot. The solution was flushed with N2, capped, and 
allowed to crystallize in a –20 oC freezer overnight. The mother liquor was removed by 
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cannulation and the resulting crystals washed with Et2O (4 × 100 mL). The product was 
then dried under high vacuum overnight, yielding a gray colored solid (114 g, 76%). 
 
Experimental Procedures for A-Ring β-Hydroxyallylsilane 1.64 
 Preparation of 3-((tert-butyldiphenylsilyl)oxy)propan-1-ol 
(1.94): A 2000 mL round bottomed flask was fitted with a magnetic stir bar and a 
septum. CH2Cl2 (1350 mL) was added to the flask, followed by tert-butyldiphenylsilyl 
chloride (60 mL, 230 mmol, 1.0 equiv). 1,3-propanediol 12 (82 mL, 1130 mmol, 4.9 
equiv), triethylamine (63 mL, 450 mmol, 2.0 equiv), and DMAP (1.39 g, 11 mmol, 0.05 
equiv) were then subsequently added. The solution was stirred at rt for 3 days, then 
quenched with water (500 mL). The layers were separated and the organic layer was 
washed with water (2 × 250 mL). The solution was then washed once again with brine 
(100 mL) and dried with Na2SO4. The solution was filtered through a fritted funnel and 
concentrated under reduced pressure to yield an oil that crystallized upon cooling in a –20 
oC freezer overnight. The product was purified via flash chromatography using a 12 × 30 
cm silica gel column eluting with 10 % EtOAc/hexanes, collecting 125 mL fractions. 
Product containing fractions (6–36) were combined and concentrated, producing a 
colorless oil (73.6 g, 96 %) that crystallized upon cooling. Rf = 0.32 (25 % EtOAc/ 
hexanes); mp: 41 oC – 43 oC; 300 MHz 1HNMR (CDCl3) δ 7.71–7.68 (m, 4H), 7.46–7.38 
(m, 6H), 3.89–3.81 (m, 4H), 2.39 (t, J = 5.4 Hz, 1H), 1.82 (quint, J = 5.7 Hz, 2H) 1.07 (s, 




 Preparation of 3-((tert-butyldiphenylsilyl)oxy)propanal (1.9): 
To a 2000 mL round bottomed flask equipped with a stir bar was added CH2Cl2 (960 mL) 
and oxalyl chloride (13.1 mL, 149 mmol, 1.6 equiv). The mixture was chilled to –78 oC, 
and a solution of dimethyl sulfoxide (20 mL, 280 mmol, 3.0 equiv) in CH2Cl2 (30 mL) 
was added dropwise via cannula to the stirring solution. The solution was stirred for 1.5 h 
at –78 oC and then alcohol 1.94 (30.3 g, 96.4 mmol, 1.0 equiv) in CH2Cl2 (150 mL) was 
added via cannula; CH2Cl2 (10 mL) was used to complete the transfer. After 1 h, 
triethylamine (67 mL, 480 mmol, 5.0 equiv) was added. After stirring for an additional h, 
aqueous pH 7.0 phosphate buffer (0.1 M, 197 mL) was then added and the mixture was 
allowed to warm to rt. The mixture was washed with water (2 × 300 mL) and with brine 
(500 mL). The solution was dried over Na2SO4, filtered, and concentrated to give a 
yellow oil. The product was purified by column chromatography using a 12 × 30 cm 
silica gel column, eluting with 5% EtOAc/hexanes, collecting 125 mL fractions. Product 
containing fractions 12–22 were concentrated, yielding a nearly colorless oil (25.5 g, 82 
%) that crystallized upon cooling. Rf = 0.76 (25 % EtOAc/hexanes.); mp 46 oC – 49 oC; 
300 MHz 1HNMR (CDCl3) δ 9.83 (t, J = 2.2 Hz, 1H), 7.69–7.66 (m, 4H), 7.46–7.38 (m, 
6H), 4.04 (t, J = 6.0 Hz, 2H), 2.62 (dt, J = 6.0, 2.4 Hz, 2H), 1.05 (s, 9H); 75 MHz 13C 
NMR (CDCl3) δ 202.3, 135.8, 133.5, 130.1, 128.0, 58.5, 46.6, 27.0, 19.4.  
 Preparation of (R)-1-((tert-butyldiphenylsilyl)oxy)hex-5-en-
3-ol (1.56): A 1000 mL 3-neck flask was fitted with a magnetic stir bar, reflux condenser, 
and rubber septa to close the other two necks. The flask was flame dried under vacuum 
and cooled under N2. Powdered 4Å molecular sieves (53.0 g), (R)-BINOL (6.50 g, 22.8 
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mmol, 0.40 equiv), and CH2Cl2 (230 mL) were added to the flask under a stream of N2. 
Ti(i-OPr)4 (1.0 M in CH2Cl2, 11.4 mL, 11.4 mmol, 0.20 equiv) was added followed by 
TFA (1.0 M in CH2Cl2, 0.24 mL, 0.24 mmol, 0.004 equiv), resulting in a dark red color. 
The mixture was heated at reflux for 1 h, before a solution of aldehyde 1.9 (17.8 g, 57.0 
mmol, 1.0 equiv) in CH2Cl2 (25 mL) was then added via cannula; CH2Cl2 (5.0 mL) was 
used to complete the transfer. After stirring at rt for 0.5 h, the mixture was cooled to –78 
oC and allyltributyltin (23 mL, 74.3 mmol, 1.3 equiv) was added via syringe pump over 
0.5 h. After stirring for 10 min at –78 oC, the mixture was transferred to a –20 oC freezer. 
After 1 week, the mixture was removed from the freezer and immediately poured into a 0 
oC solution of saturated aqueous NaHCO3 (230 mL). After 1 h of stirring, the mixture 
was filtered through a 9 × 2 cm bed of Celite™ and washed with CH2Cl2 (3 × 100 mL).   
The organic phase was separated from the aqueous phase and the aqueous phase was 
extracted with CH2Cl2 (3 × 100 mL). The combined organic phases were dried over 
MgSO4, filtered, and concentrated, leaving a thick-red colored oil. The product was 
purified via column chromatography using a 12 × 30 cm column of silica gel, eluting 
with 5 % EtOAc/hexanes, collecting 100 mL fractions. Fractions 25–58 where 
concentrated, yielding the homoallylic alcohol (18.7 g, 93 %) as a light yellow oil. Rf = 
0.48 (25 % EtOAc/hexanes); 300 MHz 1H NMR (CDCl3) δ 7.70–7.61 (m, 4H), 7.46–7.39 
(m, 6H), 5.86 (dddd, J = 14.4, 10.5, 7.2, 7.2 Hz, 1H), 5.15–5.09 (m, 2H), 4.03–3.94 (m, 
1H), 3.92–3.80 (m, 2H), 3.26 (d, J = 2.5 Hz, 1H), 2.32–2.25 (m, 2H), 1.76–1.69 (m, 2H), 
1.06 (s, 9H); 75 MHz 13C NMR (CDCl3) δ 135.8, 135.7, 135.2, 130.0, 128.0, 117.6, 71.1, 
63.5, 42.2, 38.0, 27.0, 19.2. The enantiomeric excess was determined using a 4.6 × 150 
mm Chiralcel OD-H column (1.0 % i-PrOH/Hexanes; 0.40 mL/min); tr (major) = 9.71 
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min, tr (minor) = 11.87 min; 95% ee.  
 Preparation of (R)-tert-butyl((3-((4-methoxybenzyl)oxy)hex-
5-en-1-yl)oxy)diphenylsilane (1.95): A 250 mL single neck flask was fitted with a 
septum and a magnetic stir bar. Toluene (100 mL), followed by homoallylic alcohol 1.56 
(3.5 g, 9.7 mmol, 1.0 equiv) were added to the flask. Scandium (III) triflate (48.4 mg, 0.1 
mmol, 0.01 equiv) was added, and a solution of 4-methoxybenzyltrichloroacetimidate 
(5.50 g, 19.6 mmol, 2.0 equiv) in toluene (10 mL) was transferred to the stirring solution 
of homoallylic alcohol 1.56 at 0 oC. The ice bath was removed and the mixture was 
stirred for an additional 6 h at rt. The solvent was removed under reduced pressure, and 
the semi-solid residue was triturated with 9:1 hexanes/ether (200 mL), and then filtered 
through Celite™. The Celite™ was then washed with of 9:1 hexanes/ether (5 × 10 mL) 
and then the solvent was removed under reduced pressure. The product was purified on a 
5 × 20 cm silica gel column, eluting with 5 % EtOAc/hexanes, collecting 30 mL 
fractions. Product containing fractions 10–31 were concentrated, leaving the product (4.2 
g, 90 %) as a yellow oil. Rf = 0.63 (25 % EtOAc/hexanes). 300 MHz 1H NMR (CDCl3) δ 
7.73–7.67 (m, 4H), 7.47–7.37 (m, 6H), 7.24 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 
5.88 (dddd, J = 14.1, 10.2, 6.9, 6.9 Hz, 1H), 5.16–5.07 (m, 2H), 4.48 (ABq, J = 11.1 Hz, 
Δν = 33.8 Hz, 1H), 3.89–3.84 (m, 1H), 3.82 (s, 3H), 3.81–3.72 (m, 2H), 2.36 (t, J = 6.6 
Hz, 2H), 1.81 (q, J = 6.6 Hz, 2H), 1.1 (s, 9H); 75 MHz 13C NMR (CDCl3) δ 135.8, 135.1, 
134.1, 131.1, 129.9, 129.5, 127.8, 117.2, 113.9, 75.2, 71.0, 60.7, 55.4, 37.2, 27.1, 19.4. 
 Preparation of (S)-5-((tert-butyldiphenylsilyl)oxy)-3-((4-
methoxybenzyl)oxy)pentanal (1.57): A solution of PMB ether 1.95 (10.1 g, 21.3 mmol, 
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1.0 equiv) in 80:20 CH2Cl2/ MeOH (300 mL) was prepared in a 500 mL single neck 
flask. A stir bar followed by sodium bicarbonate (10.1 g, 90.2 mmol, 4.2 equiv) were 
added to the flask containing the PMB ether. The solution was chilled to –78 oC and 
ozone was passed into the solution until the solution turned to a permanent slate gray 
color. Excess ozone was then flushed with oxygen for 5 min, triphenylphosphine (10.6 g, 
40.4 mmol, 1.9 equiv) was added, and the solution was allowed to stir at rt overnight. The 
solution was filtered through a coarse fritted funnel, and concentrated to a thick oil. The 
product was purified via flash chromatography on a 5 × 30 cm silica gel column, eluting 
with 5 % EtOAc/ hexanes, switching to 10 % EtOAc/hexanes once the product began to 
elute, collecting 30 mL fractions. Product containing fractions 65–112 were concentrated, 
yielding the product (6.1 g, 60 %) as a yellowish oil. Rf = 0.38 (25 % EtOAc/hexanes). 
300 MHz 1H NMR (CDCl3) δ 9.76 (t, J = 2.1 Hz, 1H), 7.70–7.65 (m, 4H) 7.49–7.36 (m, 
6H), 7.20 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.47 (s, 2H), 4.20 (quint, J = 6.6 
Hz, 2H), 3.90–3.82 (m, 1H), 3.81 (s, 3H), 3.79–3.73 (m, 1H), 2.66 (ddd, J = 16.2, 6.9, 2.4 
Hz, 1H), 2.58 (ddd, J = 16.5, 5.1, 2.1 Hz, 1H), 2.00–1.87 (m, 1H), 1.86–1.73 (m, 1H), 1.1 
(s, 9H); 75 MHz 13C NMR (CDCl3) δ 201.8, 159.4, 135.8, 133.8, 130.4, 129.9, 129.6, 
127.9, 114.0, 71.4, 71.3, 60.3, 55.5, 48.8, 37.3, 27.1, 19.4.  
 Preparation of trichloro(2-(chloromethyl)allyl)silane  (1.96):119 A 
1000 mL 3-neck flask was fitted with a magnetic stir bar, pressure equalizing addition 
funnel, reflux condenser, and a septum was fitted in the remaining neck. The flask was 
dried under vacuum with a flame, and N2 was admitted after cooling to rt. Copper (I) 
chloride (0.158 g, 1.6 mmol, 0.01 equiv) was added followed by Et2O (300 mL) to the 
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flask. Triethylamine (28.0 mL, 201 mmol, 1.26 equiv) was added, turning the solution to 
a yellow-green color. A solution of 3-chloro-2-(chloromethyl)propene (20.0 g, 160 mmol, 
1.0 equiv), and trichlorosilane (20.0 mL, 198 mmol, 1.24 equiv) in Et2O (50 mL) was 
prepared in the addition funnel. This solution was then added over a period of 4 h to the 
stirred reaction mixture in the flask; a white colored suspension soon formed. After 
stirring overnight, the solution was filtered through a fritted funnel into a dry flask and 
the filter cake was washed with Et2O (50 mL). The solvent was carefully removed on a 
rotary evaporator using a cold water bath. The product was filtered and distilled under 
water aspirator pressure, collecting the fraction boiling between 70 oC – 90 oC as a 
colorless fuming liquid (28.8 g, 81 %). 300 MHz 1H NMR (CDCl3) δ 5.35 (s, 1H), 5.16 
(s, 1H), 4.14 (d, J = 1.2 Hz, 2H), 2.55 (d, J = 0.9 Hz, 2H); 75 MHz 13C NMR (CDCl3) δ 
136.4, 119.0, 49.0, 29.8. 
 Preparation of (2-(chloromethyl)allyl)trimethylsilane (1.97): A 1000 
mL single neck flask was fitted with a magnetic stir bar and a septum. Et2O (500 mL) 
was added and the flask was flushed with N2. Trichloro(2-(chloromethyl)allyl)silane 1.96 
(35.0 g, 156 mmol, 1.0 equiv) was transferred via cannula to the flask. After chilling to –
78 oC, a solution of MeMgBr (3.0 M, 185 mL, 549 mmol, 3.5 equiv) in ether was slowly 
added via syringe. After 1 h at –78 oC, the solution was warmed to rt, and stirred 
overnight; during this time, the solution became cloudy and subsequently cleared and 
white crystals formed. The solution was then slowly poured into a solution of saturated 
aqueous NH4Cl (500 mL), which was previously chilled in an ice bath. The upper organic 
phase was then washed with brine (250 mL). After drying over MgSO4 and filtering, the 
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solution was carefully concentrated with a rotary evaporator, using a cold water bath to 
minimize the loss of the volatile product. The product was distilled under vacuum, 
collecting the fraction boiling between 20 oC – 23 oC at 1.3 mm Hg. A colorless oil was 
obtained (15.8 g, 62 %). 300 MHz 1H NMR (CDCl3) δ 5.01 (d, J = 1.5 Hz, 1H), 4.76 (d, J 
= 1.2 Hz, 1H), 3.98 (d, J = 1.2 Hz, 2H), 1.70 (d, J = 0.9 Hz, 2H), 0.05 (s, 9H); 75 MHz 
13C NMR (CDCl3) δ 143.2, 112.5, 50.1, 23.8, –1.3.  
 Preparation of trimethyl(2-((tributylstannyl)methyl)allyl)silane 
(1.7): A 50 mL single necked flask was fitted with a stir bar and rubber septum. A 
solution of LDA was prepared by first adding THF (7.0 mL), and diisopropylamine (1.0 
mL 7.1 mmol, 1.2 equiv) to the flask, chilling to 0 oC, and finally adding a solution of n-
BuLi (2.5 M, 2.65 mL, 6.6 mmol, 1.1 equiv) dropwise with stirring. After stirring for 10 
min, Bu3SnH (1.62 mL, 6.1 mmol, 1.0 equiv) was added, turning the solution to a milky 
yellow color. At this point, the Teflon stir bar turned to a black color. The solution was 
chilled to –78 oC after stirring at rt for 30 min, and 2-(chloromethyl)allyl)trimethylsilane 
1.97 (1.00 g, 6.20 mmol, 1.02 equiv) was added via cannula, followed by THF (2.0 mL) 
to rinse the cannula. The reaction mixture was stirred overnight after warming to rt. The 
solution was poured into ice water (25 mL), extracted with Et2O (3 × 25 mL), washed 
with brine (25 mL), and dried over MgSO4. After filtering and concentrating, the product 
was distilled using a Kugelrohr apparatus at 1.5 mmHg. The fraction boiling between 125 –	  140 oC oven temperature was collected as a light yellow oil (2.26 g, 87 %). 300 MHz 
1H NMR (CDCl3) δ 4.24–4.36 (m, 1H), 4.26–4.19 (m, 1H), 1.74 (s, 2H), 1.57–1.44 (m, 
7H), 1.44 (s, 2H), 1.32 (sextet, J = 7.5 Hz, 9H), 0.91 (t, J = 7.5 Hz, 16H), 0.06 (s, 9H); 75 
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MHz 13C NMR (CDCl3) δ 147.7, 103.1, 29.4, 27.6, 21.9, 14.0, 9.7, 9.0, –1.1. 
 Preparation of (4S,6S)-8-((tert-butyldiphenylsilyl)oxy)-6-
((4-methoxybenzyl)oxy)-2-((trimethylsilyl)methyl)oct-1-en-4-ol (1.15): A solution of 
aldehyde 1.57 (9.50 g, 19.3 mmol, 1.0 equiv) was prepared in CH2Cl2 (200 mL) in a 500 
mL flask under N2. After cooling to –78 oC, MgBr2•Et2O (9.96 g, 38.6 mmol, 2.0 equiv) 
was added in one portion. The resulting yellow solution was stirred for 15 min at –78 oC. 
Freshly distilled stannane 1.7 (9.66 g, 23.2 mmol, 1.2 equiv) was added dropwise via 
syringe to the reaction mixture, and the reaction was complete by TLC after 40 min of 
stirring. The reaction mixture was first quenched with a solution of saturated aqueous 
NaHCO3 (83 mL) and then water (412 mL) was added. The organic phase was separated 
and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were washed with brine (200 mL) and dried over MgSO4. After filtration, the 
solution was concentrated to obtain a clear oil that was purified via column 
chromatography on a 6 × 30 cm silica gel column eluting with 5 % EtOAc/hexanes. 
Three columns were required to remove all tin compounds and impurities with very 
similar Rf values to obtain the product as a clear oil (7.9 g, 66 %). Rf = 0.43 (25 % 
EtOAc/hexanes). 300 MHz 1H NMR (CDCl3) δ 7.71–7.66 (m, 4H), 7.49–7.39 (m, 6H), 
7.22 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.67 (dd, J = 6.9, 2.1 Hz, 2H), 4.49 (s, 
2H), 4.05–3.95 (m, 2H), 3.85–3.71 (m, 1H), 3.81 (s, 3H), 2.69 (d, J = 2.1 Hz, 1H), 2.18–
2.02 (m, 2H), 2.01–1.87 (m, 1H), 1.80 (quint, J = 6.3 Hz, 2H), 1.66 (ddd, J = 8.4, 8.4, 3.9 
Hz, 2H), 1.55 (d, J = 2.4 Hz, 2H), 1.29 (d, J = 3.0 Hz, 2H), 1.08 (s, 9H), 0.04 (s, 9H); 75 
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MHz 13C NMR (CDCl3) δ 159.4, 144.8, 135.8, 134.0, 130.8, 129.8, 129.8, 127.9, 114.0, 
110.2, 74.0. 71.6, 66.2, 60.7, 55.5, 46.9, 40.8, 37.2, 27.1, 27.0, 19.4, –1.2.  
             Preparation of (3R)-ethyl 3-((tert-
butyldimethylsilyl)oxy)-4-((2R)-6-((S)-4-((tert-butyldiphenylsilyl)oxy)-2-((4-
methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)butanoate (1.62): 
A solution of hydroxyallylsilane 1.15 (5.40 g, 8.9 mmol, 1.0 equiv) and aldehyde 1.61 
provided by Kevin McGowan (2.70 g, 9.85 mmol, 1.1 equiv) was prepared in Et2O (90 
mL) in a 250 mL flask equipped with a stir bar and septum. After cooling to –78 oC, a 
solution of TMSOTf in Et2O (1.04 M, 10.3 mL, 10.7 mmol, 1.2 equiv) was added 
dropwise. The reaction was complete after 25 min based on TLC; i-Pr2NEt (10 mL) was 
added to quench the reaction mixture at –78 oC. After 5 min, the flask was transferred to 
a 0 oC bath and a solution of saturated aqueous NaHCO3 (50 mL) was added. After 20 
min, the organic phase was separated, and the aqueous phase was extracted with Et2O (3 
× 50 mL). After drying over MgSO4, and filtering, the solution was concentrated. The 
product was purified via flash chromatography using a 5 × 20 cm column of silica gel, 
eluting with 5 % EtOAc/hexanes, collecting 30 mL fractions. Fractions 17–32 contained 
pure product, and fractions 33–47 had to be re-purified via column chromatography. A 
light yellow oil (6.25 g, 89 %) was obtained upon concentration of the pure fractions. Rf 
= 0.63 (25 % EtOAc/hexanes). 300 MHz 1H NMR (CDCl3) δ 7.72–7.66 (m, 4H), 7.48–
7.35 (m, 6H), 7.18 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 4.71 (d, J = 4.8 Hz, 2H), 
4.42 (ABq, J = 10.8 Hz, Δν = 15.7 Hz, 2H), 4.38–4.33 (m, 1H), 4.14–3.97 (m, 2H), 3.92–
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3.83 (m, 1H), 3.82–3.77 (m, 2H), 3.79 (s, 3H), 3.58–3.38 (m, 2H), 2.52 (d, J = 3.3 Hz, 
1H), 2.50 (d, J = 1.2 Hz, 1H), 2.24 (d, J = 12.6 Hz, 1H), 2.16 (d, J = 12.9 Hz, 1H), 1.93 
(q, J = 12.9 Hz, 2H), 1.89–1.77 (m, 3H), 1.70–1.61 (m, 3H), 1.18 (t, J = 7.2 Hz, 3H), 1.07 
(s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 75 MHz 13C NMR (CDCl3) δ 171.9, 
159.2, 144.8, 135.8, 134.1, 134.0, 131.2, 129.8, 129.6, 129.7, 113.9, 108.7, 75.1, 75.0, 
73.0, 71.8, 66.9, 60.7, 60.5, 55.5, 44.0, 42.8, 42.5, 41.3, 41.3, 37.8, 27.1, 26.0, 19.4, 18.2, 
14.3, –4.2, –4.3.  
 Preparation of ethyl (R)-3-hydroxy-4-((2R,6S)-6-((S)-
4-hydroxy-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-pyran-2-
yl)butanoate (1.97): To a 50 mL polyethylene vial was added 1.62 (914 mg, 1.16 mmol, 
1.0 equiv), followed by 9:1 THF/ pyridine (11.6 mL 0.1 M). To the stirring solution, 20% 
HF•Pyr (29 mL, 25 mL/ mmole) was added. After stirring for 6 h, the reaction mixture 
was quenched by pipetting the solution into a stirring solution of saturated aqueous 
NaHCO3 (300 mL). After the effervesence subsided, the solution was extracted with 
EtOAc (3 × 50 mL), washed with brine (100 mL), dried over Na2SO4, filtered, and 
concentrated. The product was purified on a 3 × 15 cm silica gel column, eluting with a 
gradient of 25 –	  100% EtOAc/ hexanes, collecting 10 mL fractions. Fractions 40–76 were 
concentrated to yield the product (448 mg, 89%) as a clear oil. Rf = 0.14  (50% 
EtOAc/hexanes); [ ] =20Dα  +38.2o (c = 1.70, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.28 
(d, J = 8.0 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 4.73 (s, 2H), 4.49 (ABq, J = 11.5 Hz, Δν = 
43.0 Hz, 2H), 4.27–4.20 (m, 1H), 4.15 (q, J = 6.5 Hz, 2H), 3.80 (s, 3H), 3.80–3.74 (m, 
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2H), 3.71–3.66 (m, 2H), 3.54–3.46 (m, 2H), 2.52 (dd, J = 15.5, 7.5 Hz, 1H), 2.44 (dd, J = 
15.5, 5.5 Hz, 1H), 2.23 (d, J = 13 Hz, 1H), 2.19 (d, J = 13 Hz, 1H), 1.97 (q, J = 11.5 Hz, 
2H), 1.90–1.83 (m, 1H), 1.78–1.65 (m, 5H), 1.26 (t, J = 6.5 Hz, 3H); 125 MHz 13C NMR 
(CDCl3) δ 172.0, 159.4, 143.6, 130.5, 129.8, 114.0, 109.3, 78.2, 75.6, 74.1, 71.5, 67.6, 
60.6, 59.7, 55.3, 42.4, 42.0, 41.8, 41.4, 41.0, 40.9, 36.6, 14.3; 125 MHz DEPT (CDCl3) 
CH3 δ 55.3, 14.3; CH2 δ 109.2, 71.5, 60.6, 59.7, 42.4, 41.8, 41.4, 41.0, 40.9, 36.6; CH δ 
129.8, 114.0, 78.2, 75.6, 74.1, 67.6; C δ 172.0, 159.4, 143.6, 130.5; IR (neat) 3448, 3073, 
2939, 1733, 1653, 1613, 1586, 1514, 1465, 1421, 1372, 1328, 1302, 1248, 1176, 1086, 
1035, 892, 822 cm-1; HRMS (ESI) calcd 459.2359 for  (M+Na), found 459.2367. 
 Preparation of (R)-ethyl 4-((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-3-hydroxybutanoate (1.63): To a stirring solution of diol 1.97 (441 mg, 
1.01 mmol, 1.0 equiv) and DMAP (43 mg, 0.35 mmol, 0.35 equiv) in CH2Cl2 (10.1 mL, 
0.1 M) in a 25 mL flask under N2 was added i-Pr2NEt (350 µL, 2.0 mmol, 2.0 equiv). 
TBDPSCl (260 µL, 1.0 mmol, 1.0 equiv) was then added dropwise. After stirring 
overnight, the reaction mixture was quenched by the addition of saturated aqueous 
NaHCO3 solution (25 mL). The mixture was extracted with CH2Cl2 (3 × 25 mL), washed 
with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The crude product was 
purified on a 3 × 15 cm silica gel column, eluting with a gradient of 5 –	  25% EtOAc/ 
hexanes, collecting 10 mL fractions. Fractions 6–82 were combined and concentrated to 
yield the product (597 mg, 88%) as a clear oil. Rf = 0.30 (25 % EtOAc/hexanes). 500 
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MHz 1H NMR (CDCl3) δ 7.73–7.64 (m, 4H), 7.47–7.35 (m, 6H), 7.22 (d, J = 8.5 Hz, 
2H), 6.87 (d, J = 7.5 Hz, 2H), 4.74 (d, J = 9.5 Hz, 2H), 4.42 (ABq, J = 11.5 Hz, Δν = 
40.2 Hz, 2H), 4.31–4.22 (m, 1H), 4.16 (ddd, J = 7.5, 7.5, 2.5 Hz, 2H), 3.81 (s, 3H), 3.84–
3.75 (m, 4H), 3.59–3.49 (m, 2H), 2.55 (dd, J = 15.5, 7.5 Hz, 1H), 2.47 (dd, J = 15.5, 5.5 
Hz, 1H), 2.25 (d, J = 12.5 Hz, 1H), 2.19 (d, J = 13 Hz, 1H), 2.01 (t, J = 12 Hz, 1H), 1.95 
(t, J = 12 Hz, 1H), 1.88–1.62 (m, 6H), 1.26 (t, J = 7.5 Hz, 3H), 1.09 (s, 9H); 125 MHz 
13C NMR (CDCl3) δ 172.1, 159.2, 143.9, 135.8, 134.0, 131.0, 129.8, 129.7, 127.8, 113.9, 
109.2, 78.3, 75.4, 72.6, 71.5, 67.8, 60.6, 60.5, 55.4, 42.5, 42.1, 41.9, 37.4, 27.0, 19.3, 
14.3. 
 Preparation of (R)-ethyl 4-((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-3-((trimethylsilyl)oxy)butanoate (1.64): A solution of ethyl ester 1.63 (274 
mg, 0.42 mmol, 1.0 equiv) was prepared in CH2Cl2 (7.0 mL) in a 100 mL flask. Et3N 
(180 µL, 1.3 mmol, 3.0 equiv) and TMSCl (80 µL, 0.64 mmol, 1.5 equiv) were then 
added. After stirring for 3 h, the reaction mixture was quenched by the addition of 
saturated aqueous NaHCO3 solution (10 mL). The aqueous phase was then extracted with 
CH2Cl2 (3 × 10mL). The combined organic layers were washed with brine (10 mL), the 
organic phase was dried over MgSO4, filtered, and concentrated. The resulting oil was 
purified on a 3 × 10 cm silica gel column with 10 % EtOAc/hexanes, collecting 5 mL 
fractions. Fractions 4–12 were combined and concentrated to yield the product (317 mg, 
96 %) as a colorless oil. Rf = 0.53 (25 % EtOAc/ hexanes). 500 MHz 1H NMR (CDCl3) δ 
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7.73–7.65 (m, 4H), 7.48–7.36 (m, 6H), 7.17 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 
4.71 (d, J = 11.0 Hz, 2H), 4.41 (ABq, J = 10.5 Hz, Δν = 27.7 Hz, 2H), 4.39-4.33 (m, 1H), 
4.16–4.02 (m, 2H), 3.91–3.85 (m, 1H), 3.84–3.75 (m, 2H), 3.80 (s, 3H), 3.55-3.47 (m, 
1H), 3.43–3.36 (m, 1H), 2.50 (d, J = 7.0 Hz, 1H), 2.48 (s, 1H), 2.26 (d, J = 13.5 Hz, 1H), 
2.17 (d, J = 13 Hz, 1H), 1.93 (q, J = 13 Hz, 1H), 1.88–1.79 (m, 3H), 1.69–1.61 (m, 3H), 
1.20 (t, J = 7.5 Hz, 3H), 1.06 (s, 9H), 0.11 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 171.7, 
159.2, 144.7, 135.8, 134.1, 131.2, 129.7, 129.5, 127.8, 113.9, 108.7, 75.1, 72.8, 71.7, 
66.8, 60.7, 60.4, 55.4, 44.2, 43.0, 42.4, 41.3, 41.1, 37.8, 27.1, 19.3, 14.4, 0.50.  
 Preparation of (S)-1-((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-4-((trimethylsilyl)methyl)pent-4-en-2-ol (1.42): A 10 mL flask was 
equipped with a magnetic stir bar, and CeCl3•7H2O (674 mg, 1.81 mmol, 10.0 equiv) was 
added. The flask was heated with stirring at 170 oC at 0.05 mm Hg for 16 h. The resulting 
anhydrous CeCl3 was cooled under vacuum, and subsequently stirred with THF (1.5 mL) 
for 2 h. Meanwhile, a 25 mL 2-neck flask was connected to a reflux condenser and the 
condenser was connected to a vacuum adaptor. A stir bar and magnesium turnings (125 
mg, 5.14 mmol, 28.4 equiv) were added and the second neck was closed with a rubber 
septum. The flask was flame dried under vacuum; after cooling and admitting N2, an 
iodine crystal was added and the flask was heated until purple vapors appeared. THF (4.6 
mL) was added and the mixture was heated to reflux. TMSCH2Cl, (400 µL, 2.87 mmol, 
15.9 equiv) was added dropwise. The solution soon became colorless and then darker 
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after refluxing for 1.5 h, indicating Grignard reagent formation. The concentration of the 
solution was estimated to be 1.8 M based on the amount of TMSCH2Cl used. The slurry 
of CeCl3 was chilled to –78 oC and the Grignard reagent (1.80 mL, 1.8 mmol, 10 equiv) 
was added dropwise to the CeCl3 slurry. After stirring for 1 h at –78 oC, TMS ether 1.64 
(135 mg, 0.18 mmol, 1.0 equiv) in THF (0.5 mL) was added. The solution was allowed to 
warm up to rt after stirring for 2 h at –78 oC. After stirring overnight, the solution was 
diluted with THF (10 mL), chilled to –78 oC, and aqueous 1.0 M HCl was added five 
drops at a time until the spot with Rf = 0.63 via TLC was the predominant product. The 
mixture was then quenched by the addition of saturated aqueous Rochelle salt solution 
(10 mL), and stirred for 1 h. The resulting solution was extracted with CH2Cl2 (3 × 10 
mL). The organic phase was washed with brine (10 mL) and dried over MgSO4. After 
filtration and concentration, the crude product was purified on a 3 × 10 cm silica gel 
column, eluting with 5 % EtOAc/hexanes, collecting 5 mL fractions. Fractions 9–38 
contained the product (62 mg, 48 %). Rf = 0.63 (30 % EtOAc/hexanes). 500 MHz 1H 
NMR (CDCl3) δ 7.74–7.69 (m, 4H), 7.48–7.39 (m, 6H), 7.23 (d, J = 8.5 Hz, 2H), 6.87 (d, 
J = 8.0 Hz, 2H), 4.74 (d, J = 9.0 Hz, 2H), 4.69 (d, J = 16.5 Hz, 2H), 4.45 (ABq, J = 11 
Hz, Δν = 30.1 Hz, 2H), 4.04–3.98 (m, 1H), 3.81 (s, 3H), 3.85–3.77 (m, 3H), 3.62–3.52 
(m, 3H), 2.26 (d, J = 13.5 Hz, 1H), 2.25 (d, J = 13.5 Hz, 1H), 2.20 (d, J = 13 Hz, 1H), 
2.10 (dd, J = 14, 6.0 Hz, 1H) 2.05–1.94 (m, 2H), 1.84 (q, J = 6.5 Hz, 2H), 1.77–1.64 (m, 
4H), 1.60 (s, 2H), 1.10 (s, 9H), 0.07 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 159.2, 144.6, 
144.1, 135.8, 134.0, 134.0, 131.1, 129.7, 129.6, 127.8, 113.9, 110.0, 109.0, 79.3, 75.5, 




Synthetic Procedures for Protected DAG Lactone 1.77 
 Preparation of Ethyl 2-(hydroxymethyl)acrylate (1.84): A 3-neck 
250 mL flask was equipped with a large magnetic stir bar and a reflux condenser. Water 
(40 mL), paraformaldehyde (17.2 g, 573 mmol, 4.2 equiv), and aqueous H3PO4 (1.0 M, 
1.53 mL, 1.53 mmol, 0.01 equiv) were added. The mixture was heated at reflux for 2.5 h 
at which time most of the solids had dissolved. After cooling to rt, triethyl 
phosphonoacetate 17 (27.0 mL, 136 mmol, 1.0 equiv) was added. The solution was 
stirred for 5 min, before a solution of K2CO3 (20.7 g, 150 mmol, 1.1 equiv) in water (22 
mL) was added dropwise, keeping the temperature between 35 oC and 40 oC by 
immersing the flask in a tepid water bath. After an additional 5 min of stirring, the 
mixture was placed in a 0 oC bath and then diluted with Et2O (40 mL) and brine (40 mL). 
The biphasic solution was separated, and the aqueous phase was extracted with Et2O (3 × 
40 mL). The combined organic phases were washed with brine (2 × 50 mL) and dried 
over MgSO4. After filtering and concentrating, the resulting liquid was distilled at 0.6 
mmHg, collecting the fraction boiling between 49 oC – 88 oC as a clear liquid, (13.2 g, 
74%). The product was immediately used in the next step. 300 MHz 1H NMR (CDCl3) δ 
6.17 (q, J = 1.2 Hz, 1H), 5.77 (q, J = 1.2 Hz, 1H), 4.22 (d, J = 6.0 Hz, 2H), 4.14 (q, J = 
7.2 Hz, 2H), 3.36 (t, J = 6.3 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H); 75 MHz 13C NMR (CDCl3) 
δ 166.3, 139.7, 125.1, 61.8, 60.8, 14.1. 
 Preparation of Ethyl 2-((trityloxy)methyl)acrylate (1.82): 
Acrylate ester 1.84, (11.4 g, 88 mmol, 1.0 equiv), CH2Cl2 (137 mL, 0.64 M), and 
pyridine (8.80 mL, 114 mmol, 1.3 equiv) were combined in a 500 mL flask fitted with a 
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stir bar and rubber septum under N2. After cooling to 0 oC, trityl chloride (26.6 g, 95 
mmol, 1.1 equiv) was added. The flask was removed from the ice bath and stirred 
overnight at rt. After quenching by the addition of saturated aqueous NH4Cl solution (150 
mL), the mixture was extracted with CH2Cl2 (3 × 30 mL), and the combined organic 
layers were washed with brine (100 mL). The organic phase was then dried over MgSO4, 
filtered, and concentrated to yield a yellow crystalline solid, which was recrystallized 
from a minimum amount of boiling EtOH to yield the product (31.2 g, 97 %) as an off-
white colored crystalline material. Rf = 0.59  (50 % EtOAc/hexanes); mp: 94 – 96 oC; 
300 MHz 1H NMR (CDCl3) δ 7.48–7.42 (m, 6H), 7.34–7.20 (m, 9H), 6.35 (d, J = 1.8 Hz, 
1H), 6.21 (d, J = 1.8 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.87 (s, 2H), 1.24 (t, J = 7.2 Hz, 
3H); 75 MHz 13C NMR (CDCl3) δ 166.0, 144.1, 138.1, 128.8, 128.1, 127.3, 124.6, 87.3, 
62.4, 60.8, 14.3.   
 Preparation of 2-((trityloxy)methyl)prop-2-en-1-ol (1.81): A 
solution of acrylate ester 1.82 (9.0 g, 24 mmol, 1.0 equiv) was prepared in CH2Cl2 (100 
mL) in a 250 mL flask and chilled to –78 oC under an atmosphere of N2. DIBAL-H (1.0 
M, 73 mL, 73 mmol, 3.0 equiv) was added via syringe. After stirring at –78 oC for 1 h, 
the mixture was quenched by the slow addition of MeOH (1.0 mL), followed by pouring 
into a saturated aqueous Rochelle’s salt solution (100 mL) in a 1000 mL Erlenmeyer 
flask. The solution was filtered through a 6 × 3 cm Celite™ after 3 h of stirring. The 
mixture was extracted with CH2Cl2 (3 × 100 mL). The organic phase was washed with 
brine (100 mL), dried over MgSO4, filtered, and concentrated. The product was purified 
on a 5 × 10 cm silica gel column, eluting with 10 % EtOAc/hexanes, collecting 30 mL 
fractions. After concentrating fractions 28–	  56, a white crystalline solid was obtained (6.8 
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g, 85 %). Rf = 0.31 (25 % EtOAc/hexanes); mp: 78 – 80 oC; 300 MHz 1H NMR (CDCl3) 
δ 7.47–7.42 (m, 6H), 7.34–7.20 (m, 9H), 5.26 (d, J = 0.9 Hz, 1H), 5.17 (d, J = 1.2 Hz, 
1H), 4.13 (d, J = 6.3 Hz, 2H), 3.70 (s, 2H), 1.75 (t, J = 6.3 Hz, 1H); 75 MHz 13C NMR 
(CDCl3) δ 145.9, 144.1, 128.8, 128.1, 127.3, 112.2, 87.3, 65.6, 65.0. 
 Preparation of (S)-(2-((trityloxy)methyl)oxiran-2-yl)methanol (1.85):   
A 50 mL flask was equipped with a stir bar and 4Å molecular sieves (7.2 g). The flask 
was chilled to –20 oC after adding CH2Cl2 (12 mL). L-(+)-diethyl tartarte (1.0 M in 
CH2Cl2, 1.74 mL, 1.74 mmol, 0.12 equiv), and Ti(i-OPr)4 (1.0 M in CH2Cl2 , 1.45 mL, 
1.45 mmol, 0.10 equiv) were added via syringe. After stirring for 10 min, t-BuOOH in 
decane (5.5 M, 5.3 mL, 29 mmol, 2.0 equiv) was added. After stirring for 0.5 h, a 
solution of allylic alcohol 1.81 (4.80 g, 14.5 mmol, 1.0 equiv) in CH2Cl2 (12 mL) was 
added. The mixture was stirred overnight in a –20 oC freezer after which time no more 
conversion to product was noted via TLC. The mixture was warmed to 0 oC, H2O (4.0 
mL) was added, and the mixture was stirred for 1 h. Brine (2.0 mL) and aqueous NaOH 
solution (50 %, 1.0 mL) were added and the mixture was stirred for an additional h. The 
mixture was diluted with CHCl3 (25 mL) and H2O (25 mL) and filtered through a 6 × 4 
cm bed of Celite™. The organic phase was separated and the aqueous phase was 
extracted with CHCl3 (3 × 50 mL). The combined organic phases were washed with brine 
(100 mL), dried over MgSO4, filtered, and concentrated. The product was purified on a 3 
× 15 cm silica gel column, eluting with 10 % EtOAc/hexanes, collecting 30 mL fractions. 
Fractions 30–64 were combined and concentrated to yield a white crystalline solid (3.6 g, 
72 %). Rf = 0.45 (50 % EtOAc/hexanes); mp: 120–122 oC; EtOAc/hexanes); [ ] =20Dα  –16 
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(c = 1.3, CHCl3); 300 MHz 1H NMR (CDCl3) δ 7.43 (d, J = 8.1 Hz, 6H), 7.32–7.16 (m, 
9H), 3.79 (ABq, J = 12.3 Hz, Δν = 52 Hz, 2H), 3.27 (t, J = 12.3 Hz, 2H), 2.84 (d, J = 4.8 
Hz, 1H), 2.68 (d, J = 4.5 Hz, 1H), 2.23 (s, 1H); 75 MHz 13C NMR (CDCl3) δ 143.7, 
128.7, 128.0, 127.3, 86.9, 64.5, 62.1, 59.2, 48.9. The enantiomeric excess was determined 
using a 4.6 × 150 mm Chiralcel OD-H column (5.0 % i-PrOH/ hexanes; 0.50 mL/min); tr 
(major) = 13.5 min, tr (minor) = 18.6 min; 90 % ee. 
 Preparation of (S)-2-(((benzyloxy)methoxy)methyl)-2-
((trityloxy)methyl)oxirane (1.80): A solution of epoxy-alcohol 1.85 (2.01 g, 5.80 mmol, 
1.0 equiv) was prepared in CH2Cl2 (58 mL, 0.1 M) in a 100 mL flask equipped with a 
magnetic stir bar. i-Pr2NEt (2.5 mL, 14.5 mmol, 2.5 equiv) was added, followed by 
BOM-Cl (1.80 mL, 13.3 mmol, 2.3 equiv) to the stirring solution. After stirring 
overnight, the mixture was quenched with saturated aqueous NaHCO3 solution (60 mL) 
and extracted with CH2Cl2 (3 × 25 mL). The combined organic phases were washed with 
brine (60 mL), dried over MgSO4, filtered, and concentrated. The product was purified on 
a 5 × 20 cm silica gel column using 10 % EtOAc/hexanes, collecting 30 mL fractions. 
Fractions 18–32 were combined and concentrated, yielding an oil that crystallized upon 
chilling overnight in a –20 oC freezer (2.0 g, 75 %). Rf = 0.47 (25 % EtOAc/hexanes); 
[ ] =20Dα  –8.04 o (c = 3.65, CHCl3); mp: 75 – 86 oC; 300 MHz 1H NMR (CDCl3) δ 7.47–
7.41 (m, 6H), 7.36–7.19 (m, 14H), 4.71 (s, 2H), 4.51 (s, 2H), 3.83 (ABq, J = 11.4 Hz, Δν 
= 9.75 Hz, 2H), 3.29 (q, J = 10.5 Hz, 2H), 2.78 (dd, J = 15, 4.8 Hz, 2H); 75 MHz 13C 
NMR (CDCl3) δ 143.9, 137.8, 128.9, 128.6, 128.2, 128.1, 127.9, 127.3, 94.9, 86.9, 69.6, 
68.0, 64.1, 58.1, 49.4; 125 MHz DEPT (CDCl3) CH3 δ; CH2 δ 94.9, 69.6, 68.0, 64.1, 49.4; 
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CH δ 128.9, 128.6, 128.2, 128.1, 127.9, 127.3; C δ 143.9, 137.8, 86.9, 58.1; IR (neat) 
3060, 3031, 2932, 2880, 1597, 1491, 1449, 1213, 1166, 1104, 1073, 1048, 900, 747, 703, 
631 cm-1; HRMS (ESI) calcd 489.2042 for C31H30O4Na (M+Na), found 489.2047. 
 Preparation of (S)-1-((benzyloxy)methoxy)-2-
((trityloxy)methyl)pent-4-yn-2-ol (1.86): A solution of epoxide 1.80 (2.7 g, 5.8 mmol, 
1.0 equiv) was prepared in DMSO (14 mL) in a 50 mL flask under N2. Lithium acetylide 
ethylenediamine complex (1.34 g, 14.5 mmol, 2.5 equiv) was weighed out in a dry box 
and transferred to the stirring solution of the epoxide. After 2 h, the solution was cooled 
in an ice bath and slowly quenched by the addition of saturated aqueous NH4Cl solution 
(25 mL). The solution was then extracted with CH2Cl2 (3 × 25 mL). The organic phase 
was then dried over MgSO4, filtered, and concentrated. The product was dissolved in the 
minimum amount of CHCl3, and purified on a 5 × 20 cm silica gel column, eluting with 
10 % EtOAc/hexanes, collecting 30 mL fractions. Fractions 10–38 were concentrated, 
yielding the product (2.5 g, 88 %) as a colorless oil. Rf = 0.26, (25 % EtOAc/ hexane); 
[ ] =20Dα  –5.55 o (c = 12.2, CHCl3); 300 MHz 1H NMR (CDCl3) δ 7.47–7.41 (m, 6H), 
7.34–7.20 (m, 14H), 4.72 (s, 2H), 4.53 (s, 2H), 3.73 (ABq, J = 10.2 Hz, Δν = 8.8 Hz, 
2H), 3.24 (s, 2H), 2.74 (s, 1H), 2.60 (d, J = 2.4 Hz, 2H), 1.95 (t, J = 2.4 Hz, 1H); 75 MHz 
13C NMR (CDCl3) δ 143.8, 137.7, 128.9, 128.6, 128.1, 128.0, 128.0, 127.3, 95.3, 86.9, 
80.0, 73.4, 71.3, 71.3, 69.7, 65.4, 25.7; 125 MHz DEPT (CDCl3) CH3 δ; CH2 δ 95.4, 71.4, 
69.8, 65.5, 25.8; CH δ 129.0, 128.7, 128.2, 128.1, 128.0, 127.4; C δ 143.8, 137.7, 86.9, 
80.0, 73.4, 71.3; IR (neat) 3556, 3454, 3295, 3060, 3031, 2936, 2881, 2119, 1597, 1492, 
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1449, 1047, 991, 903, 767, 746, 702, 633 cm-1; HRMS (ESI) calcd 515.2198 for 
C33H32O4Na (M+Na), found 515.2202. 
 Preparation of (S)-1-((benzyloxy)methoxy)-2-
((trityloxy)methyl)pent-4-en-2-ol (1.87): A solution of homopropargylic alcohol 1.86 
(1.99 g, 4.0 mmol, 1.0 equiv) was prepared in 50% EtOAc/hexanes (35 mL) in a 100 mL 
3-neck flask. The center neck of the flask was fitted with a valve connected to a balloon 
filled with H2. The other 2 necks were closed with rubber septa. Lindlar’s catalyst 
containing 5 % Pd (0.90 g) and quinoline (0.84 mL, 7.3 mmol, 1.8 equiv) were then 
added and the flask was flushed with H2. The reaction was complete by TLC after 2 h of 
stirring. The mixture was filtered through a 3 × 2 cm bed of Celite™ and concentrated. 
The crude product was purified on a 3 × 20 cm silica gel column, eluting with 10 % 
EtOAc/hexanes, collecting 10 mL fractions. Fractions 12–30 were concentrated, yielding 
the product (1.91 g, 96 %) as a colorless oil. Rf = 0.33 (25 % EtOAc/hexanes); [ ] =20Dα –
2.5o (c = 0.96, CHCl3); 300 MHz 1H NMR (CDCl3) δ 7.46–7.41 (m, 6H), 7.36–7.19 (m, 
14H), 5.72 (dddd, J = 14.7, 9.9, 7.2, 7.2 Hz, 1H), 5.08–5.02 (m, 1H), 5.02–4.95 (m, 1H), 
4.72 (s, 2H), 4.53 (s, 2H), 3.65 (ABq, J = 9.9 Hz, Δν = 33.7 Hz, 2H), 3.12 (s, 2H), 2.58 
(s, 1H), 2.38 (d, J = 7.2 Hz, 2H); 75 MHz 13C NMR (CDCl3) δ 143.9, 137.7, 133.2, 
128.9, 128.7, 128.1, 128.0, 127.3, 118.7, 95.4, 86.8, 73.6, 72.2, 69.7, 65.7, 39.6; 125 
MHz DEPT (CDCl3) CH3 δ; CH2 δ 118.7, 95.4, 72.2. 69.7, 65.7, 39.6; CH δ 133.2, 128.9, 
128.7, 128.1, 128.0, 127.3; C δ 143.9, 137.7, 86.8, 73.6; IR (neat) 3563, 3456, 3062, 
3030, 2935, 2880, 1641, 1597, 1492, 1449, 1046, 701 cm-1; HRMS (ESI) calcd 517.2355 
for C33H34O4Na (M+Na), found 517.2350. 
	  	  
79	  
 Preparation of (S)-5-((benzyloxy)methoxy)-4-
((trityloxy)methyl)pentane-1,4-diol (1.88): A solution of homoallylic alcohol 1.87 (1.91 
g, 3.86 mmol, 1.0 equiv) was prepared in THF (19 mL) in a 100 mL flask under N2 with 
stirring. A solution of 9-BBN (0.5 M, 19.0 mL, 11.6 mmol, 3.0 equiv) was added and the 
mixture was stirred for 15 min. The mixture was then placed in an ultrasonic bath for 1 h, 
after which time no further conversion to product was noticeable via TLC. The mixture 
was chilled in an ice bath and aqueous NaOH (2.0 M, 10 mL) was carefully added. 
Aqueous H2O2 (30%, 5.0 mL) was then carefully added in small portions to prevent loss 
of the reaction mixture due to the exothermic nature of the oxidation of the organoborane. 
After stirring for 1 h at rt, the mixture was extracted with EtOAc (3 × 30 mL) and then 
washed with brine (50 mL). The organic phase was then dried over MgSO4, filtered, and 
concentrated. The product was then purified on a 5 × 20 cm silica gel column, eluting 
with a 10–35 % gradient of EtOAc/ hexanes, collecting 10 mL fractions. Fractions 96–
120 were combined and concentrated to yield the product (1.61 g, 81 %) as a viscous oil. 
Rf = 0.28 (25 % EtOAc/hexanes); [ ] =20Dα  –2.2o (c = 2.1, CHCl3); 300 MHz 1H NMR 
(CDCl3) δ 7.44–7.41 (m, 6H), 7.32–7.21 (m, 14H), 4.72 (s, 2H), 4.53 (s, 2H) 3.69 (ABq, 
J = 9.9 Hz, Δν = 46.5 Hz, 2H), 3.69 (t, J = 6.0 Hz, 2H), 3.14 (dd, J = 12.9, 8.5 Hz, 2H), 
2.96 (s, 1H), 2.19 (s, 1H), 1.70–1.61 (m, 2H), 1.53–1.45 (m, 2H); 75 MHz 13C NMR 
(CDCl3) δ 143.9, 137.7, 128.9, 128.7, 128.1, 128.0, 128.0, 127.3, 95.5, 86.8, 73.6, 72.4, 
69.8, 65.4, 63.4, 31.5, 26.2; 125 MHz DEPT (CDCl3) CH3 δ; CH2 δ 95.5, 72.4, 69.8, 65.4, 
63.4, 31.5, 26.2; CH δ 129.0, 128.7, 128.1, 128.1, 128.0, 127.3; C δ 143.9, 137.7, 86.8, 
73.6; IR (neat) 3387, 3086, 3060, 2934, 2878, 1597, 1491, 1449, 1049, 746, 701 cm-1; 
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HRMS (ESI) calcd 535.2498 for C33H36O5Na (M+Na), found 535.2450. 
 Preparation of (S)-5-(((benzyloxy)methoxy)methyl)-5-
((trityloxy)methyl)dihydrofuran-2(3H)-one (1.89): A solution of diol 1.88 (1.32 g 2.58 
mmol, 1.0 equiv) was prepared in CH2Cl2 (26 mL) in a 100 mL flask fitted with a 
magnetic stir bar and septum under N2. After chilling to 0 oC, i-Pr2NEt (3.20 mL, 18.1 
mmol, 7.0 equiv), and DMSO (1.80 mL, 25.8 mmol, 10.0 equiv) were added to the stirred 
solution. SO3 • Pyr (1.65 g, 10.3 mmol, 4.0 equiv) was added in 4 portions over 20 min. 
After 1 h, the reaction mixture was quenched by the addition of   saturated aqueous 
NaHCO3 solution (50 mL), and extracted with CH2Cl2 (3 × 25 mL). The combined 
organic phases were washed with brine (50 mL), dried over MgSO4, filtered, and 
concentrated to yield a yellow colored oil that was used in the next step without 
purification. 
 A solution of the crude aldehyde from the previous step was prepared in t-BuOH 
(36 mL) in a 250 mL flask, 2-methyl-2-butene (36 mL) was added, along with an 
aqueous solution of KH2PO4 (1.25 M, 12.4 mL). After cooling to –10 oC, NaClO2, (80 %, 
1.45 g, 16.1 mmol, 5.0 equiv) was added in 4 portions over 20 min. The reaction mixture 
was then allowed to warm to rt overnight. The reaction mixture was then extracted with 
Et2O (3 × 25 mL), and the combined organic phases were washed with brine (50 mL).  
The organic phase was then dried over MgSO4, filtered, and then concentrated to yield 
the crude carboxylic acid as a viscous yellow oil. The product was then purified on a 2.5 
× 15 cm silica gel column, eluting with 3% MeOH/ CH2Cl2, collecting 10 mL fractions. 
Fractions 22–48 contained a mixture of the carboxylic acid and the desired lactone and 
were concentrated to yield an oil which was used in the subsequent step without 
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characterization (1.08g, 80 %, 2-steps). 
The crude product from the previous step (0.20 g, 0.38 mmol, 1.0 equiv) was 
dissolved in toluene (58 mL, 0.006 M) in a 100 mL flask. DMAP (0.27 g, 2.2 mmol, 6.1 
equiv) was added, followed by the slow addition of benzoyl chloride (60 µL, 0.5 mmol, 
1.3 equiv). The reaction mixture was then quenched with saturated aqueous NaHCO3 
solution (10 mL) after stirring overnight. After separating the organic phase, the aqueous 
phase was extracted with EtOAc (3 × 10 mL). The combined organic phases were 
washed with brine (10 mL) and dried over MgSO4. The mixture was filtered and the 
solvent removed. The product was purified on a 2.5 × 20 cm silica gel column, eluting 
with a gradient from 10 – 75 % EtOAc/hexanes, collecting 5 mL fractions. Fractions 28–
38 were concentrated to yield the product (0.15 g, 79 %) as a viscous oil. Rf = 0.65 (50 % 
EtOAc/ hexanes); [ ] =20Dα  + 6.6 o (c = 4.6, CHCl3); 300 MHz 1H NMR (CDCl3) δ 7.46–
7.39 (m, 6H), 7.36–7.20 (m, 14H), 4.72 (s, 2H), 4.53 (s, 2H), 3.69 (ABq, J = 10.5 Hz, Δν 
= 37.4 Hz, 2H), 3.24 (ABq, J = 9.9 Hz, Δν = 38.3 Hz, 2H), 2.62 (t, J = 8.7 Hz, 2H), 2.15–
1.94 (m, 2H); 75 MHz 13C NMR (CDCl3) δ 177.1, 143.3, 137.5, 128.6, 128.4, 128.0, 
127.9, 127.8, 127.2, 94.7, 87.0, 86.4, 70.5, 69.6, 66.2, 29.1, 26.5; 125 MHz DEPT 
(CDCl3) CH3 δ; CH2 δ 94.7, 70.5, 69.6, 66.2, 29.1, 26.5; CH δ 128.6, 128.4, 128.0, 127.9, 
127.8, 127.2; C δ 177.1, 143.3, 137.5, 87.0, 86.4; IR (neat) 3060, 3031, 2938, 2879, 
1779, 1597, 1492, 1450, 1414, 1381, 1048, 747, 704, 634 cm-1; HRMS (ESI) calcd 
531.2147 for  C33H32O5Na (M+Na), found 531.2148. 
 Preparation of Ethyl (5S)-5-(((benzyloxy)methoxy)methyl)-2-
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oxo-5-((trityloxy)methyl)tetrahydrofuran-3-carboxylate (1.90): To a 500 mL flask 
containing 60% NaH (6.84 g, 171 mmol, 9.0 equiv), and a stir bar  under N2 was slowly 
added EtOH (190 mL, 0.1 M) at 0 oC. After 20 min, the ice bath was removed and diethyl 
malonate (29 mL, 190 mmol, 10.0 equiv) was added. After stirring for 30 min at rt, a 
solution of epoxide 1.80 (8.90 g, 19.0 mmol, 1.0 equiv) in THF (30 mL) was added via 
cannula, THF (20 mL) was used to complete the transfer. After stirring for 8 days at rt, 
the reaction was quenched with saturated aqueous NH4Cl solution (250 mL), and diluted 
with H2O (200 mL). The solution was then extracted with 50% EtOAc/ hexanes (3 × 100 
mL), washed with brine (2 × 100 mL), dried over Na2SO4, filtered, and concentrated. The 
crude product was then purified on a 5 × 20 cm silica gel column, eluting with 15 % 
EtOAc/ hexanes, collecting 30 mL fractions. Fractions 18–82 contained the product as 
well as diethyl malonate. The product was heated under high vacuum to remove the 
remaing diethyl malonate, yielding the product as a mixture of two diastereomers (9.87 g, 
89%). Used without characterization. 
 Preparation of (S)-5-(((benzyloxy)methoxy)methyl)-5-
((trityloxy)methyl)dihydrofuran-2(3H)-one (1.89): A solution of diester 1.90 (3.0 g, 
5.2 mmol, 1.0 equiv) was prepared in EtOH (52 mL, 0.1 M) in a 100 mL flask. To the 
stirred solution, aqueous NaOH (1.0 M, 12.9 mL, 12.9 mmol, 2.5 equiv) was added. After 
stirring for 24 h, the solution was concentrated and then quenched with a solution of 
AcOH (2.0 mL) in brine (50 mL). The solution was then extracted with EtOAc (3 × 25 
mL), washed with brine (50 mL), dried over Na2SO4, filtered, and then concentrated and 
evaporated with toluene to remove any remaining AcOH. The crude carboxylic acid was 
used as is (2.82 g, 99%) 
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To a stirring solution of the previously produced carboxylic acid  (2.82g, 5.1 
mmol, 1.0 equiv) in toluene (102 mL, 0.05 M) in a 250 mL flask was added quinoline 
(730 µL, 6.1 mmol, 1.2 equiv). A reflux condenser was attached and the mixture was 
flushed with N2 and heated at 80 oC overnight. After cooling to rt, the solution was 
washed with aqueous HCl (1.0 M, 2 × 50 mL), saturated aqueous NaHCO3 solution (100 
mL), brine (100 mL), and dried over Na2SO4. After filtration and concentration, the 
product was purified on a 3 × 15 cm silica gel column, eluting with 25% EtOAc/ hexanes, 
collecting 10 mL fractions. Fractions 8–24 were combined and concentrated to yield the 
product (2.33 g, 90%) as a clear oil spectroscopically identical as material produced in 
the preceeding manner. Rf = 0.65 (50 % EtOAc/ hexanes); [ ] =
20
Dα  +6.6 o (c = 4.6, 
CHCl3); 300 MHz 
1H NMR (CDCl3) δ 7.46–7.39 (m, 5H), 7.36–7.20 (m, 15H), 4.72 (s, 
2H), 4.53 (s, 2H), 3.69 (ABq, J = 10.5 Hz, Δν = 37.4 Hz, 2H), 3.24 (ABq, J = 9.9 Hz, Δν 
= 38.3 Hz, 2H), 2.62 (t, J = 8.7 Hz, 2H), 2.15–1.94 (m, 2H); 75 MHz 13C NMR (CDCl3) 
δ 177.1, 143.3, 137.5, 128.6, 128.4, 128.0, 127.9, 127.8, 127.2, 94.7, 87.0, 86.4, 70.5, 
69.6, 66.2, 29.1, 26.5. 
 Preparation of 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (1.97): 
A solution of 1,3-propanediol (18 mL, 250 mmol, 5.0 equiv) and TBSCl (7.54 g, 50 
mmol, 1.0 equiv) in CH2Cl2 (294 mL, 0.17 M) was prepared in a 500 mL flask under N2 
to which was subsequently added DMAP (305 mg, 2.5 mmol, 0.05 equiv), along with 
Et3N (14.0 mL, 100 mmol, 2.0 equiv). The reaction mixture was stirred overnight at rt 
and quenched with a solution of saturated aqueous NaHCO3 (100mL). The aqueous phase 
was extracted with CH2Cl2 (3 × 15 mL), washed with brine (100mL), dried over MgSO4, 
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filtered, and concentrated. The product was purified on a 5 × 20 cm silica gel column, 
eluting with 10 % EtOAc/hexanes, collecting 30 mL fractions. Fractions 12–46 were 
concentrated to give the product (8.4 g, 88%) as a colorless oil. Rf = 0.53 (50% EtOAc/ 
hexanes). 300 MHz 1H NMR (CDCl3) δ 3.86–3.74 (m, 4H), 2.78–2.68 (m, 1H), 1.77 
(quint, J = 5.4 Hz, 2H), 0.89 (s, 9H), 0.08 (s, 6H); 75 MHz 13C NMR (CDCl3) δ 63.1, 
62.6, 34.3, 26.1, 18.4, –5.3. 
 Preparation of 3-((tert-butyldimethylsilyl)oxy)propanal (1.79): To 
a stirring solution of alcohol 1.97 (4.24 g, 22.3 mmol, 1.0 equiv) in CH2Cl2 (223 mL, 0.1 
M) contained in a 500 mL flask under N2 at 0 oC was added i-Pr2NEt (27 mL, 156 mmol, 
7.0 equiv), followed by DMSO (15.8 mL, 223 mmol, 10.0 equiv) After stirring for 10 
min, SO3 • Pyr (14.2 g, 89 mmol, 4.0 equiv) was added in 4 equal portions 5 min apart 
over 20 min. After stirring for 1 h at 0 oC, the reaction mixture was quenched with 
saturated aqueous NaHCO3 solution (150 mL). The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 × 25 mL).  The combined organic phase was 
washed with brine (250 mL), dried over Na2SO4, filtered, and concentrated. The product 
was purified on a 4 × 10 cm silica gel column, eluting with 10 % EtOAc/ hexanes, 
collecting 30 mL fractions. Fractions 6–10 were concentrated to yield the product (3.7 g, 
89 %) as a light yellow oil. Rf = 0.59 (25% EtOAc/hexanes). 300 MHz 1H NMR (CDCl3) 
δ 9.80 (t, J = 2.1 Hz, 1H), 3.99 (t, J = 6.0 Hz, 2H), 2.60 (dt, J = 6.3, 2.1 Hz, 2H), 0.88 (s, 
9H), 0.07 (s, 6H); 75 MHz 13C NMR (CDCl3) δ 202.3, 57.6, 46.8, 26.0, 18.4, –5.3.  




2(3H)-one (1.77): A 1.0 M solution of LDA in THF was prepared by adding i-Pr2NH, 
(0.77 mL, 5.5 mmol, 1.1 equiv) to a 5.0 mL volumetric flask under N2.The solution was  
chilled to –78 oC, and  n-BuLi ( 2.5 M, 2.0 mL, 5.0 mmol, 1.0 equiv) was then added 
dropwise. After 5 min, the mixture was transferred to a 0 oC bath and THF added to make 
5 mL of solution. THF (2.0 mL) was added to a 15 mL flask under N2, which was chilled 
to –78 oC, and the previously prepared solution of LDA (1.0 M, 0.52 mL, 0.52 mmol, 1.1 
equiv) was added. A solution of lactone 1.89 (238 mg, 0.47 mmol, 1.0 equiv) in THF (1.0 
mL) was then added via cannula to the LDA containing solution; the transfer was 
completed with THF (1.7 mL). After stirring for 45 min at –78 oC, a solution of aldehyde 
1.79 (133 mg, 0.71 mmol, 1.5 equiv) in THF (1.0 mL) was added. THF (1.0 mL) was 
used to complete the transfer of the aldehyde containing solution. The reaction mixture 
was stirred for 2 h, allowing the –78 oC bath to expire. The reaction mixture was then 
quenched with saturated aqueous NH4Cl solution (25 mL), extracted with EtOAc (3 × 15 
mL), and washed with brine (50 mL). After drying over Na2SO4, the solution was filtered 
and concentrated. The product was purified on a 2 × 10 cm silica gel column, eluting with 
25% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 6–12 contained the product, 
which was used as is without further characterization. 
The aldol product (326 mg) was taken up in CH2Cl2 (4.7 mL, 0.1 M) contained in 
a 15 mL flask under N2. The stirring solution was cooled to 0 oC. Et3N (200 µL, 1.40 
mmol, 3.0 equiv) was added to the solution, followed by MsCl (68 µL, 0.75 mmol, 1.6 
equiv) After stirring for 10 min, DBU (210 µL, 1.40 mmol, 3.0 equiv) was added 
dropwise. After 15 min, all starting material was consumed via TLC; the reaction mixture 
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was then quenched with a solution of saturated aqueous NaHCO3 (50 mL). After 
extraction with CH2Cl2 (3 × 15 mL), the organic phase was washed with brine (50 mL) 
and dried over Na2SO4. The solution was filtered and concentrated, and the resulting oil 
was purified on a 2 × 15 cm silica gel column, eluting with 10% EtOAc/ hexanes, 
collecting 5.0 mL fractions. Fractions 12–22 contained the desired Z-isomer (150 mg, 
47%) Rf = 0.64 (25% EtOAc/ hexanes); [ ] =20Dα  –1.73 o (c = 1.62, CHCl3);  500 MHz 1H 
NMR (CDCl3) 7.48–7.46 (m, 4H), 7.36–7.32 (m, 14H), 7.20–7.16 (m, 4H), 6.31 (dddd, J 
= 9.0, 4.0, 1.5, 1.5 Hz, 1H), 4.70 (s, 2H), 4.53 (s, 2H) 3.75–3.67 (m, 4H), 3.25 (ABq, J = 
10 Hz, Δν = 61.2 Hz, 2H), 3.06–3.01 (m, 1H), 2.97–2.93 (m, 1H), 2.81 (d, J = 16.5 Hz, 
1H), 2.72 (d, J = 18.5 Hz, 1H), 0.91 (s, 9H), 0.08 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 
169.2, 143.6, 140.4, 137.7, 128.8, 128.8, 128.6, 128.1, 127.9, 127.3, 126.3, 94.9, 87.1, 
83.0, 70.2, 69.7, 65.9, 62.3, 34.1, 31.4, 26.1, 18.6, –5.1; 125 MHz DEPT (CDCl3) CH3 δ 
26.1, –5.1; CH2 δ 94.9, 70.2, 69.7, 65.9, 62.3, 34.1, 31.4; CH δ 140.4, 128.8, 128.6, 
128.1, 127.9, 127.3, 126.3 C δ 169.2, 143.6, 137.7, 128.8, 87.1, 83.0, 18.6; IR (neat) 
3058, 2953, 2928, 2857, 1758, 1491, 1449, 1363, 1256, 1201, 1178, 1095, 1047, 992, 
941, 836, 777, 746, 700, 668, 632 cm-1; HRMS (ESI) calcd 701.3280 for C42H50O6SiNa 
(M+Na), found 701.3284. 
Preparation of (S,Z)-5-(((benzyloxy)methoxy)methyl)-3-
(3-((tert-butyldimethylsilyl)oxy)propylidene)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (1.93): To a stirring solution of 1.77 (80 mg, 0.12 mmol, 1.0 equiv) in CH2Cl2 
(2.4 mL, 0.05 M) at 0 oC was added a TFA/TFAA solution in CH2Cl2 (0.5 M, 720 µL, 
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0.36 mmol, 3.0 equiv) The reaction mixture turned bright yellow and was stirred at 0 oC 
for 45 min. The reaction mixture was quenched with Et3N (0.34 mL, 2.4 mmol, 20 equiv) 
After 5 min, the mixture was evaporated with methanol (3 × 25 mL), followed by toluene 
(10 mL) The product was purified on a 2 × 13  cm silica gel column, eluting with 25% 
EtOAc/ hexanes, collecting 5 mL fractions. Fractions 6–24 were concentrated to yield the 
product (45.5 mg, 69%) as a colorless oil. Rf = 0.14 (25% EtOAc/ hexanes);[ ] =20Dα 	  –8.1 
o (c = 0.61, MeOH);  500 MHz 
1H NMR (CDCl3) 7.37–7.27 (m, 5H), 6.35 (dddd, J = 9.5, 
4.5, 2.0, 2.0 Hz, 1H), 4.77 (s, 2H), 4.60 (s, 2H), 3.75–3.64 (m, 6H), 2.93 (dd, J = 13.5, 
6.0 Hz, 2H), 2.83 (dd, J = 16.5, 2.5 Hz, 1H), 2.78 (dd, J = 14.5, 2.0 Hz, 1H), 2.25 (s, 1 
H), 0.90 (s, 9H), 0.06 (s, 6H). δ 125 MHz 13C NMR (CDCl3) δ; 169.2, 141.8, 137.7, 
128.7, 128.1, 128.0, 125.7, 95.2, 83.5, 70.0, 69.7, 65.4, 62.3, 33.2, 31.4, 26.1, 18.5, 5.1; 
125 MHz DEPT (CDCl3) CH3 δ 26.1, –5.1; CH2 δ 95.2, 70.0, 69.7, 65.4, 62.3, 33.2, 31.4; 
CH δ 141.8, 128.7, 128.1, 128.0; C δ 169.2, 137.7, 125.7, 83.5, 18.5; IR (neat) 3443, 
3033, 2954, 2930, 2885, 2858, 1755, 1672, 1575, 1498, 1472, 1463, 1381, 1364, 1257, 
1200, 1177, 1101, 1046, 939, 837, 778 cm-1; HRMS (ESI) calcd 459.2179 for 
C23H36O6SiNa (M+Na), found 459.2181. 
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SYNTHESIS AND BIOLOGICAL EVALUATION OF  
3-DAG LACTONE C-RING BRYOSTATIN 
ANALOGS 	  
          Introduction to C-Ring Analogs 
 Several natural products in the bryostatin family consist of C-ring varients. 
Several natural C20 esters analogs exist; these variations have little effect on the binding 
potency. Bryostatins 16, 17 are missing the C19 ketal and C20 ester functionality which 
have been replaced by an olefin (Figure 2.1).1 The binding affinity of these compounds is 
reduced by 3 orders of magnitude. Bryostatin 16 has the same E geometry of the C21 
enoate as bryostatin 1 and has a binding affinity of 118 nM. The enoate of bryostatin 17 
has a Z geometry, resulting in an approximately 2 fold loss of affinity.  
Bryostatins 10, 13, and 18 are all C20 deoxygenated; relatively little binding 
affinity is lost in bryostatin 10.2 Bryostatin 18 has a Z C21 enoate, resulting in a minor 
loss of binding affinity.1 Bryostatins 3, 19, 20 contain a C22 oxygenated C-ring, where 
the enoate has cyclized onto the new C22 alcohol.3 The binding constant for bryostatin 3 
is known, Ki = 2.8 nM, indicating very little loss of affinity in this series. Neristatin, a 
related natural product to bryostatin, contains a highly modified C-ring and still retains a 




Figure 2.1 Natural Bryostatin C-Ring Analogs 
 
U937 leukemia cells; this indicates that molecules with bryostatin like top-halfs probably 
will retain bryostatin-like properties as long as the lower half has a high affinity for PKC.  
In comparison to analogs of the AB-ring system of bryostatin, relatively few 
synthetic C-ring analogs of the natural product have been produced to date (Figure 2.2).  
The collaboration between Pettit and Blumberg, mentioned previously (Figure 1.5), 
resulted in several C-ring modifications.5 Inversion of the C26 alcohol resulted in the loss 
of affinity by 2 orders of magnitude, while esterification resulted in a loss of affinity 












loss of affinity. Wender’s most studied analog, “Picolog” is missing the C27 methyl 
group and still retains high affinity.6 Keck’s Merle 24 and 25 are both missing the C22 
enoate, resulting in a loss of binding affinity by 2 orders of magnitude.7 Inversion of the 
C20 ester in Merle 25 results in some loss of affinity versus Merle 24. The synthesis of 
potent bryostatins remains difficult due to the length of the C-ring synthesis.  Very little 
work to date has been conducted with respect to replacing the C-ring of bryostatin 
analogs with a suitable surrogate that retains the same binding affinity of the natural 
product.  
 
Design of Merle’s 39, and 47, 48 
In the search for simplified bryostatin analogs, the Keck group turned its attention 
towards the synthesis of simplified C-ring domains that retain the high binding affinity of 
bryostatin 1. The Marquez diacylglycerol lactones have high binding affinity and are 
relatively simple to construct compared to the C-ring of the natural product.8 
Interchanging the C-ring of bryostatin for a Marquez type lactone could possibly yield a 
simplified analog retaining the affinity of the natural product. For simplicity of synthesis, 
the Merle 23 type top-half was chosen, since the biology of this top-half is well explored 
and would make comparison of the biological results straightforward.9 A Marquez 
lactone scaffold with high binding affinity was chosen to serve as the C-ring.10 The only 
remaining questions were how to attach the lactone piece to the top-half and the chirality 
of gamma carbon of the lactone. 
DAG lactones are thought to bind in two different orientations termed sn-1 and 
sn-2 modes (Figure 2.3).11 Simulation of binding of DAG lactones by the Marquez group 
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using Autodock 2.4, using the crystal structure of PMA bound to the C1b domain of PKC 
δ, determined that two different binding modes are possible. The binding modes differ 
with respect to which carbonyl is bound to PKC. The sn-1 mode is depicted on the left 
and the sn-2 mode is depicted on the right, respectively. The sn-1 mode is thought to be 
the primary mode of binding for DAGs, while the sn-2 mode is more energetically 
favorable for DAG lactones. In this binding model, only one carbonyl is involved in an 
interaction with the protein. Synthesis of DAG analogs missing the side chain ester result 
in compounds with a binding affinity of a 100 fold less then the parent compound; this 
indicates that both carbonyls are important in binding.12 
A series of DAG lactones were synthesized as the racemates that incorporated the 
ester side chain and the enoate into a macrocyclic structure.13 These compounds retained 
much of the binding affinity of the open chain compounds (Figure 2.4). These 
compounds would have been more potent if they were constructed from the (R) lactone. 
The 22-membered macrolactone was found to be the most potent of these compounds. 
Larger and smaller lactone sizes resulted in the loss of binding affinity. Contraction 
seemed to result in the sharpest decrease in affinity, but expansion seen to decrease the 
affinity only slightly. 
The results of these studies indicate that the two possible attachment modes in the 
diester analog could lead to active analogs (Figure 2.5). The proper chirality of the 
lactone in the analog with respect to PKC binding was unknown. It was assumed that the 
optimum chirality determined by Marquez in his studies on DAG lactones would be the 
optimum chirality needed for good binding affinity in these bryostatin/DAG hybrid 



















Figure 2.5 C-Ring Orientations 
 
then that of the racemate (Figure 2.6).10 
 
Results and Discussion 
Synthesis of Merle 39 
 The first analog based upon the Marquez lactone C-Ring motif was Merle 39. 
Merle 39 was based upon a modular C1/ C16 diester top-half to allow for alteration of 
orientation if binding affinity of the first compound was unsatisfactory. The 
retrosynthesis of Merle 39 is shown in Figure 2.7. The protecting group scheme was 
chosen to allow for selective removal of protecting groups at the proper stage. A 


























esterification was envisioned to be used to couple the AB bis-pyran acid 2.1 and C-ring 
alcohol 1.93. 
 
Scaled A-ring Synthesis and Elaboration 
 In order to produce material for the synthesis of new bryostatin analogs, a 
program was undertaken to produce multigram quantities of hydroxyallylsilane 1.15. The 
route used is the same as in Figure 1.17 and therefore is not repeated here.14 In total, 
approximately 60 grams of the required hydroxyallylslilane were produced. This 
hydroxylallylsilane was coupled with aldehyde 1.43, generously provided by Kevin 
McGowan to yield pyran 1.62 (Figure 1.18). Elaboration to the B-ring precursor 
hydroxyallylsilane 1.42 was the same as in Figure 1.19 and will not be described here. 
Elaboration of hydroxyallylsilane 1.42 was envisioned to proceed via pyran 
annulation with a protected glycolaldehyde15 derivative (Figure 2.8). A screen of 
protected glycolaldehydes determined that the TBS protected compound 2.2 gave a high 
yield of pyran product 2.3, which was spectroscopically identical to that produced by Dr. 
Sherry Chavez, by a different route.16 NOESY experiments determined that the new 
stereocenter was of the desired configuration. Elaboration to carboxylic acid 2.1 was 
accomplished by selective TBS deprotection,17 Parikh-Doering18 and Pinnick oxidations19 
provided the desired carboxylic acid in high yield (Figure 2.9). Coupling of AB bis pyran 
carboxylic acid 2.1 with C-ring alcohol 1.93 was accomplished with Keck Boden-
modified Steglich esterification conditions.20 This esterification produced the tricyclic 
ester 2.4 in good yield, allowing the synthesis of Merle 39 to progress.  





































presence of the C26 secondary TBS group using a mixture of TBAF, AcOH in DMF.21 
Deprotection of the C1 TBDPS group in the presence of the C26 primary TBS proved 
difficult and was not amendable for scale up due to poor selectivity (Figure 2.10).  
Due to its reactivity, it was decided to deprotect the C26 TBS group and reprotect 
it as an ethoxyethyl ether (EE) which is orthogonal to conditions that are used for TBDPS 
deprotection. Deprotection of the C26 TBDPS group on 2.4 was accomplished by the 
conditions developed by Corey22 using 3:1:1 AcOH, H2O, THF at 45 oC. This yielded the 
C26 alcohol in 74% yield on a 100 mg scale. Protection of the C26 alcohol was 
accomplished with ethyl vinyl ether in CH2Cl2 with PPTS.23 The C1 TBDPS was then 
removed under the standard TBAF, AcOH, DMF conditions in good yield affording 
alcohol 2.7.21  
The C1 hydroxyl group was functionalized by consecutive Parikh-Doering18 and 
Pinnick19 oxidations to provide the C1 carboxylic acid 2.8 in an 82% yield over 2-steps 
(Figure 2.11).  Deprotection of the C26 ethoxy ethyl group was accomplished by stirring 
with MeOH and catalytic PPTS, giving the C26 alcohol in 51% yield.24 Cyclization of the 
resulting seco-acid was accomplished by Yamaguchi conditions,25 producing the 
macrolactone 2.9 in 57% yield. Deprotection of the C3 PMB and C26 BOM ether of 2.9 
was initially accomplished with bromocatechol borane in CH2Cl2 at –78 oC in the 
presence of K2CO3 (Figure 2.12).26 Separation of Merle 39 from reaction byproducts via 
column chromatography or preparative TLC proved to be exceedingly difficult. It was 
later found that a 2-step sequence where the PMB group was removed with DDQ27 
followed by BOM deprotection with LiBF4 in MeCN/ H2O at 80 oC28 provided a product 










Figure 2.11 Functionalization of C1 and Macrolactonization 
 
Figure 2.12 Completion of Merle 39 
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Biological Evaluation of Merle 39 
Merle 39 was determined to have a binding constant of 6985 nM for PKC α, 
indicating a dramatic loss of affinity. Merle 39 is over 5 orders of magnitude less potent 
than the model compound Merle 23. Merle 39 exhibits a dramatic loss of potency in 
U937 cells (Figure 2.13). 
In the attachment assay, it appears PMA like and inhibits growth; the EC50 is 34.5 
µM. Merle 39 at very high doses weakly promotes attachment and TNF α secretion in 
U937 cells, indicating PMA-like behavior. These results could be due to instability of the 
compound under biological conditions due to the diester linkage. Merle 39 is only weakly 
active with respect to the inhibition of Toledo leukemia cells as compared to the potent 
inhibitors PMA and bryostatin, with an EC50 value of 9.35 µM (Figure 2.14). 
From the biological results, Merle 39 is dramatically less potent then Merle 23, 
but displays a similar biological activity profile at high concentrations. Due to the diester 
linkage, Merle 39 is considerably more polar then Merle 23. The CLog P was calculated 
using ChemBioDraw version 14.0.0.118 and found to be –1.48, whereas Merle 23 has a 
CLog P of 3.06. From this information, Merle 39 appears to be unoptimized with respect 
to lipohilicity and possibly the orientation of the C-ring. 
 
Synthesis of Merle 47 
Due to Merle 39’s low binding affinity to PKC, it was decided to test the 
hypothesis that the orientation of the DAG lactone C-ring in Merle 39 was not oriented in 
the correct position to bind to the C1 domain of PKC with high affinity. To test this 















Figure 2.14 Activity of Merle 39 in Toledo Cells 
 
the AB-top-half of the analog. Reversal of the C-ring attachment points would change 
orientation of the top-half with respect to the C-ring, but not the relative stereochemistry. 
The resultant changes are shown in Figure 2.15.  The effects of this alteration on the 
biological properties of the analog were unknown.  
The synthesis of Merle 47 commenced with TBS deprotection of lactone 1.77, 
giving alcohol 2.10 in high yield (Figure 2.16).29 Esterification of alcohol 2.10 with AB-
ring carboxylic acid 2.1 proved to be difficult (Figure 2.17). Standard Keck-Boden-
modified Steglich conditions20 provided the tricyclic ester 2.11 in low overall yields. The 
low yields were attributed to a facile elimination of the resulting ester under basic 
conditions. Modified Yamaguchi esterification30 resulted in somewhat better yields and 
allowed the synthesis to progress. The C1 TBDPS group of 2.11 was deprotected with 





Figure 2.15 Design of Merle 47 
 
	  
Figure 2.16 TBS Deprotection 
 
and Pinnick19 oxidations produced C1 carboxylic acid 2.13 in excellent yield over two 
steps. Deprotection of the C26 trityl ether with formic acid in ether31 provided the seco-
acid which was used without characterization (Figure 2.18). Yamaguchi 
macrolactonization25 gave the desired macrolactone 2.14 in moderate yield over two 
steps. Deprotection of the C3 PMB ether with DDQ27 and deprotection of the BOM 










Figure 2.18 Completion of Merle 47 
 
Biological Evaluation of Merle 47 
 Merle 47 was evaluated for PKC binding affinity and found to have a Ki of 4934 
nM. This is a 400 nM improvement over Merle 39. This indicates that the orientation of 
the DAG lactone in Merle 47 is possibly more favorable compared to Merle 39. The 
overall orientation of the top-half of Merle 47 has changed with respect to Merle 39, 
while retaining the original chirality at the gamma carbon of the butyrolactone. 
Biological evaluation of Merle 47 was made difficult due to the inherent instability of this 
compound due to the facile elimination of the C16 ester due to its connection to the C-
ring enoate. The compound was less potent in all cell culture assays then Merle 39; the 




 The overall polarity of Merles 39 and 47 was substantially increased due to the 
ester linkage on the left-hand side of these molecules as compared to Merle 23. The 
increased polarity of these analogs likely decreased the biological activity of these 
compounds with respect to Merle 23. Reintroduction of the olefin linkage and gem-
dimethyl group present in Merle 23 would decrease the polarity and likely improve the 
biological profile of the resulting analog.  
 
Design and Synthesis of Merle 48 
Building upon the results of Merle 39, and 47, a third generation DAG lactone 
analog was designed. Much of the loss of binding affinity in Merle’s 39 and 47 was 
attributed to the low lipophilicity of these compounds. The bryostatin family of natural 
products contains a gem-dimethyl group at C18 and trans-olefin centered between C16-
C17. Merle 23, a potent bryostatin analog with a simplified top-half, also bears these 
functionalities. Reintroduction of these functionalities into a DAG lactone analog would 
increase the lipophilicity and thus improve the binding affinity. The rational for the 
design of Merle 48 is shown in Figure 2.19. Merle 48 is based upon Merle 47 which is 
more potent then our initial analog Merle 39. The enoate side chain of Merle 47 would be 
amendable to reintroduction of these functionalities. The enoate side chain was designed 
to retain the 22-membered macrolactone of the previous two analogs. Elimination of the 
C16 ester in Merle 48 would also circumvent the stability problems seen during the 
biological evaluation of Merle 47. 




Figure 2.19 Merle 48 Design Rational 
  
pyran to give known β-hydroxyallyl silane 1.42 and aldehyde 2.15 (Figure 2.20) This 
disconnection allows for the efficient construction of the B-ring of the analog via pyran 
annulation. Pyran annulations of fully functionalized C-ring aldehydes and β-hydroxy- 
allylsilane 1.42 are well known and would be expected to provide the desired product in 
high yield.32  
Disconnection of the enoate side chain on 2.15 would give lactone 2.17, which 
would be easily accessible from known lactone 1.89. Aldehyde 2.16 could be produced 
from known ester 1.47. Ester 1.47 was previously used in the synthesis of bryostatin 
analogs bearing the natural C-ring.33 Commencement of the synthesis of Merle 48 began 
with an aldol reaction of the lithium enolate of methyl isobutryate with known aldehyde 
1.79 to give aldol product 2.18 (Figure 2.21). Mesylation and elimination of 2.18 using 
conditions developed by Kevin McGowan provided ester 1.47. Reduction of ester 1.47 
with LiAlH4 and subsequent Parikh-Doering oxidation18 gave aldehyde 2.19.  
Wittig olefination34 of aldehyde 2.19 with (methoxymethyl)triphenyl 
phosphonium chloride in THF with KOt-Bu gave enol ether 2.20 in high yield. 


























mainly the deprotected alcohol 2.21, not the desired aldehyde 2.16. In order to 
circumvent these selectivity issues, aldehyde 2.19 was olefinated with methyl 
triphenylphosphonium bromide in THF with KOt-Bu to give olefin 2.22 in high yield 
(Figure 2.22).35 
Hydroboration/ oxidation of olefin 2.22 with 9-BBN gave alcohol 2.23 in good 
yield.36 Oxidation of this alcohol under Parikh-Doering conditions18 gave aldehyde 2.16. 
Synthesis of lactone 2.17 commenced with deprotection of the trityl group of 1.89 with 
TFA/ TFAA to give alcohol 2.14 in high yield.37 Alcohol 2.14 was protected as the TIPS 
ether with TIPSOTf38 to give lactone 2.17 in high yield.  
  Deprotonation of lactone 2.17 with LDA, aldol condensation with aldehyde 2.16, 
and finally dehydration gave enoate 2.24 as a 1:1.2 mixture of Z and E enoates in good 
yield. Improvement in selectivity was needed in order to produce material for the 
synthesis to progress. Reaction of the enolate of lactone 2.17 with diethyl 
chlorophosphate, followed by base-induced rearrangement of the intermediate enol 
phosphate, gave the corresponding phosphonate which was used without characterization 
(Figure 2.23).39 
Treatment of the intermediate phosphonate with KHMDS, 18-crown-6 at –78 oC, 
followed by addition of aldehyde 2.16 and rapid warming to rt lead to enoate 2.24 as a 
5:1 Z/ E mixture of enoates in moderate yield.40 Deprotection of the TBS group was 
accomplished with 3:1:1 AcOH/ THF/ H2O at 45 oC, providing alcohol 2.25 in good 
yield.22 Parikh-Doering oxidation18 of alcohol 2.25 gave aldehyde 2.15 in moderate yield.  
Coupling of aldehyde 2.15 and β-hydroxyallylsilane 1.42 was accomplished via 














Figure 2.23 Completion of C-ring Aldehyde 2.16  
 
1HNMR (Figure 2.24). Attempted deprotection of the C1 TBDPS of 2.26 with TBAF, 
AcOH, DMF led to the removal of the C26 TIPS group.21 
Deprotection of the C1 TBDPS was accomplished with HF•Pyridine at 0 oC, 
providing C1 alcohol 2.27 in moderate yield. Parikh-Doering18 and subsequent Pinnick19 
oxidation gave the C1 carboxylic acid 2.28 in acceptable yield over 2-steps. Removal of 
the C26 TIPS group was accomplished by stirring the carboxylic acid in HF•pyridine at 
rt for 2 days. The crude seco acid was cyclized by Yamaguchi macrolactonization,25 
yielding macrolactone 2.29 in moderate yield over 2-steps. Completion of Merle 48 was 









deprotection of the C26 BOM acetal with LiBF4 in MeCN/ H2O at 80 oC.28 Merle 48 was 
obtained in moderate yield over 2-steps. 
 
Biological Evaluation of Merle 48 
 Merle 48 was found to have a binding constant of 363 nM towards PKCα. This is 
a 13-fold increase from that of Merle 47. The dramatic increase in affinity can be 
attributed to the increased lipophilicity imparted by the deletion of the C16 ester, along 
with the reinstallation of the C16-C17 olefin, as well as the C18 gem-dimethyl group.  In 
U937 cells, Merle 48 is Merle 23-like, it inhibits proliferation and induces attachment, 
but is considerably less potent then PMA (Figure 2.25). Bryostatin was found to reverse 
these effects of Merle 48. Merle 48 was found to induce the secretion of TNF α at high 
concentrations of the ligand (Figure 2.26).  
 In the Toledo cell system, Merle 48 was found to inhibit growth similarly to PMA 
and bryostatin 1, but at much higher concentrations (Figure 2.27). Merle 48 was 2 orders 
of magnitude more potent then Merle 47 in this assay. The results from these assays 
indicate that Merle 48 is much more stable under biological conditions. These results are 
promising, due to the dramatic increase in binding relative to Merles 39 and 47.  
 
Molecular Modeling Studies 
 Molecular modeling studies of Merles 39, 47, and 48 were conducted by Dr. 
Megan Peach of the NIH. A conformational search of the three analogs was conducted 
using by the program MacroModel.41 These modeling studies indicate that the hydrogen 




Figure 2.25 Biological Evaluation of Merle 48 in U937 Cells 
 
 




Figure 2.27 Biological Results in Toledo Cells
analogs was lost upon substitution of the natural C-ring for the DAG lactone. This results 
in the nearly perpendicular conformation of the A and B rings as opposed to the coplanar 
conformation seen in the natural product (Figure 2.28). This study suggests that 
membrane orientation and penetration of these compounds may be much different then 
bryostatin 1. Bryostatins and previous analogs have highly rigid structures due to this 
intramolecular hydrogen bonding network. 
Docking studies with the C1b domain of PKC were conducted with the program 
GOLD, version 5.2.2 to model the interaction between the ligand and protein.42 These 
studies indicate that only Merle 39 has a reasonable binding mode with the C1b domain 
of PKC (Figure 2.29). In Merle 39, the DAG lactone binds to threonine 242, leucine 251, 
and glycine 253 in a sn-2 fashion. Modeling studies of Merles 47 and 48 indicate 
that a reasonable mode of binding does not exist due to the reversed orientation of the 
top-half in relation to the C-ring. The starting point in these docking studies is the crystal 
structure of PMA bound to the C1b domain of PKC. PMA has a much different structure 




Figure 2.28 Crystal Structure of Bryo 1 and Energy Minimized Structure of Merle 39 
 
 




the modeling study and the actual results observed for Merle 48. No crystal structures of 
a DAG lactone bound to the C1 domain have been reported to date. 
 
Future Direction 
Modeling studies on Merles 39, 47, 48 indicated that the intramolecular hydrogen 
bonding network present in bryostatin 1 and Merle 23 to have been disrupted. The 
coplanarity of the AB ring system was also shown to be significantly altered by the 
introduction of the DAG lactone. Expansion of this ring system by two carbons should 
result in the restoration of the co-planarity of the AB rings and restoration of the 
hydrogen bonding network in analog 2.30 (Figure 2.30).  Marquez has reported a small 
loss in affinity for 26 membered macrocyclic DAG lactones as opposed to the 22 
membered systems.13 The conformational preferences of this system should negate any 
detrimental effects of the ring expansion. Further adjustment of conformational 
preference could be achieved by reintroduction of the internal hydrogen bonding network 
in analog 2.31. 
 
 




 In order to synthesize bryostatin analogs with a simplified C-ring scaffold, new 
analogs Merle 39, 47, 48 were synthesized. A DAG lactone core was inserted in the place 
of the natural C-ring. Merle 39 was found to be a weak PKC ligand, and biologically 
mimicked Merle 23 in several assays. Merle 47, which was a reversed version of Merle 
39, was found to have a slightly higher binding affinity. Merle 47 was unstable 
biologically, making biological evaluation difficult. Both Merles 39 and 47 are very polar 
compounds compared to past high affinity analogs. Merle 48 was the result of an attempt 
to increase the lipophilicity of DAG lactone analogs. A large increase in binding was 
observed in this compound, likely a result of its increased lipophilicity. Molecular 
modeling studies indicated that the DAG scaffold significantly changes the conformation 
of the AB-top-half due to the loss of the internal hydrogen bonding network; this could 
account for the relatively poor binding affinity of these compounds.  
 
Experimental Section 
General Experimental Procedures 
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, and 
CH2Cl2, were distilled from CaH2. Reagent grade DMF, DMSO, and acetone were 
purchased, stored over 4Å molecular sieves, and used without further purification. Et2O, 
THF, and toluene were distilled from Na under an atmosphere of N2. MeOH was distilled 
from dry Mg turnings. The titer of n-BuLi was determined by the method of Baclawski 
and Kofron.114 Ti(i-OPr)4 was distilled prior to use. All other reagents were used without 
further purification. Yields were calculated for material judged homogenous by thin layer 
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chromatography and nuclear magnetic resonance (NMR). Thin layer chromatography 
was performed on Merck Kieselgel 60Å F254 plates or Silicycle 60Å F254 eluting with 
the solvent indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic 
solution of 12-molybdophosphoric acid, a solution of ninhydrin in 1-butanol, a solution 
of p-anisaldehyde in ethanol acidified with sulfuric acid, an aqueous potassium 
permanganate solution, or a solution of ceric ammonium molybdate, acidified with 
sulfuric acid. Flash column chromatography was performed with Silicycle Flash Silica 
Gel 40 – 63 µm or Silicycle Flash Silica Gel 60 – 200 µm, slurry packed with hexanes in 
glass columns. Glassware for reactions was oven dried at 125 °C and cooled under a dry 
atmosphere prior to use. Liquid reagents and solvents were introduced by oven-dried 
syringes through septum-sealed flasks under a nitrogen atmosphere. Enantiomeric excess 
(ee) were determined using a Rainin Dynamax HPLC with a Knauer variable wavelength 
detector set at 254 nm, using a Chiracel OD-H column. Nuclear magnetic resonance 
spectra were acquired at 300, 500 MHz for 1H and 75, 125 MHz for 13C. Chemical shifts 
for proton nuclear magnetic resonance (1H NMR) spectra are reported in parts per 
million relative to the signal of residual CDCl3 at 7.27 ppm or (CH3)4Si at 0.00 ppm. 
Chemicals shifts for carbon nuclear magnetic resonance (13C NMR and DEPT) spectra 
are reported in parts per million relative to the centerline of the CDCl3 triplet at 77.23 
ppm. Chemical shifts of the unprotonated carbons (‘C’) for DEPT spectra were obtained 
by comparison with the 13C NMR spectrum. The abbreviations s, d, dd, ddd, dddd, 
ddddd dt, quint, t, and m stand for the resonance multiplicity singlet, doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, 
doublet of doublet of doublet of doublet of doublets, doublet of triplets, quintet, triplet, 
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and multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell 
with a 1 dm path length. Specific rotations ([α], Unit: °cm2/g) are based on the equation α 
= (100·α)/(l·c) and are reported as unit-less numbers where the concentration c is in g/l00 
mL and the path length l is in decimeters. Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a time 
of flight (TOF) high-resolution mass spectrometer. Compounds were named using 
ChemBioDraw 14.0.0. 
 
Experimental Procedures for Merle 39 
 Preparation of (Z)-2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-
3,10-disiladodec-6-ene (2.32): A 500 mL flask was equipped with a stir bar and 
imidazole (9.3 g, 137 mmol, 4.0 equiv) and DMAP (1.64 g, 13.4 mmol, 0.4 equiv) were  
then added. After flushing with N2, CH2Cl2 (150 mL) was added, followed by cis-1,4-
but-2-enediol (3.0 g, 34 mmol, 1.0 equiv). After cooling to 0 oC, a solution of TBSCl 
(12.3 g, 81.6 mmol, 2.4 equiv) in CH2Cl2 (135 mL) was added via cannula to the stirring 
solution. The reaction mixture was stirred overnight at rt, and then quenched with water 
(300 mL), extracted with CH2Cl2 (3 × 30 mL), and washed with brine (200 mL). After 
drying over MgSO4, the solution was filtered and concentrated. The crude product was 
then purified via column chromatography on a 5 × 25 cm silica gel column, eluting with 
2% EtOAc/hexanes, collecting 30 mL fractions. Fractions 6–24 were combined and 
concentrated to yield the product (10.2 g, 94%). Rf = 0.76 (25% EtOAc/hexanes). 300 
MHz 1H NMR (CDCl3) δ 5.57 (t, J = 3.3 Hz, 2H), 4.24 (dd, J = 3.3, 0.9 Hz, 4H), 0.91 (s, 
18H), 0.07 (s, 12H): 75 MHz 13C NMR (CDCl3) δ 130.4, 59.8, 26.1, 18.5, –5.0. 
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 Preparation of 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (2.2): 
To a 100 mL flask with a stir bar was added 2.32 (2.95 g, 9.3 mmol, 1.0 equiv) and 
CH2Cl2 (50 mL, 0.2 M). After cooling to –78 oC, O3 was passed into the solution until a 
persistent blue color appeared in the solution and the solution was flushed with O2, and 
this process was repeated twice. After flushing out the remaining O3, PPh3 (2.93 g, 11.2 
mmol, 1.2 equiv) was added. The dry ice bath was allowed to expire overnight. The 
solution was then concentrated and the crude product purified on a 5 × 10 cm silica gel 
column. The product was eluted with 5% EtOAc/hexanes, collecting 30 mL fractions. 
Fractions 2–16 contained the desired product. The product was then distilled using a 
Kughelrohr apparatus, using house vacuum, 40 mmHg, bath temperature 125 oC, yielding 
the product aldehyde (1.95 g, 61%) as a colorless oil. Rf = 0.53 (25% EtOAc/hexanes). 
300 MHz 1H NMR (CDCl3) δ 9.71 (d, J = 0.9 Hz, 1H), 4.22 (t, J = 0.6 Hz, 2H), 0.93 (s, 
9H), 0.11 (s, 6H): 75 MHz 13C NMR (CDCl3) δ 202.6, 69.8, 26.0, 18.6, –5.2. 
 Preparation of tert-butyl((S)-4-((2S,6R)-6-(((2S,6R)-
6-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylenetetrahydro-2H-pyran-2-
yl)methyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-((4-methoxybenzyl) 
oxy)butoxy)diphenylsilane (2.3): To a 25 mL flask fitted with a stir bar was 
added silane 1.42 (262 mg, 0.367 mmol, 1.0 equiv) and aldehyde 2.2 (319 mg, 1.83 
mmol, 5.0 equiv). The flask was flushed with N2 and Et2O (10.5 mL, 0.035 M) was 
added. After cooling to –78 oC, a solution of TMSOTf in Et2O (610 µL of 0.9 M, 0.55 
mmol, 1.5 equiv) was added dropwise to the stirring solution. After 3 h, the reaction 
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mixture was quenched by dropwise addition of i-Pr2NEt (1.0 mL). After 5 min, saturated 
aqueous NaHCO3 solution (5.0 mL) was added and the mixture was stirred until it had 
reached rt. The mixture was extracted with EtOAc (3 × 10 mL), the organic phase was 
washed with brine (25 mL), and dried over Na2SO4. The solution was filtered and 
concentrated. The crude product was purified on a 3 × 10 cm silica gel column, eluting 
with 4 % EtOAc/hexanes, collecting 10 mL fractions. Fractions 4–14 were concentrated 
to yield the product (272 mg, 93%) which was spectroscopically identical to that reported 
by Chavez. Rf = 0.44 (10% EtOAc /hexanes); 500 MHz 1H NMR (CDCl3) δ 7.71–7.68 
(m, 4H), 7.46–7.38 (m, 6H), 7.20 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 4.73 (dd, J 
= 8.0, 1.5 Hz, 2H), 4.69 (d, J = 1.5 Hz, 1H), 4.60 (d, J = 1.5 Hz, 1H), 4.43 (ABq, J = 11 
Hz, Δν = 30.4 Hz, 2H), 3.98–3.93 (m, 1H), 3.85–3.80 (m, 1H), 3.81 (s, 3H), 3.78–3.75 
(m, 1H), 3.71 (dd, J = 10, 5.0 Hz, 1H), 3.59–3.48 (m, 4H), 3.40–3.36 (m, 1H), 2.28 (d, J 
= 13 Hz, 3H), 2.18 (d, J = 13.5 Hz, 1H), 2.03–1.90 (m, 5H), 1.86–1.73 (m, 2H), 1.70–
1.58 (m, 3H), 1.08 (s, 9H), 0.91 (s, 9H), 0.07 (d, J = 2.0 Hz, 6H): 125 MHz 13C NMR 
(CDCl3) δ 159.3, 145.0, 144.4, 135.8, 134.1, 131.2, 129.8, 129.6, 127.9, 114.0, 109.0, 
108.7, 79.0, 75.1, 75.0, 74.9, 72.7, 72.2, 66.8, 60.6, 55.5, 43.0, 42.6, 41.5, 41.0, 40.9, 
38.1, 37.7, 27.1, 26.2, 19.4, 18.6, –5.0. HRMS (ESI) calcd 821.4609 for C48H70O6NaSi2 
(M+Na); found 821.4614. 
 Preparation of ((2R,6S)-6-(((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)methyl)-4-methylenetetrahydro-2H-pyran-2-yl)methanol (2.33): To a 
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stirring solution of 2.3 (220 mg, 0.275 mmole, 1.0 equiv) in i-PrOH (6.9 mL 0.04 M) 
contained in a 15 mL flask under N2 was added ZrCl4 (32 mg, 0.14 mmol, 0.5 equiv). The 
reaction mixture was stirred at rt for 60 h. The reaction mixture was quenched with 
saturated aqueous NaHCO3 solution (25 mL) and extracted with EtOAc (3 × 25 mL), 
then washed with brine (25 mL), dried over Na2SO4, filtered, and concentrated. The 
product was purified on a 3 × 10 cm silica gel column, eluting with a gradient of 10 – 
30% EtOAc/hexanes, collecting 10 mL fractions. Fractions 16–28 were concentrated to 
yield the product alcohol (132 mg, 70%) as a colorless oil. Rf = 0.58 (25% EtOAc/ 
hexanes); 500 MHz 1H NMR (CDCl3) δ 7.70–7.76 (m, 4H), 7.45–7.37 (m, 6H), 7.19 (d, J 
= 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 4.73  (dd, J = 11, 2.0 Hz, 2H), 4.69 (s, 1H), 4.47 
(s, 1H), 4.42 (ABq, J = 10.5 Hz, Δν = 41.7 Hz, 2H), 3.96–3.82 (m, 1H), 3.84–3.80 (m, 
1H), 3.81 (s, 3H), 3.77–3.73 (m, 1H), 3.65–3.63 (m, 1H), 3.60–3.49 (m, 3H), 3.48–3.39 
(m, 2H), 2.27 (t, J = 13 Hz, 2H), 2.17 (d, J = 13 Hz, 1H), 2.08 (q, J = 12 Hz, 3H), 2.02–
1.90 (m, 4H), 1.86–1.73 (m, 2H), 1.69–1.57 (m, 4H), 1.07 (s, 9H): 125 MHz 13C NMR 
(CDCl3) δ 159.3, 144.8, 143.7, 135.8, 134.1, 131.2, 129.8, 129.6, 127.9, 114.0, 109.5, 
108.8, 78.7, 75.2, 75.0, 74.9, 72.6, 72.0, 66.2, 60.6, 55.5, 42.9, 42.5, 41.4, 41.1, 40.8, 
37.9, 36.5, 27.1, 19.4, 14.1; HRMS (ESI) calcd 707.3744 for C42H56O6NaSi (M+Na), 
found 707.3755.  
Preparation of ((2R,6S)-6-(((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)methyl)-4-methylenetetrahydro-2H-pyran-2-yl)methyl acetate (2.34): To 
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a stirring solution of alcohol 2.33 (36 mg, 0.053 mmol, 1.0 equiv) in pyridine (1.75 mL, 
0.03 M) contained in a 5 mL flask under N2 was added Ac2O (150 µL, 1.6 mmol, 30 
equiv). The reaction mixture was stirred overnight at rt and quenched with saturated 
aqueous NaHCO3  solution (25 mL). The mixture was extracted with EtOAc (3 × 10 mL), 
dried over Na2SO4, filtered, and concentrated. The crude product was purified on a 2 × 10 
cm silica gel column, eluting with 15% EtOAc/ hexanes, collecting 5 mL fractions. 
Fractions 6–12 were concentrated to yield the product (36 mg, 92%) as a colorless oil. Rf 
= 0.76 (50% EtOAc/hexanes); [ ] =20Dα  +3.2o (c = 0.76, CHCl3); 500 MHz 1H NMR 
(CDCl3) δ 7.70–7.67 (m, 4H), 7.45–7.37 (m, 6H), 7.19 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 
8.5 Hz, 2H), 4.72 (d, J = 10 Hz, 2H), 4.69 (s, 1H), 4.59 (s, 1H). 4.42 (ABq, J = 10.5 Hz, 
Δν = 37.8 Hz, 2H), 4.11 (dd, J = 12, 6.5 Hz, 1H), 4.06 (dd, J = 12, 4.0 Hz, 1H), 3.94–
3.92 (m, 1H), 3.83–3.80 (m, 1H), 3.80 (s, 3H), 3.77–3.74 (m, 1H), 3.57–3.50 (m, 3H), 
3.47–3.46 (m, 1H), 2.27 (t, J = 15.5 Hz, 2H), 2.17 (d, J = 12.5 Hz, 2H), 2.06 (s, 3H), 
2.02–1.91 (m, 6H), 1.84–1.74 (m, 3H), 1.67–1.58 (m, 3H), 1.06 (s, 9H); 125 MHz 13C 
NMR (CDCl3) δ 171.2, 159.4, 145.0, 143.4, 135.9, 134.1, 131.2, 129.8, 129.6, 127.9, 
114.0, 109.8, 108.7, 76.1, 75.3, 75.1, 74.9, 72.7, 72.2, 67.1, 60.6, 55.5, 42.8, 42.5, 41.4, 
41.0, 40.4, 38.0, 37.0, 27.2, 21.1, 19.4. 125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.2, 21.1; 
CH2 δ 109.8, 108.7, 72.2, 67.1, 60.6, 42.8, 42.5, 41.4, 41.0, 40.4, 38.0, 37.0; CH δ 135.9, 
129.8, 129.6, 127.9, 114.0, 76.1, 75.3, 75.1, 74.9, 72.7; C δ 171.2, 159.4, 145.0, 143.4, 
134.1, 131.2, 19.4; IR (neat) 3071, 2939, 2858, 1740, 1684, 1653, 1558, 1515, 1472, 
1428, 1362, 1248, 1111, 1040, 823, 703 cm-1; HRMS (ESI) calcd 749.3850 for 
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 Preparation of (2R,6S)-6-(((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)methyl)-4-methylenetetrahydro-2H-pyran-2-carboxylic acid (2.1): A 
solution of alcohol 2.33 (131 mg, 0.19 mmol, 1.0 equiv) was prepared in CH2Cl2 (1.9 
mL, 0.1 M) in a 10 mL flask under N2. After cooling to 0 oC, i-Pr2NEt (230 µL, 1.33 
mmol, 7.0 equiv) was added, followed by DMSO (140 µL, 1.9 mmol, 10 equiv). After 10 
min, SO3•Pyr (121 mg, 0.76 mmol, 4.0 equiv) was added in 4 equal portions over 20 min 
to the stirring solution. The reaction mixture was stirred for 1 h at 0 oC and then quenched 
with saturated aqueous NaHCO3 solution (25 mL), extracted with EtOAc (3 × 10 mL), 
washed with brine (25 mL), dried over Na2SO4, filtered, and concentrated. The crude 
product was purified through a 3 × 10 cm silica gel column, collecting 10 mL fractions. 
The product containing fractions were concentrated to yield the aldehyde (127 mg, 97%) 
which was used immediately for the subsequent oxidation step. 
A solution of the previously prepared aldehyde  (127 mg, 0.190 mmol, 1.0 equiv) 
in t-BuOH (2.65 mL) was prepared in a 10 mL flask, 2-methyl-2-butene (2.65 mL) was 
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added, along with an aqueous solution of KH2PO4 (1.35 M. 930 µL, 6.0 equiv) to the 
stirring solution. The reaction mixture was cooled to –10 oC, powdered 80% NaClO2 
(106 mg, 5.0 equiv) was added. The reaction mixture was stirred overnight, allowing the 
cooling bath to expire. The mixture was then quenched with pH 4.0 acetate buffer (0.1 M, 
15 mL). After extracting with EtOAc (3 × 10 mL), the organic phase was washed with 
brine (25 mL), dried over Na2SO4, filtered, and then concentrated. The product was 
purified on a 3 × 10 cm silica gel column, eluting with a 60:15:1 toluene/ EtOAc/ AcOH 
mixture, collecting 5 mL fractions. Fractions 6–16 were concentrated to yield the 
carboxylic acid product (119 mg, 92%) as a colorless oil. Rf = 0.21 (60:15:1 toluene 
/EtOAc/ AcOH); 500 MHz 1H NMR (CDCl3) δ 7.71–7.68 (m, 4H), 7.46–7.38 (m, 6 H), 
7.19 (dd, J = 8.5, 2.0 Hz, 2H), 6.86 (dd, J = 8.5, 2.0 Hz, 2H), 4.77 (d, J = 21 Hz, 2H), 
4.74 (s, 1H), 4.66 (s, 1H), 4.38 (ABq, J = 10.5 Hz, Δν = 35.6 Hz, 2H), 3.94–3.88 (m, 
2H), 3.85–3.79 (m, 1H), 3.81 (s, 3H), 3.78–3.73 (m, 1H), 3.70–3.65 (m, 1H), 3.56–3.52 
(m, 1H), 3.46–3.41 (m, 1H), 2.62 (d, J = 13 Hz, 1H), 2.37–2.31 (m, 1H), 2.26–2.17 (m, 
3H), 2.08–1.91 (m, 5H), 1.88–1.81 (m, 1H), 1.80–1.73 (m, 1H), 1.72–1.60 (m, 3H), 1.07 
(s, 9H): 125 MHz 13C NMR (CDCl3) δ 173.2, 159.3, 144.4, 141.4, 135.8, 134.0, 131.1, 
129.8, 129.6, 127.9, 114.0, 111.3, 109.1, 76.1, 76.1, 75.1, 74.6, 72.7, 71.9, 60.6, 55.5, 
42.6, 42.4, 41.3, 41.1, 39.8, 37.8, 37.2, 27.1, 19.4; HRMS (ESI) calcd 721.3537 for 
C42H54O7NaSi (M+Na), found 721.3553. 






pyran-2-yl)methyl)-4-methylenetetrahydro-2H-pyran-2-carboxylate (2.4): A stirring 
solution of carboxylic acid 2.1 (91 mg, 0.13 mmol, 1.0 equiv) and alcohol 1.93 (68 mg, 
0.16 mmol, 1.2 equiv) was prepared in CH2Cl2 (1.3 mL, 0.1 M) in a 5 mL flask under N2. 
After cooling to 0 oC, EDCI•HCl (100 mg, 0.52 mmol, 4.0 equiv), DMAP (48 mg, 0.39 
mmol, 3.0 equiv) and DMAP•HCl (41 mg, 0.26 mmol, 2.0 equiv) were then added. After 
warming to rt, the reaction mixture was stirred for 6 h. The reaction mixture was then 
quenched with saturated aqueous NaHCO3 solution (25 mL), extracted with CH2Cl2 (3 × 
15 mL), washed with brine (25 mL) and dried over Na2SO4. After filtration and 
concentration, the product was purified on a 3 × 10 cm silica gel column, eluting with a 
gradient consisting of 100 mL 10% EtOAc/ hexanes, 300 mL 25% EtOAc/ hexanes, 
collecting 10 mL fractions. Fractions 36–64 were concentrated to yield the product (135 
mg, 93%) as a colorless oil. Rf = 0.44 (25% EtOAc/ hexanes);[ ] =20Dα  +7.5o (c = 0.85, 
PhCH3);  500 MHz 
1H NMR (CDCl3) δ 7.70–7.68 (m, 5H), 7.45–7.33 (m, 10H), 7.18 (d, 
J = 9.0 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 6.36 (t, J = 7.5 Hz, 1H), 4.76 (s, 2H), 4.73 (d, J 
= 4.0 Hz, 2H), 4.71 (s, 1H), 4.62(s, 1H), 4.60 (s, 2H), 4.40 (ABq, J = 10.5 Hz, Δν = 42.7 
Hz, 2H), 4.28 (ABq, J = 12 Hz, Δν = 64.9 Hz, 2H), 3.92 (dd, J = 12, 2.5 Hz, 2H), 3.83–
3.79 (m, 1H), 3.80 (s, 3H), 3.77–3.71 (m, 4H), 3.67 (dd, J = 15, 10 Hz, 2H), 3.62–3.50 
(m, 2H), 3.50–3.42 (m, 1H), 3.06–2.97 (m, 1H), 2.92–2.84 (m, 1H), 2.85 (d, J = 16.5 Hz, 
1H), 2.75 (d, J = 16.5 Hz, 1H), 2.44 (d, J = 13.5 Hz, 1H), 2.30–2.23 (m, 3H), 2.18 (t, J = 
12 Hz, 1H), 2.09–1.90 (m, 5H), 1.86–1.72 (m, 3H), 1.71–1.59 (m, 4H), 1.06 (s, 9H), 0.90 
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(s, 9H), 0.07 (s, 6H). 125 MHz 13C NMR (CDCl3) δ 170.3, 168.5, 159.3, 144.8, 142.1, 
142.0, 137.7, 135.8, 134.1, 134.0, 131.2, 129.8, 129.5, 128.7, 128.1, 127.9, 125.0, 114.0, 
110.8, 108.8, 95.2, 81.2, 76.6, 75.6, 75.0, 74.6, 72.8, 72.0, 70.1, 69.6, 66.0, 62.2, 60.6, 
55.5, 42.6, 42.5, 41.4, 41.1, 39.9, 37.9, 37.6, 33.8, 31.4, 27.2, 26.1, 19.4, 18.5, –5.1; 125 
MHz DEPT (CDCl3) CH3 δ 55.3, 27.2, 26.1, –5.1; CH2 δ 110.8, 108.8, 95.2, 72.0, 70.1, 
69.6, 66.0, 62.2, 60.6, 42.6, 42.5, 41.4, 41.1, 39.9, 37.9, 37.6, 33.8, 31.4; CH δ 170.3, 
142.1, 135.8, 129.8, 129.5, 128.7, 128.1, 127.9, 114.0, 76.6, 75.6, 75.0, 74.6, 72.8; C δ 
168.5, 159.3, 144.8, 142.0, 137.7, 134.1, 134.0, 131.2, 125.0, 81.2, 19.4, 18.5; IR (neat) 
2933, 2857, 1762, 1653, 1612, 1514, 1472, 1429, 1362, 1249, 1173, 1106, 1048, 893, 
836, 777, 737, 702 cm-1; HRMS (ESI) calcd  for C65H88O12Si2Na (M+Na), 1139.5712 
found 1139.5618. 





(2.5): A solution of 2.4 (175 mg, 0.157 mmol, 1.0 equiv) was prepared in 3:1:1 AcOH/ 
THF/ H2O (15.7 mL, 0.01 M) in a 25 mL flask. The stirring solution was heated at 45 oC 
for 1.5 h, after which the reaction was complete. The reaction mixture was diluted with 
brine (100 mL), and extracted with EtOAc (3 × 25 mL). After drying over Na2SO4, and 
filtering, the solution was concentrated. The product was purified on a 2 × 15 cm silica 
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gel column, eluting with a gradient of 25–50% EtOAc/ hexanes, collecting 5 mL 
fractions. Fractions 35–72 were concentrated to yield the product (117 mg, 74%) as a 
colorless oil. Rf = 0.28 (50% EtOAc/ hexanes); [ ] =20Dα +9.7o (c = 0.57, CH2Cl2);  500 
MHz 1H NMR (CDCl3) δ 7.70–7.67 (m, 5H), 7.45–7.30 (m, 10H), 7.18 (d, J = 9.0 Hz, 
2H), 6.86 (d, J = 8.5 Hz, 2H), 6.33 (dddd, J = 12, 7.5, 2.0, 2.0 Hz, 1H), 4.77 (s, 2H), 
4.74–4.72 (m, 3H), 4.61 (s, 1H), 4.57 (s, 2H), 4.40 (ABq, J = 10.5 Hz, Δν = 45.6 Hz, 
2H), 4.30 (ABq, J = 12 Hz, Δν = 42 Hz, 2H), 3.93 (dd, J = 11.5, 2.0 Hz, 1H), 3.94–3.88 
(m, 1H), 3.84–3.80 (m, 1H), 3.80 (s, 3H), 3.77–3.72 (m, 3H), 3.68 (s, 2H), 3.61–3.56 (m, 
1H), 3.56–3.50 (m, 1H), 3.49–3.43 (m, 1H), 2.96 (dd, J = 13.5, 6.5 Hz, 2H), 2.82 (ABq, J 
= 19 Hz, Δν = 33.9 Hz, 2H), 2.43 (d, J = 13.5 Hz, 1H), 2.31–2.23 (m, 3H), 2.17 (d, J = 
13.5 Hz, 1H), 2.09–2.04 (m, 2H), 2.02–1.90 (m, 3H), 1.84–1.74 (m, 2H), 1.69–1.61 (m, 
3H), 1.06 (s, 9H). 125 MHz 13C NMR (CDCl3) δ 170.3, 169.0, 159.3, 144.7, 142.0, 
140.9, 137.6, 135.8, 134.0, 131.1, 129.8, 129.5, 128.7, 128.1, 127.9, 127.9, 126.3, 114.0, 
110.8, 108.9, 95.2, 81.6, 76.6, 75.6, 75.1, 74.6, 72.8, 72.1, 70.1, 69.6, 66.1, 61.9, 60.6, 
55.5, 42.6, 42.4, 41.3, 41.1, 39.8, 37.9, 37.5, 33.9, 31.1, 27.1; 125 MHz DEPT (CDCl3) 
CH3 δ 55.5, 27.1; CH2 δ 110.8, 108.9, 95.2, 72.1, 70.1, 69.6, 66.1, 61.9, 60.6, 42.6, 42.4, 
41.3, 39.8, 37.9, 37.5, 33.9, 31.1, 27.1; CH δ 140.8, 135.8, 129.8, 129.5, 128.7, 128.1, 
127.9, 114.0, 76.6, 75.6, 75.1, 74.6, 72.8; C δ 170.3, 169.0, 159.3, 144.7, 142.0, 137.6, 
134.0, 131.1, 126.3, 81.6, 70.1; IR (neat) 3496, 3070, 2939, 2888, 2857, 1760, 1671, 
1654, 1612, 1514, 1472, 1428, 1363, 1248, 1173, 1111, 1048, 895, 823, 739, 703 cm-1; 









2-carboxylate (2.6): A solution of alcohol 2.5 (38.2 mg, 0.038 mmol, 1.0 equiv) in a 4:1 
mixture of CH2Cl2/ ethyl vinyl ether (3.80 mL, 0.01 M) was prepared in a 10 mL flask 
under N2. After cooling to 0 oC, PPTS (1.0 mg, 0.004 mmol, 0.1 equiv) was added, and 
the mixture was then stirred at 0 oC for 1 h. The reaction mixture was warmed to rt, and 
stirred for 1 h. The reaction mixture was quenched with brine (10 mL), extracted with 
EtOAc (3 × 10 mL), dried over Na2SO4, filtered, and concentrated. The product was 
purified on a 1 × 10 cm silica gel column, eluting with a gradient of 100 mL 15% EtOAc, 
followed by 100 mL 25% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 18–30 
where concentrated to yield the product (32 mg, 78%) as a colorless oil. Rf = 0.77 (50% 
EtOAc/ hexanes); [ ] =20Dα + 6.5o (c = 1.6, CHCl3);  500 MHz 1H NMR (CDCl3) 7.70–7.67 
(m, 5H), 7.45–7.28 (m, 10H), 7.18 (d, J = 8.5 Hz, 2H) 6.86 (d, J = 8.5 Hz, 2H), 6.34 (t, J 
= 7.0 Hz, 1H), 4.76 (s, 2H), 4.75–4.68 (m, 4H), 4.61 (s, 1H), 4.59 (s, 2H), 4.40 (ABq, J 
=10.5 Hz, Δν = 43.8 Hz, 2H), 4.28 (ABq, J = 12.5 Hz, Δν = 64.5 Hz, 2H), 3.94–3.88 (m, 
2H), 3.84–3.81 (m, 1H), 3.80 (s, 3H), 3.77–3.72 (m, 1H), 3.70–3.64 (m, 4H), 3.63–3.51 
(m, 4H), 3.50–3.44 (m, 2H), 3.09–3.02 (m, 1H), 2.98–2.91 (m, 1H), 2.85 (d, J = 16.5 Hz, 
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1H), 2.75 (d, J = 16.5 Hz, 1H), 2.43 (d, J = 13 Hz, 1H), 2.30–2.15 (m, 4H), 2.06 (ddd, J = 
14, 8.5, 6.5 Hz, 1H), 2.02–1.94 (m, 2H), 1.91 (d, J = 12.5 Hz, 1H), 1.80 (ddddd, J = 13, 
13, 13, 6.5, 6.5 Hz, 2H), 1.73–1.63 (m, 4H), 1.31 (d, J = 5.0 Hz, 3H), 1.21 (t, J = 6.5 Hz, 
3H), 1.06 (s, 9H). 125 MHz 13C NMR (CDCl3) δ 170.3, 168.5, 159.3, 144.8, 142.0, 
141.7, 137.6, 135.8, 134.1, 131.1, 129.8, 129.5, 128.7, 128.1, 127.9, 127.9, 125.3, 114.0, 
110.8, 108.8, 99.8, 95.2, 81.3, 76.6, 75.6, 75.0, 74.6, 72.8, 72.0, 70.1, 69.5, 66.0, 64.0, 
61.3, 60.6, 55.5, 42.6, 42.5, 41.3, 41.0, 39.9, 37.9, 37.6, 33.7, 28.6, 27.2, 20.1, 19.4, 15.5; 
125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.1, 20.1, 15.5; CH2 δ 110.8, 108.9, 95.1, 72.1, 
70.1, 69.5, 66.0, 64.0, 61.3, 60.6, 42.6, 42.5, 41.4, 41.0, 39.9, 37.9, 37.6, 33.7, 28.6; CH δ 
141.7, 135.8, 129.8, 129.5, 128.7, 128.1, 127.9, 127.9, 114.0, 99.8, 76.6, 75.6, 75.0, 74.6, 
72.8; C  δ 170.3, 168.5, 159.3, 144.8, 142.0, 137.6, 134.1, 131.1, 125.3, 81.3, 19.4; IR 
(neat) 2939, 2887, 1761, 1656, 1612, 1513, 1428, 1378, 1248, 1172, 1110, 1049, 894, 
823, 738, 703 cm-1. 




methylenetetrahydro-2H-pyran-2-carboxylate (2.7): A solution of 2.6 (90.3 mg, 0.084 
mmol, 1.0 equiv) was prepared in DMF (1.70 mL, 0.05 M) in a 5 mL flask. A solution of 
AcOH in DMF (1.0 M, 84 µL, 1.0 equiv) and TBAF in THF (1.0 M, 84 µL, 1.0 equiv) 
were mixed together and added to the reaction mixture. The mixture was stirred at rt 
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overnight, and then quenched with a solution of saturated aqueous NaHCO3 (5.0 mL) and 
diluted with brine (10 mL). After extraction with EtOAc (3 × 10 mL), the solution was 
dried over Na2SO4, filtered, and concentrated. The crude product was then purified on a 1 
× 10 cm silica gel column, eluting with a gradient of 25 % –60 % EtOAc/ hexanes, 
collecting 5 mL fractions. Fractions 50–90 were concentrated to yield the product (70.1 
mg, 100%) as a colorless oil. Rf = 0.15 (50% EtOAc/ hexanes); [ ] =20Dα  +9.5o (c = 1.1, 
CHCl3);  500 MHz 
1H NMR (CDCl3) 7.36–7.29 (m, 5H), 7.26 (d, J = 8.0 Hz, 2H), 6.89 
(d, J = 8.5 Hz, 2H), 6.34 (t, J = 7.0 Hz, 1H), 4.77 (s, 2H), 4.77 (s, 1H), 4.72 (s, 2H), 4.70 
(q, J = 5.5 Hz, 1H), 4.67 (s, 1H), 4.59 (s, 2H), 4.47 (ABq, J = 10.5 Hz, Δν = 26.5 Hz, 
2H), 4.28 (ABq, J = 11.5 Hz, Δν = 42.0 Hz, 2H), 3.95 (dd, J = 12.5, 2.5 Hz, 1H), 3.90–
3.85 (m, 1H), 3.83–3.81 (m, 1H), 3.80 (s, 3H), 3.75–3.62 (m, 6H), 3.50–3.44 (m, 3H), 
3.08–3.02 (m, 1H), 3.00–2.94 (m, 1H,), 2.89–2.71 (m, 2H), 2.45 (d, J = 13 Hz, 1H), 2.25 
(q, J = 13 Hz, 2H), 2.18 (d, J = 13.5 Hz, 2H), 2.07–2.01 (m, 2H), 1.99–1.94 (m, 3H), 
1.92–1.89 (m, 1H), 1.80–1.70 (m, 2H), 1.68–1.63 (m, 2H), 1.31 (d, J = 5.5 Hz, 3H), 1.21 
(t, J = 6.5 Hz, 3H). 125 MHz 13C NMR (CDCl3) δ 170.3, 168.5, 159.6, 144.4, 142.1, 
141.7, 137.6, 130.6, 129.7, 128.7, 128.1, 125.3, 114.2, 110.8, 109.1, 99.9, 95.2, 81.3, 
76.7, 75.8, 75.4, 75.3, 74.8, 72.0, 70.1, 69.5, 66.1, 64.0, 61.3, 60.4, 55.5, 42.5, 41.7, 41.4, 
40.9, 39.9, 37.6, 36.8, 33.8, 31.2, 28.6, 20.1, 15.5; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 
20.1, 15.5; CH2 δ 110.8, 109.1, 95.2, 72.0, 70.1, 69.5, 66.1, 64.0, 61.3, 60.4, 42.5, 41.7, 
41.4, 40.9, 39.9, 37.6, 36.8, 33.8, 31.2, 28.6; CH δ 141.7, 129.7, 128.7, 128.1, 114.2, 
99.9, 76.7, 75.8, 75.4, 75.3, 74.8; C δ 170.3, 168.5, 159.6, 144.4, 142.1, 137.6, 130.6, 
125.3, 81.3; IR (neat) 3478, 2940, 2886, 1760, 1653, 1612, 1514, 1441, 1378, 1249, 
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1173, 1108, 1048, 898, 822, 747, 700 cm-1; HRMS (ESI) calcd 859.4245 for 
C47H64O13Na (M+Na), found 859.4240. 




butanoic acid (2.8): To a stirring solution of 2.7 (17.1 mg, 0.02 mmol, 1.0 equiv) in 
CH2Cl2 (200 µL, 0.1 M) in a 5 mL via was added i-Pr2NEt (20 µL, 0.13 mmol, 7.0 
equiv), followed by DMSO (10 µL, 0.19 mmol, 10.0 equiv). The solution was chilled to 0 
oC and SO3•Pyr (12 mg, 0.08 mmol, 4.0 equiv) was added in one portion. After stirring 
for 1.5 h at 0 oC, the reaction mixture was quenched with saturated aqueous NaHCO3 
solution (2.0 mL). After extraction with EtOAc (3 × 5 mL), the solution was dried over 
Na2SO4, filtered, and concentrated. The crude aldehyde was purified on a plug of silica 
gel in a Pasteur pipette, eluting with 25% EtOAc/ hexanes. The crude aldehyde was used 
as is without characterization.  
 The aldehyde (0.02 mmol, 1.0 equiv) was taken up in t-BuOH (270 µL) in a 5 mL 
vial. To a stirring solution of aldehyde, 2-methyl-2-butene (270 µL) was added, followed 
by an aqueous KH2PO4 solution (1.25 M, 90 µL, 0.11 mmol, 6.0 equiv). The rapidly 
stirred mixture was chilled to –10 oC in a MeOH/ ice bath. To the cold solution 80% 
NaClO2 (11 mg, 0.1 mmol, 5.0 equiv) was added in one portion. After stirring for 1 h at –
10 oC, the reaction was quenched with aqueous pH 4.0 acetate buffer (0.1 M, 5.0 mL). 
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After extracting with EtOAc (4 × 5.0 mL), the solution was dried over Na2SO4, filtered, 
and concentrated. The product was purified on a 0.5 × 5 cm Pasteur pipette silica gel 
column, eluting with 80/20/1 toluene/ EtOAc/ AcOH, collecting 1.0 mL fractions. 
Fractions 4–14 were concentrated to yield the product (14 mg, 82%) as a colorless oil. Rf 
= 0.37 (80/ 20/ 1 PhCH3/ EtOAc/ AcOH);[ ] =20Dα  +14o (c = 0.45, CHCl3);  500 MHz 1H 
NMR (CDCl3) 7.38–7.28 (m, 5H), 7.25 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 6.34 
(ddd, J = 5.0, 5.0, 2.0 Hz, 1H), 4.77 (s, 2H), 4.74 (q, J = 5.0 Hz, 1H), 4.73–4.69 (m, 4H), 
4.60 (s, 2H), 4.49 (ABq, J = 11 Hz, Δν = 60 Hz, 2H), 4.32 (dd, J = 13, 4.5 Hz, 1H), 4.28 
(dd, J = 15, 3.5 Hz, 1H), 4.09–4.07 (m, 1H), 3.94 (dd, J = 11.5, 2.0 Hz, 1H), 3.81–3.80 
(m, 1H), 3.80 (s, 3H), 3.72–3.62 (m, 3H), 3.58–3.54 (m, 1H), 3.52–3.46 (m, 2H), 3.43–
3.37 (m, 1H), 3.10–2.92 (m, 2H), 2.81 (ABq, J = 16.5 Hz, Δν = 40.8 Hz, 2H), 2.63 (d, J = 
5.0 Hz, 1H), 2.45 (d, J = 12.5 Hz, 1H), 2.27–2.19 (m, 3H), 2.15 (d, J = 12.5 Hz, 1H), 
2.08–2.02 (m, 1H), 1.96 (q, J = 12 Hz, 3H), 1.79 (dd, J = 14, 8.0 Hz, 1H), 1.70 (ddd, J = 
10, 5.0, 5.0 Hz, 1H), 1.65 (ddd, J = 11, 5.5, 5.0 Hz, 1H), 1.32 (t, J = 5.5 Hz, 3H), 1.21 (t, 
J = 7.0 Hz, 3H). 125 MHz 13C NMR (CDCl3) δ 173.8, 170.8, 168.6, 159.5, 144.3, 141.8, 
141.3, 137.6, 130.4, 129.6, 128.7, 128.1, 125.5, 114.1, 111.0, 109.1, 99.8, 95.2, 81.4, 
76.6, 75.9, 75.1, 75.0, 73.3, 72.0, 70.1, 69.6, 66.5, 64.0, 61.3, 55.5, 42.7, 42.0, 41.2, 41.0, 
40.1, 40.0, 37.5, 33.9, 28.5, 20.0, 15.5; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 20.0, 15.5; 
CH2 δ 111.0, 109.1, 95.2, 72.0, 70.1, 69.6, 66.5, 64.0, 61.3, 42.7, 42.0, 41.2, 40.1, 40.0, 
37.5, 33.9, 28.5; CH δ 141.3, 129.6, 128.7, 128.1, 114.1, 99.8, 76.6, 75.9, 75.1, 75.0, 
73.3, 41.0; C δ 173.8, 170.8, 168.6, 159.5, 144.3, 141.8, 137.6, 130.4, 125.5, 81.4; IR 
(neat) 2938, 1761, 1684, 1653, 1514, 1379, 1249, 1173, 1108, 1047, 899, 823, 740, 699 
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cm-1; HRMS (ESI) calcd 873.4037 for C47H62O14Na (M+Na), found 873.4047. 
 Preparation of (R)-4-((2S,6R)-6-(((2S,6R)-6-((((R,Z)-2-
(((benzyloxy)methoxy)methyl)-4-(3-hydroxypropylidene)-5-oxotetrahydrofuran-2-
yl)methoxy)carbonyl)-4-methylenetetrahydro-2H-pyran-2-yl)methyl)-4-
methylenetetrahydro-2H-pyran-2-yl)-3-((4-methoxybenzyl)oxy)butanoic acid (2.35): 
To a stirring solution of carboxylic acid 2.8 (46 mg, 0.05 mmol, 1.0 equiv) in MeOH (5.4 
mL, 0.01 M) in a 10 mL flask under N2 was added PPTS (6.4 mg, 0.03 mmol, 0.47 
equiv). After stirring overnight, the reaction mixture was diluted with brine (25 mL), and 
extracted with EtOAc (3 × 10 mL). After drying over Na2SO4, the solution was filtered 
and concentrated. The crude product was purified on a 1 × 10 cm silica gel column, 
eluting with 50 mL 50 % EtOAc/ hexanes and then 50/ 40/ 10 hexanes/ EtOAc/ MeOH, 
collecting 5 mL fractions. Fractions 12–42 were concentrated to yield the seco-acid (39.2 
mg, 93%) as a colorless oil. Rf = 0.21 (50/ 40/ 10 Hexanes/ EtOAc/ MeOH); [ ] =20Dα  
+12.1o (c = 0.860, MeOH);  500 MHz 
1H NMR (CDCl3) 7.38–7.29 (m, 5H), 7.25 (d, J = 
8.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 6.34 (t, J = 7.5 Hz, 1H), 4.78 (m, 3H), 4.75–4.72 
(m, 2H), 4.68 (s, 1H), 4.61 (s, 2H), 4.49 (ABq, J = 10.5 Hz, Δν = 52.2 Hz, 2H), 4.32 
(ABq, J = 12 Hz, Δν = 27.9 Hz, 2H), 4.11–4.08 (m, 1H), 3.95 (dd, J = 12, 2.5 Hz, 1H), 
3.80 (s, 3H), 3.82–3.74 (m, 2H), 3.68 (dd, J = 11, 1.0 Hz, 2H), 3.58–3.52 (m, 1H), 3.47 
(t, J = 10.5 Hz, 1H), 3.42–3.35 (m, 3H), 3.10 (dddd, J = 13.5, 7.0, 7.0, 7.0 Hz, 1H), 3.00–
2.98 (m, 3H), 2.63 (d, J = 6.0 Hz, 2H), 2.45 (d, J = 13 Hz, 1H), 2.36 (s, 1H), 2.29–2.20 
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(m, 3H), 2.16 (d, J = 13 Hz, 1H), 2.08–2.02 (m, 1H), 1.97 (q, J = 10.5 Hz, 2H), 1.79 (dd, 
J = 13, 8.0 Hz, 1H), 1.72–1.62 (m, 2H). 125 MHz 13C NMR (CDCl3) δ 170.7, 169.3, 
159.5, 144.2, 141.9, 140.4, 137.6, 130.4, 129.6, 129.3, 128.7, 128.4, 128.1, 125.5, 114.1, 
111.0, 109.2, 95.2, 81.8, 76.7, 75.9, 75.3, 74.9, 73.6, 72.1, 70.2, 69.8, 66.7, 61.9, 55.5, 
42.8, 42.0, 41.2, 41.1, 40.3, 39.9, 37.6, 34.0, 30.9; 125 MHz DEPT (CDCl3) CH3 δ 55.5; 
CH2 δ 111.0, 109.2, 95.2, 72.1, 70.2, 69.8, 66.7, 61.9, 42.8, 42.0, 41.2, 41.1, 40.3, 39.9, 
37.6, 34.0, 30.9; CH δ 140.4, 129.6, 128.7, 128.4, 128.1, 114.1, 76.7, 75.9, 75.3, 74.9, 
73.6; C δ 170.7, 169.3, 159.5, 144.2, 141.9, 137.6, 130.4, 129.3, 125.5, 81.8; IR (neat) 
3467, 3072, 3032, 2936, 2891, 1757, 1673, 1654, 1613, 1586, 1514, 1498, 1455, 1439, 
1421, 1399, 1374, 1302, 1249, 1174, 1108, 1081, 1045, 898, 848, 822 cm-1; HRMS (ESI) 
calcd 801.3462 for C43H54O13Na (M+Na), found . 
 Preparation of (1R,3S,7R,11R,21R,23S,Z)-11-
(((benzyloxy)methoxy)methyl)-21-((4-methoxybenzyl)oxy)-5,25-dimethylene-
9,12,18,27,28-pentaoxatetracyclo[21.3.1.13,7.111,14]nonacos-14-ene-8,13,19-trione 
(2.9):  To a 100 mL flask under N2 was added toluene (14.5 mL), followed by 2,4,6-
trichlorobenzoyl chloride (230 µL of  0.1 M, 0.023 mmol, 1.0 equiv), Et3N (460 µL of 
0.1 M, 0.046 mmol, 2.0 equiv), and DMAP (23 µL of 0.1 M, 0.002 mmol, 0.1 equiv). All 
of these solutions were prepared in toluene. A solution of seco-acid 2.35 (17.8 mg, 0.02 
mmol, 1.0 equiv) in toluene (14.5 mL) was added via syringe pump at 0.75 mL/ h to the 
stirring solution at 40 oC. The addition was complete after 20 h. The transfer was 
completed by washing the syringe with toluene (1.0 mL) and adding this to the reaction 
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mixture via syringe pump at 0.75 mL/ h. After stirring at 40 oC for 3 h, the reaction 
mixture was cooled to rt and quenched with saturated aqueous NaHCO3 solution (50 
mL). The mixture was extracted with EtOAc (3 × 10 mL). The combined organic phase 
was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The 
product was purified on a 1 × 10 cm silica gel column, eluting with 25% EtOAc/ hexanes, 
collecting 5 mL fractions. Fractions 17–37 were concentrated to the yield the product (9.3 
mg, 54%) as a colorless oil. Rf = 0.56 (50% EtOAc/ hexanes);[ ] =20Dα  +27o (c = 0.69, 
CHCl3);  500 MHz 
1H NMR (CDCl3) 7.39–7.31 (m, 5H), 7.22 (d, J = 9.0 Hz, 2H), 6.88 
(d, J = 8.5 Hz, 2H), 6.28 (t, J = 7.0 Hz, 1H), 4.81 (s, 1H), 4.80 (s, 2H), 4.75 (s, 2H), 4.69 
(s, 2H), 4.62 (s, 2H), 4.41 (s, 2H), 4.27 (ddd, J = 15, 8.0, 3.5 Hz, 1H), 4.16–4.09 (m, 3H), 
3.81 (s, 3H), 3.74 (dd, J = 12, 2.5 Hz, 1H), 3.60 (t, J = 11 Hz, 1H), 3.43 (t, J = 11 Hz, 
1H), 3.27 (t, J = 11 Hz, 1H), 3.18–3.10 (m, 1H), 2.83 (dd, J = 17, 2.5 Hz, 1H), 2.76 (dd, J 
= 15.5, 2.5 Hz, 1H), 2.72 (d, J = 17 Hz, 1H), 2.56 (dd, J = 15.5, 10.5 Hz, 1H), 2.46 (d, J = 
13 Hz, 1H), 2.27 (t, J = 12.5 Hz, 1H), 2.20 (t, J = 11.5 Hz, 2H), 2.06–2.00 (m, 2H), 1.97–
1.92 (m, 2H), 1.80 (m, 1H), 1.75–1.69 (m, 2H), 1.66–1.61 (m, 2H). 125 MHz 13C NMR 
(CDCl3) δ 171.5, 170.0, 168.8, 159.5, 143.9, 141.6, 138.1, 137.6, 130.6, 129.5, 128.8, 
128.2, 127.3, 114.1, 111.3, 109.5, 95.3, 82.3, 77.8, 77.5, 76.6, 75.9, 74.8, 74.4, 73.0, 70.3, 
69.9, 67.8, 64.0, 55.5, 43.0, 42.2, 41.7, 41.3, 39.6, 37.6, 34.3, 27.2; 125 MHz DEPT 
(CDCl3) CH3 δ 55.5; CH2 δ 111.3, 109.5, 95.3, 73.0, 70.3, 69.9, 67.8, 64.0, 43.0, 42.2, 
41.7, 41.3, 39.6, 37.6, 34.3, 27.2; CH δ 138.1, 129.5, 128.8, 128.2, 114.1, 77.8, 76.6, 
75.9, 74.9, 74.4; C δ 171.5, 170.0, 168.8, 159.5, 143.9, 141.6, 137.6, 130.6, 127.3, 82.3, 
77.5; IR (neat) 3073, 2929, 2856, 1819, 1760, 1739, 1692, 1674, 1613, 1581, 1550, 1514, 
1454, 1440, 1405, 1369, 1326, 1301, 1249, 1207, 1178, 1083, 1044, 987, 899 cm-1; 
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HRMS (ESI) calcd 783.3356 for C43H52O12Na (M+Na), found 783.3356. 
 Preparation of Merle 39 (1R,3S,7R,11R,21R,23S,Z)-21-
hydroxy-11-(hydroxymethyl)-5,25-dimethylene-9,12,18,27,28-pentaoxatetracyclo 
[21.3.1.13,7.111,14]nonacos-14-ene-8,13,19-trione: To a stirring solution of 
macrolactone 2.9 (6.9 mg, 0.01 mmol, 1.0 equiv) in CH2Cl2 (900 µL, 0.01 M) contained 
in a 5 mL vial at 0 oC was added H2O (20 µL), followed by DDQ (21 mg, 0.1 mmol, 10.0 
equiv). The reaction mixture was stirred at 0 oC for 2 h and then quenched with a solution 
of saturated aqueous NaHCO3 (10 mL). The reaction mixture was extracted with CH2Cl2 
(3 × 10 mL), dried over Na2SO4, filtered, and concentrated. The crude product was used 
without purification. 
 To the previously described crude alcohol contained in a 5 mL vial, a solution of  
LiBF4 in 25:1 MeCN/ H2O (0.25 M, 1.62 mL, 0.41 mmol, 45 equiv) was added. After 
flushing with N2, the vial was capped and heated at 80 oC overnight with stirring. After 
cooling to rt, the solvent was evaporated and the reaction mixture was quenched with 
brine (10 mL), and extracted with EtOAc (3 × 10 mL). After drying over Na2SO4, the 
solution was filtered and concentrated. The product was purified on a 1 × 5 cm silica gel 
column, eluting with 60% EtOAc/ pentane, collecting 1 mL fractions. Fractions 11–56 
were concentrated to yield the product (3.4 mg, 73% over 2-steps) as a colorless oil. Rf = 
0.40  (50/ 40/ 10 hexanes/ EtOAc/ MeOH); [ ] =20Dα  +6.2o (c = 0.065, CHCl3);  500 MHz 
1H NMR (CDCl3) 6.29 (t, J = 7.5 Hz, 1H), 4.83 (d, J = 18 Hz, 2H), 4.74 (s, 2H), 4.65 (d, 
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J = 12 Hz, 1H), 4.38 (ddd, J = 15, 8.0, 3.5 Hz, 1H), 4.20–4.17 (m, 1H), 4.14 (d, J = 12 
Hz, 2H), 3.82 (dd, J = 12.5, 2.5 Hz, 1H), 3.79–3.76 (m, 1H), 3.70 (dd, J = 12, 6.5 Hz, 
1H), 3.55–3.49 (m, 1H), 3.46–3.41 (m, 2H), 3.32–3.25 (m, 2H), 2.92 (dd, J = 16.5, 3.0 
Hz, 1H), 2.85–2.79 (m, 1H), 2.71 (dd, J = 15.5, 1.5 Hz, 1H), 2.46 (d, J = 13 Hz, 1H), 
2.41 (dd, J = 16, 10.5 Hz, 1H), 2.30 (d, J = 14.5 Hz, 1H), 2.24 (d, J = 12.5 Hz, 1H), 2.18 
(d, J = 13.5 Hz, 2H), 2.05–1.92 (m, 5H), 1.79–1.66 (m, 4H). 125 MHz 13C NMR (CDCl3) 
δ 173.6, 173.3, 170.2, 143.8, 141.8, 138.7, 127.7, 111.0, 109.5, 83.8, 76.8, 76.8, 75.2, 
67.8, 67.2, 65.1, 64.2, 42.6, 42.4, 41.2, 41.2, 39.7, 37.6, 33.2, 29.9, 27.4; 125 MHz DEPT 
(CDCl3) CH3 δ; CH2 δ 111.0, 109.5, 67.2, 65.1, 64.2, 42.6, 42.4, 41.2, 41.2, 39.7, 37.6, 
33.2, 29.9, 27.4; CH δ 138.7, 76.8, 75.2, 67.8; C δ 173.6, 173.3, 170.2, 143.8, 141.8, 
127.7, 83.8; IR (neat) 3488, 2924, 1755, 1652, 1408, 1368, 1327, 1262, 1179, 1104, 907, 
733 cm-1; HRMS (ESI) calcd 543.2206 for C27H36O10Na (M+Na), found 543.2216. 
 







Experimental Procedures for  Merle 47 
 Preparation of (S,Z)-4-(((benzyloxy)methoxy)methyl)-2-(3-
hydroxypropylidene)-4-((trityloxy)methyl)cyclopentan-1-one (2.10): To a solution of 
lactone 1.93 (150 mg, 0.22 mmol, 1.0 equiv) in THF (4.40 mL, 0.05 M) contained in a 15 
mL polyethylene centrifuge tube was added NH4F (41 mg, 1.1 mmol, 5.0 equiv). TBAF 
(1.0 M, 1.11 mL, 1.11 mmol, 5.0 equiv) was added. After stirring for 1.5 h, the reaction 
mixture was quenched with brine (20 mL) and extracted with EtOAc (3 × 10 mL). The 
organic phase was dried over Na2SO4, filtered, and concentrated. The product was 
purified on a 2 × 10 cm silica gel column, eluting with 35% EtOAc/ hexanes, collecting 5 
mL fractions. Fractions 18–44 were concentrated to yield the product as a colorless oil 
(118 mg, 95%). Rf = 0.40  (50% EtOAc/ hexanes); [ ] =20Dα  +0.48o (c = 1.67, CHCl3);  500 
MHz 1H NMR (CDCl3) δ 7.44–7.43 (m, 6H), 7.39–7.24 (m, 14H), 6.28 (dddd, J = 7.5, 
4.5, 2.0, 2.0 Hz, 1H), 4.72 (s, 2H), 4.53 (s, 2H), 3.83–3.74 (m, 2H), 3.70 (q, J = 10 Hz, 
2H), 3.34 (d, J = 9.5 Hz, 1H), 3.17 (d, J = 11.5 Hz, 1H), 3.10–3.04 (m, 1H), 3.00–2.94 
(m, 1H), 2.83 (dd, J = 14, 2.0 Hz, 1H), 2.74 (dd, J = 16.5, 2.0 Hz, 1H), 1.78 (s, 1H). 125 
	  	  
157	  
MHz 13C NMR (CDCl3) δ 169.9, 143.6, 139.4, 137.7, 128.8, 128.6, 128.1, 128.1, 128.0, 
127.7, 127.4, 95.0, 87.2, 83.5, 70.2, 69.8, 65.9, 62.1, 34.2, 31.2; 125 MHz DEPT (CDCl3) 
CH3 δ; CH2 δ 95.0, 70.2, 69.8, 65.9, 62.1, 34.2, 31.2; CH δ 139.4, 128.8, 128.6, 128.1, 
128.0, 127.4; C δ 169.9, 143.6, 137.7, 127.7, 87.2, 83.5; IR (neat) 3472, 3087, 2928, 
2876, 1754, 1672, 1491, 1449, 1370, 1214, 1172, 1078, 1045, 992, 944, 900, 747, 700 
cm-1; HRMS (ESI) calcd 587.2410 for C36H36O6Na (M+Na), found 587.2420. 




methylenetetrahydro-2H-pyran-2-carboxylate (2.11): To a stirring solution of 
carboxylic acid 2.1 (117 mg, 0.167 mmol, 1.0 equiv) in PhCH3 (1.67 mL, 0.1 M) in a 10 
mL flask under N2 was added Et3N (93 µL, 0.67 mmol, 4.0 equiv). After stirring for 5 
min, 2,4,6-trichlorobenzoyl chloride (40 µL, 0.23 mmol, 1.4 equiv) was added. The 
reaction mixture was stirred for 1 h. A solution of alcohol 2.10 (165 mg, 0.29 mmol, 1.8 
equiv) and DMAP (36 mg, 0.29 mmol, 1.8 equiv) in PhCH3 (500 µL) was added. PhCH3 
(2 × 250 µL) was used to complete the transfer. The reaction mixture was stirred for 1 h, 
and then quenched with saturated aqueous NaHCO3 solution (25 mL). The mixture was 
extracted with EtOAc (3 × 10 mL), washed with brine (15 mL), dried over Na2SO4, 
filtered, and concentrated. The product was purified on a 2 × 15 cm silica gel column, 
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eluting with 15% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 14–32 were 
concentrated to yield the product as a colorless oil (127 mg, 61%). Rf = 0.48 (25% 
EtOAc/ hexanes); [ ] =20Dα  +2.48o (c = 1.62);  500 MHz 1H NMR (CDCl3) δ 7.70–7.67 (m, 
4H), 7.45–7.37 (m, 12H), 7.35–7.23 (m, 16H), 7.19 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 
Hz, 2H), 6.13 (t, J = 7.0 Hz, 1H), 4.73 (d, J = 4.0 Hz, 2H), 4.71 (s, 2H), 4.61 (s, 2H), 4.52 
(s, 2H), 4.41 (ABq, J = 10.5 Hz, Δν = 41.2 Hz, 2H), 4.25 (ddddd, J = 13.5, 10.5, 10.5, 
6.5, 6.5 Hz, 2H), 3.94–3.91 (m, 2H), 3.85–3.81 (m, 1H), 3.80 (s, 3H), 3.77–3.73 (m, 1H), 
3.68 (ABq, J = 10.5 Hz, Δν = 22.9 Hz, 2H), 3.63–3.60 (m, 1H), 3.58–3.51 (m, 1H), 3.50–
3.45 (m, 1H), 3.32 (d, J = 10 Hz, 1H), 3.17 (d, J = 9.5 Hz, 1H), 3.20–3.14 (m, 1H), 3.13–
3.09 (m, 1H), 2.79 (d, J = 16.5 Hz, 1H), 2.71 (d, J = 16.5 Hz, 1H), 2.48 (d, J = 12.5 Hz, 
1H), 2.31 (d, J = 13 Hz, 1H), 2.27–2.23 (m, 2H), 2.17 (d, J = 13.5 Hz, 1H), 2.10 (ddd, J = 
14.0, 8.0, 5.5 Hz, 1H), 2.01 (t, J = 12 Hz, 2H), 1.93 (t, J = 12 Hz, 1H), 1.84–1.74 (m, 
2H), 1.72–1.62 (m, 4H), 1.07 (s, 9H). 125 MHz 13C NMR (CDCl3) δ 170.9, 169.1, 159.3, 
144.8, 143.5, 142.3, 137.7, 137.4, 135.8, 134.0, 131.1, 129.8, 129.5, 128.8, 128.6, 128.1, 
128.0, 127.9, 127.9, 127.4, 114.0, 110.6, 108.8, 95.0, 87.2, 83.4, 77.0, 75.7, 75.0, 74.6, 
72.8, 72.1, 70.2, 69.8, 66.0, 63.9, 60.6, 55.5, 42.6, 42.5, 41.4, 41.1, 39.9, 38.0, 37.7, 34.0, 
27.2, 27.2, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.2; CH2 δ 110.6, 108.8, 95.0, 
72.1, 70.2, 69.8, 66.0, 63.9, 60.6, 42.6, 42.5, 41.4, 41.1, 39.9, 38.0, 37.7, 34.0, 27.2; CH δ 
137.4, 135.8, 129.8, 129.5, 128.8, 128.6, 128.1, 128.0, 127.9, 127.4, 114.0, 77.0, 75.7, 
75.0, 74.6, 72.8; C δ 170.9, 169.1, 159.3, 144.8, 143.5, 142.3, 137.7, 134.0, 131.1, 127.9, 
87.2, 83.4, 19.4; IR (neat) 2936, 1758, 1611, 1513, 1449, 1428, 1362, 1248, 1174, 1110, 
1046, 898, 823, 745, 703, 632 cm-1; HRMS (ESI) calcd 1267.5943 for C78H88O12NaSi 
(M+Na), found 1267.5942. 
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methylenetetrahydro-2H-pyran-2-carboxylate (2.12): A solution of ester 2.11 (25 mg, 
0.02 mmol, 1.0 equiv) was prepared in THF (200 µL, 0.1 M) in a 2 mL polyethylene vial. 
To the stirring solution, a 20% HF•pyridine solution in pyridine (500 µL) (25 mL/ mmol) 
was added. After stirring for 2.5 h, the reaction mixture was quenched with brine (10 mL) 
and saturated aqueous NaHCO3 solution (5 mL). The mixture was extracted with EtOAc 
(4 × 5 mL), dried over Na2SO4, filtered, and concentrated. The product was purified on a 
1 × 10 cm silica gel column, eluting with 45% EtOAc/ hexanes, collecting 5 mL 
fractions. Fractions 6–22 were concentrated to yield the product as a clear oil (16.1 mg, 
80%). Rf = 0.37  (50% EtOAc/ hexanes); [ ] =20Dα  +2.1o (c = 0.59);  500 MHz 1H NMR 
(CDCl3) δ 7.42–7.40 (m, 6H), 7.35–7.23 (m, 16H), 6.89 (d, J = 9.0 Hz, 2H), 6.14 (t, J = 
7.0 Hz, 1H), 4.77–4.73 (m, 2H), 4.71 (s, 2H), 4.69 (d, J = 16 Hz, 2H), 4.52 (s, 2H), 4.47 
(ABq, J = 10.5 Hz, Δν = 19.5 Hz, 2H), 4.30–4.22 (m, 2H), 3.95 (dd, J = 11.5, 2.5 Hz, 
1H), 3.91–3.86 (m, 1H), 3.84–3.81 (m, 1H), 3.80 (s, 3H), 3.75–3.71 (m, 1H), 3.68 (q, J = 
6.0 Hz, 2H), 3.59–3.55 (m, 1H), 3.51–3.44 (m, 2H), 3.32 (d, J = 10 Hz, 1H), 3.22–3.15 
(m, 1H), 3.16 (d, J = 10 Hz, 1H), 3.13–3.08 (m, 1H), 2.80 (dd, J = 16.5, 2.0 Hz, 1H), 2.72 
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(d, J = 16 Hz, 1H), 2.51 (d, J = 13 Hz, 1H), 2.30–2.23 (m, 3H), 2.19 (d, J = 12.5 Hz, 1H), 
2.10–1.90 (m, 5H), 1.81–1.64 (m, 5H). 125 MHz 13C NMR (CDCl3) δ 170.9, 169.1, 
159.5, 144.4, 143.6, 142.4, 137.7, 137.4, 130.6, 129.7, 128.8, 128.7, 128.7, 128.1, 128.0, 
128.0, 127.4, 114.2, 110.6, 109.1, 95.0, 87.2, 83.4, 77.0, 75.8, 75.5, 75.4, 74.9, 72.0, 70.2, 
69.8, 66.0, 63.9, 60.5, 55.5, 42.5, 41.7, 41.4, 41.0, 40.0, 37.7, 36.8, 34.1, 27.2; 125 MHz 
DEPT (CDCl3) CH3 δ 55.5; CH2 δ 110.6, 109.1, 95.0, 72.0, 70.2, 69.8, 66.0, 63.9, 60.5, 
42.5, 41.7, 41.4, 41.0, 40.0, 37.7, 36.8, 34.1, 27.2; CH δ 137.4, 129.7, 128.8, 128.7, 
128.1, 128.0, 127.4, 114.2, 77.0, 75.8, 75.5, 75.4, 74.9; C δ 170.9, 169.1, 159.5, 144.4, 
143.6, 142.4, 137.7, 130.6, 128.7, 128.0, 87.2, 83.4; IR (neat) 3503, 2936, 2884, 1756, 
1684, 1652, 1616, 1516, 1490, 1448, 1362, 1249, 1175, 1078, 1045, 898, 748, 704, 633 




methylenetetrahydro-2H-pyran-2-yl)-3-((4-methoxybenzyl)oxy)butanoic acid (2.13): 
To a stirring  solution of alcohol 2.12 (25 mg, 0.03 mmol, 1.0 equiv) in CH2Cl2 (250 µL, 
0.1 M) contained in a 5 mL vial under N2 was added i-Pr2NEt (30 µL, 0.18 mmol, 7.0 
equiv), followed by DMSO (20 µL, 0.3 mmol, 10 equiv). After cooling to 0 oC, SO3•Pyr 
(16 mg, 0.10 mmol, 4.0 equiv) was added. The reaction mixture was stirred for 2 h at 0 
oC and quenched with saturated aqueous NaHCO3 solution (5 mL). After dilution with 
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brine (5 mL), the mixture was extracted with EtOAc (3 × 5 mL), dried over Na2SO4, 
filtered, and concentrated. After evaporation with PhCH3 (3 × 2 mL), the crude aldehyde 
was used without purification for the subsequent Pinnick oxidation.  
 A solution of the previously described aldehdye (0.025 mmol, 1.0 equiv) in t-
BuOH (360 µL, 14.3 mL/ mmol) and 2-methyl-2-butene (360 µL, 14.3 mL/ mmol) was 
prepared in a 5 mL vial. After the addition of a solution of aqueous KH2PO4 (1.25 M, 120 
µL, 0.15 mmol, 6.0 equiv), the reaction mixture was cooled to –10 oC in an ice/ MeOH 
bath. NaClO2 80% (14.1 mg, 0.13 mmol, 5.0 equiv) was added in 1 portion to the rapidly 
stirred mixture. The cooling bath was allowed to expire overnight. The reaction mixture 
was quenched with aqueous pH 4.0 acetate buffer (0.1 M, 5 mL) and brine (5 mL). After 
extraction with EtOAc (3 × 5 mL), the organic phase was dried over Na2SO4, filtered, and 
concentrated. The crude carboxylic acid was purified on a 1 × 10 cm silica gel column, 
eluting with 80/20/1 PhCH3/ EtOAc/ AcOH, collecting 5 mL fractions. Fractions 4–12 
were concentrated and evaporated with PhCH3 (3 × 5 mL) to remove residual AcOH, 
yielding the product as a colorless oil (22 mg, 86% over 2 steps). Rf = 0.35 (80/20/1 
PhCH3/ EtOAc/ AcOH);[ ] =20Dα  + 6.33o (c = 1.08);  500 MHz 1H NMR (CDCl3) δ 7.42–
7.41 (m, 6H), 7.33–7.29 (m, 10H), 7.27–7.23 (m, 6H), 6.88 (d, J = 9.0 Hz, 2H), 6.14 (t, J 
= 7.0 Hz, 1H), 4.78 (s, 1H), 4.74–4.69 (m, 5H), 4.55 (d, J = 11 Hz, 1H), 4.52 (s, 2H), 
4.45 (d, J = 10.5 Hz, 1H), 4.30–4.23 (m, 2H), 4.10 (dddd, J = 11.5, 7.5, 5.5, 5.5 Hz, 1H), 
3.98 (dd, J = 11.5, 2.5 Hz, 1H), 3.79 (s, 3H), 3.69 (q, J = 11 Hz, 2H), 3.54–3.42 (m, 3H), 
3.32 (d, J = 10 Hz, 1H), 3.24–3.19 (m, 1H), 3.17 (d, J = 9.5 Hz, 1H), 3.11–3.06 (m, 1H), 
2.80 (d, J = 16.5 Hz, 1H), 2.72 (d, J = 15.5 Hz, 1H), 2.69–2.61 (m, 2H), 2.51 (d, J = 8.0 
Hz, 1H), 2.27–2.22 (m, 3H), 2.15 (q, J = 12.5 Hz, 1H), 2.08 (dd, J = 14.5, 7.0 Hz, 1H), 
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2.03 (t, J = 12.5 Hz, 1H), 1.96 (t, J = 12 Hz, 2H), 1.82 (ddd, J = 15, 8.5, 2.0 Hz, 1H), 
1.73–1.62 (m, 3H). 125 MHz 13C NMR (CDCl3) δ 174.5, 171.3, 169.1, 159.5, 144.3, 
143.5, 142.3, 137.6, 137.3, 130.3, 129.7, 128.8, 128.7, 128.4, 128.1, 128.1, 128.0, 127.4, 
114.1, 110.7, 109.1, 95.0, 87.2, 83.4, 76.8, 75.7, 75.1, 74.9, 73.2, 72.0, 70.2, 69.8, 65.9, 
64.0, 55.5, 42.8, 41.9, 41.2, 41.0, 40.2, 39.9, 37.7, 34.1, 27.2; 125 MHz DEPT (CDCl3) 
CH3 δ 55.5; CH2 δ 110.7, 109.1, 95.0, 72.0, 70.2, 69.8, 65.9, 64.0, 42.8, 41.9, 41.2, 41.0, 
40.2, 39.9, 37.7, 34.1, 27.2; CH δ 137.4, 129.7, 128.8, 128.7, 128.1, 128.0, 127.4, 114.1, 
76.8, 75.7, 75.1, 74.9, 73.2 ;C δ 174.5, 171.3, 169.1, 159.5, 144.3, 143.5, 142.3, 137.6, 
130.3, 128.4, 128.1, 87.2, 83.4; IR (neat) 3065, 2959, 2894, 1756, 1711, 1653, 1612, 
1514, 1449, 1369, 1249, 1176, 1080, 1043, 900, 824, 748, 701 cm-1; HRMS (ESI) calcd 
1043.4558 for C26H68O13Na (M+Na), found 1043.4554. 
 Preparation of (1R,3S,7R,16R,21R,23S,Z)-16-
(((benzyloxy)methoxy)methyl)-21-((4-methoxybenzyl)oxy)-5,25-dimethylene-
9,15,18,27,28-pentaoxatetracyclo[21.3.1.13,7.113,16]nonacos-12-ene-8,14,19- 
trione (2.14): To a  5 mL vial containing carboxylic acid 2.13 (22 mg, 0.02 mmol, 1.0 
equiv) was added 50:50 Et2O/ HCOOH (2.3 mL, 105 mL/ mmol). The vial was flushed 
with N2 and the mixture stirred for 3 h at rt. The solvent was evaporated and the crude 
product was azeotroped with PhCH3 (3 × 5 mL). The product was purified on a 1 × 10 cm 
silica gel column, eluting with 50/45/5 hexanes/ EtOAc/ MeOH, collecting 5 mL 
fractions. Fractions 4–22 were concentrated, yielding the product as a clear oil which was 
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used without further characterization.  
 The previously prepared seco-acid was dried overnight under high vacuum in a 5 
mL vial. The seco-acid was taken up in THF (820 µL, 0.03 M) and Et3N (20 µL, 0.13 
mmol, 6.0 equiv) was added to the stirred solution under N2. After cooling to 0 oC, a 
solution of 2,4,6-trichlorobenzoyl chloride in THF (0.1 M, 660 µL, 0.066 mmol, 3.0 
equiv) was added dropwise. After stirring for 5 min at 0 oC, the mixture was then stirred 
at rt for 3 h. The resulting solution was taken up in PhCH3 (14 mL) in a 25 mL gas-tight 
syringe. This solution was then added over 16 h via syringe pump at 0.875 mL/ h to a 
stirring solution of DMAP (54 mg, 0.44 mmol, 20 equiv) in PhCH3 (14 mL) contained in 
a 50 mL flask under N2 that was heated at 40 oC. This produced a final reactant 
concentration of 0.0008 M. After the addition was complete, PhCH3 (1.0 mL) was taken 
up in the syringe and added over 1 h to complete the transfer. After stirring for 3 h at 40 
oC, the reaction mixture was quenched with brine (50 mL), extracted with EtOAc (3 × 10 
mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified on a 
1 × 10 cm silica gel column, eluting with 50% EtOAc/ hexanes, collecting 5 mL 
fractions. Fractions 2–7 were concentrated to yield the product as a colorless oil (9.2 mg, 
55% over 2 steps). Rf =0.52  (50% EtOAc/ hexanes); [ ] =20Dα  +16.1o (c = 0.460); 500 MHz 
1H NMR (CDCl3) δ 7.35–7.28 (m, 5H), 7.25 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 
6.17 (t, J = 8.0 Hz, 1H), 4.95 (d, J = 6.0 Hz, 1H), 4.78 (d, J = 8.5 Hz, 1H), 4.78 (s, 1H), 
4.72–4.71 (m, 2H), 4.66 (d, J = 11.0 Hz, 1H), 4.64 (s, 1H), 4.58 (d, J = 16.5 Hz, 2H), 
4.54 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 11.5 Hz, 2H), 4.39 (d, J = 11 Hz, 1H), 4.19–4.14 
(m, 1H), 4.01 (d, J = 11.5 Hz, 1H), 4.00–3.95 (m, 1H), 3.88 (ddd, J = 11.5, 11.5, 2.0 Hz, 
2H), 3.81 (s, 3H), 3.67 (d, J = 10 Hz, 1H), 3.63–3.57 (m, 1H), 3.55–3.49 (m, 1H), 3.38–
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3.34 (m, 2H), 2.89 (d, J = 15.5 Hz, 1H), 2.81 (dd, J = 15.5, 4.0 Hz, 1H), 2.59 (d, J = 13 
Hz, 1H), 2.55 (d, J = 16 Hz, 1H), 2.45 (dd, J = 14.5, 9.5 Hz, 1H), 2.34 (d, J = 13.5 Hz, 
1H), 2.27 (t, J =12 Hz, 1H), 2.21–2.18 (m, 1H), 2.15 (t, J = 12 Hz, 2H), 1.96 (t, J = 12.5 
Hz, 2H), 1.88 (t, J = 12.5 Hz, 2H), 1.70 (dd, J = 8.0, 4.0 Hz, 2H), 1.63–1.60 (m, 1H). 125 
MHz 13C NMR (CDCl3) δ 170.4, 168.8, 159.5, 144.4, 142.4, 138.5, 137.8, 130.4, 129.4, 
128.7, 128.1, 128.0, 128.0, 127.9, 114.2, 110.6, 109.1, 94.6, 81.5, 77.6, 76.2, 74.9, 74.7, 
73.0, 72.4, 69.9, 66.6, 65.3, 62.6, 55.5, 43.1, 42.4, 41.4, 41.2, 40.8, 40.4, 37.0, 34.7, 26.5; 
125 MHz DEPT (CDCl3) CH3 δ 55.5; CH2 δ 110.6, 109.1, 94.6, 72.4, 69.9, 66.6, 65.3, 
62.3, 62.5, 43.1, 42.4, 41.4, 41.2, 40.8, 40.4, 37.0, 34.7, 26.5; CH δ 138.5, 129.4, 128.7, 
128.0, 114.1, 77.6, 76.2, 74.9, 74.7, 73.0; C δ 170.4, 168.8, 159.5, 144.4, 142.4, 137.8, 
130.4, 128.1, 128.0, 127.9, 81.5. IR (neat) 2940, 2886, 1764, 1742, 1612, 1514, 1380, 
1249, 1176, 1120, 1047, 892, 821, 740 cm-1: HRMS (ESI) calcd 783.3356 for 
C43H52NaO15 (M+Na), found 783.3367.   
 Preparation of Merle 47 (1R,3S,7R,16S,21R,23S,Z)-21-
hydroxy-16-(hydroxymethyl)-5,25-dimethylene-9,15,18,27,28-pentaoxatetracyclo 
[21.3.1.13,7.113,16]nonacos-12-ene-8,14,19-trione: To a stirring solution of 
macrolactone 2.14 (5.3 mg, 0.007 mmol, 1.0 equiv) in CH2Cl2 (700 µL, 0.01 M) 
contained in a 5 mL vial was added H2O (20 µL). After cooling to 0 oC, DDQ (16.1 mg, 
0.07 mmol, 10 equiv) was added. After stirring at 0 oC for 2 h, the reaction mixture was 
quenched with saturated aqueous NaHCO3 solution (25 mL) and extracted with CH2Cl2 
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(3 × 10 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. After 
drying under high vacuum for 1 hour, the crude product was used as is for the subsequent 
deprotection step. 
 To the aforementioned product contained in a 5 mL vial, a solution of LiBF4 in 
25:1 MeCN/ H2O (0.25 M, 1.26 mL, 45 equiv) was added. The vial was flushed with N2, 
capped, and stirred at 80 oC overnight. After cooling to rt, the reaction mixture was 
quenched with brine (10 mL), and extracted with EtOAc (3 × 10 mL). After drying over 
Na2SO4, the solution was filtered and concentrated to dryness. The crude product was 
purified on a 1 × 5 cm silica gel column, eluting with 50% EtOAc/ hexanes, collecting 1 
mL fractions. Fractions 9–50 contained the desired product. The product was purified a 
second time by the same procedure to yield the desired macrolactone as an oil (1.3 mg, 
36% 2-steps). Rf = 0.08 (50% EtOAc/ hexanes); [ ] =20Dα   –6.2o (c = 0.065); 500 MHz 1H 
NMR (CDCl3) δ 6.28 (t, J = 7.0, Hz, 1H), 4.61 (dd, J = 10, 1.5 Hz, 2H), 4.57 (s, 2H), 
4.50 (d, J = 12 Hz, 1H), 4.45–4.41 (m, 1H), 4.36–4.30 (m, 1H), 4.24 (ddd, J = 10.5, 10.5, 
2.5 Hz, 1H), 4.07 (d, J = 12 Hz, 1H), 3.87 (dd, J = 11.5, 2.5 Hz, 1H), 3.72–3.70 (m, 2H), 
3.63 (t, J = 10 Hz, 1H), 3.53–3.48 (m, 1H), 3.43 (t, J = 11.5 Hz, 2H), 2.92 (d, J = 16 Hz, 
1H), 2.87 (t, J = 5.0 Hz, 1H), 2.77 (dd, J = 13.5, 4.5 Hz, 2H), 2.69 (d, J = 16 Hz, 1H), 
2.53 (d, J = 13 Hz, 1H), 2.48 (dd, J = 14, 9.5 Hz, 1H), 2.42 (d, J = 6.0 Hz, 1H), 2.37–2.29 
(m, 2H), 2.18 (t, J = 9.0 Hz, 2H), 2.07–1.97 (m, 3H), 1.78–1.73 (m, 1H), 1.70–1.62 (m, 
3H). 125 MHz 13C NMR (CDCl3) δ; 170.4, 168.8, 143.6, 141.9, 139.2, 127.7, 111.0, 
109.6, 83.0, 77.5, 77.0, 76.3, 76.1, 75.5, 65.8, 63.4, 63.2, 43.2, 43.0, 41.9, 41.3, 41.2, 
40.6, 37.0, 34.0, 26.9; 125 MHz DEPT (CDCl3) CH3 δ; CH2 δ 111.0, 109.6, 77.5, 75.4, 
65.8, 63.4, 63.2, 43.2, 41.9, 41.4, 41.2, 40.6, 37.0, 26.9; CH δ 139.2, 77.0, 76.3, 76.1, 
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75.4, 65.8; C δ 170.4, 168.8, 143.6, 141.9, 127.7, 83.0. IR (neat) 3430, 2943, 1754, 1742, 
1581, 1382, 1257, 1194, 1081, 1030, 896, 753 cm-1; HRMS (ESI) calcd for C27H36NaO10 
(M+Na) 543.2206, found 543.2207.   
 









Compound! date! Kd,(nM)! Ki,(nM)! p!
M47! 2/5/2015! .28,+,.02! 4355! 0.8!
2/9/2015! .28,+,.02! 4593! 1.1!
2/11/2015! .28,+,.02! 5856! 0.6!
Mean! 4935! 466! SEM!
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Experimental Procedures for Merle 48 
 Preparation of methyl 5-((tert-butyldimethylsilyl)oxy)-3-
hydroxy-2,2-dimethylpentanoate (2.18): To a solution of i-Pr2NH (3.0 mL, 21.5 mmol, 
1.1 equiv) in THF (15 mL) contained in a 100 mL flask under N2 at –78 oC was added a 
solution of  n-BuLi (2.5 M, 8.6 mL, 21.5 mmol, 1.1 equiv). The solution was stirred at rt 
for 30 min. After cooling the solution to –78 oC, a solution of methyl isobutyrate (2.2 mL, 
19.5 mmol, 1.0 equiv) in THF (5 mL) was added via cannula. The solution was stirred for 
1.5 h at –78 oC, after which a solution of aldehyde 1.79 (4.4 g, 23.4 mmol, 1.2 equiv) in 
THF (5 mL) was added via cannula. The reaction mixture was stirred at –78 oC for 2 h. 
The reaction mixture was then quenched with saturated aqueous NaHCO3 solution (50 
mL). The mixture was then extracted with 50% EtOAc/ hexanes (3 × 15 mL). The 
organic phase was washed with brine (2 × 25 mL) and dried over Na2SO4. After 
filtration, the solvent was evaporated. The crude product was purified on a 4 × 10 cm 
silica column, eluting with 10% EtOAc/ hexanes, collecting 10 mL fractions. Fractions 
22–58 were combined and concentrated to yield the product (5.9 g, 94%) as a colorless 
oil: Rf = 0.54 (25 % EtOAc/ hexanes); 500 MHz 1H NMR (CDCl3) δ 3.94 (ddd, J = 8.0, 
6.0, 3.0 Hz, 1H), 3.89 (dd, J = 10, 5.0 Hz, 1H), 3.85–3.81 (m, 1H), 3.70 (s, 3H), 3.43 (d, J 
= 3.0 Hz, 1H), 1.59 (t, J = 4.5 Hz, 2H), 1.20 (s, 3H), 1.17 (s, 3H), 0.90 (s, 9H), 0.08 (s, 
6H); 125 MHz 13C NMR (CDCl3) δ 178.0, 76.3, 62.5, 52.1, 47.3, 33.9, 26.1, 21.5, 20.8, 
18.4, –5.3; 125 MHz DEPT (CDCl3) CH3 δ 52.1, 26.1, 21.5, 20.7, –5.3; CH2 δ 62.9, 33.8; 
CH δ 76.3; C δ 178.0, 47.3, 18.4; IR (neat) 3508, 2954, 2857, 1732, 1471, 1388, 1256, 
1090 cm-1; HRMS (ESI) calcd 313.1811 for C14H30O4NaSi (M+Na), found 313.1809. 
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  Preparation of methyl (E)-5-((tert-
butyldimethylsilyl)oxy)-2,2-dimethylpent-3-enoate (1.47): To a stirring solution of 
ester 2.18 (5.9 g, 20 mmol, 1.0 equiv) in toluene (81 mL, 0.25 M) contained in a 250 mL 
flask under N2 was added Et3N (5.6 mL, 40 mmol, 2.0 equiv); MsCl (1.9 mL, 24 mmol, 
1.2 equiv) was then slowly added. A white precipitate immediately formed; the reaction 
mixture was then stirred overnight at rt. The reaction mixture was then quenched with 
saturated aqueous NaHCO3 solution (150 mL). The mixture was then extracted with 50% 
EtOAc/ hexanes (3 × 25 mL). The organic phase was then washed with brine (100 mL) 
and dried over Na2SO4. After filtration, the solution was concentrated and the crude 
mesylate used as is. 
 To a stirring solution of crude mesylate in DMSO (200 mL, 0.1 M) contained in a 
500 mL flask fitted with a reflux condenser under N2 was added DBU (7.5 mL, 50 mmol, 
2.5 equiv). The reaction mixture was heated at 115 oC overnight. After cooling to rt, the 
reaction mixture was quenched with saturated aqueous NaHCO3 solution (250 mL) and 
H2O (250 mL). The mixture was extracted with 50% EtOAc/ hexanes (3 × 100 mL). The 
organic phase was washed with brine (200 mL) and dried over Na2SO4. After filtration 
and concentration, the product was purified on a 4 × 11 cm silica gel column, eluted with 
5% EtOAc/ hexanes, collecting 10 mL fractions. Fractions 28–44 were combined and 
concentrated to yield the product (3.5 g, 64%) as a colorless oil: Rf = 0.76 (25 % EtOAc/ 
hexanes); 500 MHz 1H NMR (CDCl3) 5.84 (dt, J = 15.5, 2.0 Hz, 1H), 5.59 (dt, J = 15.5, 
5.0 Hz, 1H), 4.18 (dd, J = 5.0, 1.5 Hz, 2H), 3.67 (s, 3H), 1.31 (s, 6H), 0.91 (s, 9H), 0.07 





dimethylpent-3-enal (2.19): To a stirring solution of ester 1.47 (3.24 g, 8.7 mmol, 1.0 
equiv) in Et2O (43 mL, 0.2 M) contained in a 100 mL flask under N2 at 0 oC was added 
LiAlH4 (362 mg, 9.6 mmol, 1.1 equiv). After stirring for 1 h, the reaction mixture was 
quenched by the slow addition of EtOAc (5 mL), followed by a saturated aqueous 
solution of Rochelle salts (50 mL). After stirring for 30 min, the mixture was extracted 
with 50% EtOAc/ hexanes (3 × 25 mL), dried over Na2SO4, filtered, and concentrated. 
The crude alcohol was used as is for the subsequent oxidation step.  
 To a stirring solution of the aforementioned alcohol (2.90 g, 8.7 mmol, 1.0 equiv) 
in CH2Cl2 (87 mL, 0.1 M) contained in a 250 mL flask under N2 was added DMSO (6.2 
mL, 87 mmol, 10.0 equiv) and i-Pr2NEt (10.6 mL, 61 mmol, 7.0 equiv). After cooling to 
0 oC, SO3Pyr (5.54 g, 35 mmol, 4.0 equiv) was added to the stirring solution. After 
stirring for 1 h at 0 oC, the reaction was quenched with saturated aqueous NaHCO3 
solution (100 mL). After stirring at rt for 20 min, the mixture was extracted with CH2Cl2 
(3 × 30 mL). The organic phase was washed with brine (50 mL), dried over Na2SO4, 
filtered, and concentrated. The crude aldehyde was purified on a 4 × 10 cm silica gel 
column, eluting with 10% EtOAc/hexanes, collecting 10 mL fractions. Product bearing 
fractions 16–36 were combined and concentrated to yield the aldehyde (2.78 g, 97%, over 
2 steps) as a colorless oil: Rf =  (25 % EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 
9.38 (s, 1H), 5.64 (s, 2H), 4.20 (t, J = 1.0 Hz, 2H), 1.20 (s, 6H), 0.91 (s, 9H), 0.07 (s, 
6H); 125 MHz 13C NMR (CDCl3) δ 202.8, 131.4, 131.3, 63.8, 59.9, 48.4, 26.2, 21.6, 
18.6, –5.0; 125 MHz DEPT (CDCl3) CH3 δ 26.2, 21.7, –4.9; CH2 δ 63.9; CH δ 202.8, 
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131.5, 131.3; C δ 48.6, 18.7; IR (neat) 2930, 2858, 1730, 1472, 1362, 1255, 1107, 837 
cm-1: HRMS (ESI) calcd 265.1600 for C13H26O2SiNa (M+Na), found 265.1608. 
 Preparation of (E)-tert-butyl((4,4-dimethylhexa-2,5-dien-1-
yl)oxy)dimethylsilane (2.22): To a 250 mL flask was added KOt-Bu (1.72 g, 15.3 mmol, 
1.8 equiv), followed by methyl triphenylphosphonium bromide (6.1 g, 17 mmol, 2.0 
equiv). After flushing with N2, the mixture was cooled to 0 oC and THF (75 mL) was 
added. The yellow mixture was stirred at 0 oC for 30 min. A solution of aldehyde 2.19 
(2.06 g, 8.5 mmol, 1.0 equiv) in THF (5 mL) was then added via cannula, using THF (5.0 
mL) to complete the transfer. After stirring at rt for 30 min, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution (100 mL). The mixture was extracted 
with 50% EtOAc/ hexanes (3 × 25 mL). The organic phase was washed with brine (100 
mL), dried over Na2SO4, filtered, and concentrated. The crude olefin was purified on a 2 
× 10 cm silica gel column, eluting with 10 % EtOAc/ hexanes, collecting 5 mL fractions. 
Fractions 2–14 were combined and concentrated to yield the desired product (1.92 g, 94 
%). Rf = 0.88 (10 % EtOAc/ hexanes); 500 MHz 1H NMR (CDCl3) δ 5.83 (dd, J = 17, 10 
Hz, 1H), 5.64 (dt, J = 15.5, 1.5 Hz, 1H), 5.48 (dt, J = 10.5, 5.5 Hz, 1H), 4.94 (ddd, J = 
17.5, 10.5, 1.0 Hz, 2H), 4.17 (dd, J = 5.5, 1.5 Hz, 2H), 1.12 (s, 6H), 0.92 (s, 9H), 0.07 (s, 
6H); 125 MHz 13C NMR (CDCl3) δ 147.3, 139.3, 126.1, 110.8, 64.4, 59.9, 27.1, 26.2, 
18.7, –4.8; 125 MHz DEPT (CDCl3) CH3 δ 27.1, 26.2, –4.8; CH2 δ 110.7, 64.4; CH δ 
147.3, 139.3, 126.1; C δ 59.9, 18.7; IR (neat) 3084, 2958, 2929, 2858, 1637, 1472, 1386, 
1361, 1255, 1106, 1068, 973, 914, 837, 775, 665 cm-1; HRMS (ESI) calcd 263.1807 for 
C14H28ONaSi (M+Na), found 263.1805. 
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 Preparation of (E)-6-((tert-butyldimethylsilyl)oxy)-3,3-
dimethylhex-4-en-1-ol (2.23): To a stirring solution of olefin 2.22 (1.60 g, 6.65 mmol, 
1.0 equiv) in THF (27 mL, 0.25 M) contained in a 100 mL flask was added a solution of  
9-BBN in THF (0.5 M, 20 mL, 10.0 mmol, 1.5 equiv). The reaction mixture was then 
placed in an ultrasonic bath for 1 h. The reaction mixture was quenched with H2O (50 
mL), followed by an aqueous solution of NaOH (1 M, 50 mL) and chilled in an ice bath; 
30% aqueous H2O2 (20 mL) was then added in small portions. The mixture was stirred 
for 1 h at 0 oC. The mixture was diluted with brine (50 mL), followed by extraction with 
50% EtOAc/ hexanes (3 × 25 mL). The organic phase was washed with brine (50 mL), 
dried over Na2SO4, filtered, and concentrated. The product was purified on a 4 × 15 cm 
silica gel column, eluting with 5% EtOAc/ hexanes until fraction 96 was reached; after 
this the product was eluted with 25% EtOAc/ hexanes, collecting 5 mL fractions. 
Fractions 110–138 were combined and concentrated to yield the product (1.46 g, 85%) as 
a colorless oil: Rf = 0.10 (10 % EtOAc/ hexanes); 500 MHz 1H NMR (CDCl3) δ 5.66 (dt, 
J = 16, 1.5 Hz, 1H), 5.48 (dt, J = 16, 5.5 Hz, 1H), 4.15 (dd, J = 5.0, 1.5 Hz, 2H), 3.65 (t, J 
= 7.0 Hz, 2H), 1.62 (t, J = 7.5 Hz, 2H), 1.33 (s, 1H), 1.04 (s, 6H), 0.91 (s, 9H), 0.07 (s, 
6H); 125 MHz 13C NMR (CDCl3) δ 140.6, 126.0, 64.3, 60.4, 45.7, 35.0, 27.7, 26.2, 18.6, –4.9; 125 MHz DEPT (CDCl3) CH3 δ 27.7, 26.2, –4.9; CH2 δ 64.3, 60.4, 45.6; CH δ 
140.6, 125.9; C δ 35.0, 18.6; IR (neat) 3356, 2956, 2857, 1472, 1387, 1362, 1255, 1107, 





dimethylhex-4-enal (2.16): To a 50 mL flask, alcohol 2.23 (500 mg, 1.93 mmol, 1.0 
equiv) was added. After flushing with N2, CH2Cl2 (19 mL, 0.1 M) was added. The 
solution was chilled to 0 oC, and i-Pr2NEt (2.4 mL, 14 mmol, 7.0 equiv) was added, 
followed by DMSO (1.4 mL, 19 mmol, 10.0 equiv). To the solution, SO3Pyr (1.23 g, 7.7 
mmol, 4.0 equiv) was added. The reaction mixture was then stirred at 0 oC for 1 h. The 
reaction mixture was then quenched with a solution of saturated aqueous NaHCO3 (50 
mL). After stirring for 15 min, the mixture was extracted with CH2Cl2 (2 × 10 mL). The 
organic phase was dried over Na2SO4, filtered, and concentrated. The crude product was 
purified on a 2 × 15 cm silica gel column, eluting with 5% EtOAc/ hexanes, collecting 5 
mL fractions. Product containing fractions 10–15 were combined and concentrated to 
yield the product (377 mg, 76%) as a colorless oil: Rf = 0.40 (10% EtOAc/ hexanes); 500 
MHz 1H NMR (CDCl3) δ 9.73 (t, J = 1.8 Hz, 1H), 5.75 (dt, J = 15.5, 1.5 Hz, 1H), 5.53 
(dt, J = 15.5, 4.5 Hz, 1H), 4.17 (dd, J = 5.0, 1.5 Hz, 2H), 2.34 (d, J = 3.0 Hz, 2H), 1.16 (s, 
6H), 0.91 (s, 9H), 0.07 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 203.5, 138.4, 127.0, 64.0, 
55.3, 35.3, 27.9, 26.2, 18.6, –4.9; 125 MHz DEPT (CDCl3) CH3 δ 27.9, 26.2, –4.9; CH2 δ 
64.0, 55.2; CH δ 203.5, 138.3, 127.0; C δ 35.3, 18.6; IR (neat) 2958, 2930, 2857, 2731, 
1724, 1472, 1388, 1375, 1255, 1108, 1068, 976, 837, 776, 666 cm-1; HRMS (ESI) calcd 
279.1756 for C14H28O2NaSi (M+Na), found 279.1760. 
 Preparation of (S)-5-(((benzyloxy)methoxy)methyl)-5-
(hydroxymethyl)dihydrofuran-2(3H)-one (2.14): A stirring solution of lactone 1.89 
(750 mg, 1.48 mmol, 1.0 equiv) in CH2Cl2 (30 mL, 0.05 M) contained in a 50 mL flask at 
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0 oC was prepared under N2. To this solution, a 50:50 TFA/ TFAA solution in CH2Cl2 
(1.0 M, 4.44 mL, 4.44 mmol, 3.0 equiv) was added dropwise, turning the solution bright 
yellow in color. After stirring for 30 min at 0 oC, Et3N (4.1 mL, 30 mmol, 20 equiv) was 
added and the mixture was stirred for 5 min. The solution was then transferred to a 250 
mL flask and evaporated with MeOH (3 × 75 mL). The resulting oil was dissolved in 
PhCH3 (2.0 mL) and purified on a 3 × 15 cm silica gel column. The column was eluted 
with 25% EtOAc/ hexanes (300 mL), 50% EtOAc/ hexanes (200 mL), and 75% EtOAc/ 
hexanes (100mL), collecting 10 mL fractions. Fractions 46–64 were combined and  
concentrated to yield the product (342 mg, 87%) as a light yellow oil: Rf = 0.29  (50% 
EtOAc/ hexanes); [ ] =20Dα  +2.18o (c = 6.0); 500 MHz 1H NMR (CDCl3) δ 7.36–7.34 (m, 
4H), 7.32–7.30 (m, 1H), 4.77 (dd, J = 9.5, 6.5 Hz, 1H), 4.60 (s, 2H), 3.77 (d, J = 12 Hz, 
1H), 3.69 (ABq, J = 10.5 Hz, Δν = 36.3 Hz, 2H), 3.62 (d, J = 14.0 Hz, 1H), 2.71 (s, 1H), 
2.64 (ddd, J = 14, 10, 8.0 Hz, 2H), 2.22–2.16 (m, 1H), 2.13–2.07 (m, 1H). 125 MHz 13C 
NMR (CDCl3) δ 177.6, 137.6, 128.7, 128.1, 128.0, 95.1, 87.6, 70.2, 70.0, 65.4, 29.4, 
25.7; 125 MHz DEPT (CDCl3) CH3 δ ; CH2 δ 95.1, 70.2, 70.0, 65.4, 29.4, 25.7; CH δ 
128.7, 128.1, 128.0; C δ 177.6, 137.6, 87.6; IR (neat) 3454, 2940, 1765, 1605, 1461, 
1414, 1382, 1208, 1170, 1110, 1043, 946, 736, 699 cm-1; HRMS (ESI) calcd 289.1052 
for C14H18O5Na (M+Na), found 289.1052. 
Preparation of (R)-5-(((benzyloxy)methoxy)methyl)-5-
(((triisopropylsilyl)oxy)methyl)dihydrofuran-2(3H)-one (2.17): To a stirring solution 
of alcohol 2.14 (933 mg, 3.5 mmol, 1.0 equiv) in CH2Cl2 (35 mL, 0.1 M) contained in a 
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100 mL flask under N2 was added 2,6-lutidine (1.2 mL, 11 mmol, 3.0 equiv), followed by 
TIPSOTf (1.4 mL, 5.3 mmol, 1.5 equiv). The reaction mixture was stirred overnight at rt, 
quenched with saturated aqueous NaHCO3 solution (50 mL), and extracted with CH2Cl2 
(3 × 15 mL). The organic phase was washed with brine (50 mL), dried over Na2SO4, 
filtered, and concentrated. The product was purified on a 3 × 10 cm silica gel column, 
eluting with 15% EtOAc/ hexanes, collecting 10 mL fractions. Fractions  
14–30 were combined and concentrated to yield the product (1.28 g, 86%) as a colorless 
oil: Rf = 0.48 (25% EtOAc/ hexanes); [ ] =20Dα  –1.03o (c = 1.95);  500 MHz 1H NMR 
(CDCl3) δ 7.38–7.29 (m, 5H), 4.78 (dd, J = 10, 6.5 Hz, 2H), 4.61 (s, 2H), 3.81 (ABq, J = 
10.5 Hz, Δv = 28 Hz, 2H), 3.71 (dd, J = 17, 10.5 Hz, 2H), 2.68–2.57 (m, 2H), 2.25 (ddd, 
J = 13.5, 10.5, 7.0 Hz, 1H), 2.14–2.05 (m, 1H), 1.16–1.09 (m, 3H), 1.07 (d, J = 7.0 Hz, 
18H); 125 MHz 13C NMR (CDCl3) δ 177.2, 137.8, 128.7, 128.1, 128.0, 95.2, 87.4, 70.6, 
69.9, 66.7, 29.5, 26.1, 18.1, 12.5; 125 MHz DEPT (CDCl3) CH3 δ 18.1; CH2 δ 95.2, 70.6, 
69.9, 66.7, 29.5, 26.1; CH δ 128.7, 128.1, 128.0, 12.1; C δ 177.2, 137.8, 87.4; IR (neat) 
2943, 2866, 1781, 1463, 1382, 1207, 1171, 1116, 1049, 949, 883, 811, 738, 696 cm-1; 




one (2.24): To a solution of lactone 2.17 (150 mg, 0.36 mmol, 1.0 equiv) in THF (3.6 
mL, 0.1 M) in a 10 mL flask at –78 oC was added a solution of LDA (1.0 M, 400 µL, 0.4 
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mmol, 1.1 equiv). After stirring at –78 oC for 0.5 h, a solution 1M in HMPA and 1M in 
(EtO)2POCl in THF (470 µL, 0.47 mmol, 1.3 equiv) was added to the reaction mixture. 
After stirring for 5 min, the reaction mixture was then warmed to rt and stirred for 1 h. 
After cooling the reaction mixture to –78 oC, a solution of LDA (1.0 M, 790 µL, 0.79 
mmol, 2.2 equiv) was added. The reaction mixture was stirred at –78 oC for 1.5 h. The 
reaction was then quenched at –78 oC with a solution of AcOH (1.0 mL) in Et2O (5.0 
mL). The mixture was diluted with Et2O (50 mL) and filtered through a 4 × 1 cm pad of 
Celite™. The solution was then concentrated to yield the phosphonate as a mixture of 
diastereomers which were used without further characterization.  
 To the aforementioned phosphonate (65 mg, 0.12 mmol, 1.0 equiv) contained in a 
15 mL flask, 18-crown-6 (159 mg, 0.60 mmol. 5.0 equiv) was added. The flask was 
flushed with N2 and THF (3.0 mL, 0.04 M) was added. After cooling to –78 oC, a 
solution of KHMDS in toluene (0.5 M, 270 µL, 0.13 mmol, 1.1 equiv) was added 
dropwise to the stirring mixture. After stirring for 30 min at –78 oC, a solution of 
aldehyde 2.16 (37 mg, 0.15 mmol, 1.2 equiv) in THF (500 µL) was added dropwise; the 
transfer was completed with THF (500 µL). The reaction mixture was promptly placed in 
a 30 oC water bath and stirred overnight at rt. The reaction mixture was quenched with 
saturated aqueous NH4Cl solution (10 mL), extracted with EtOAc (3 × 10 mL), washed 
with brine (25 mL), dried over Na2SO4, filtered, and concentrated. 1H NMR analysis of 
the crude product indicated a 5:1 ratio of Z to E enoates by integration of the B-enoate 
proton peaks. The product was purified on a 2 × 10 cm silica gel column, eluting with 5% 
EtOAc/ hexanes, collecting 5 mL fractions. The product containing fractions where 
combined and concentrated to yield the product (79 mg, 51% over 2-steps) as a colorless 
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oil: Rf = 0.29 (10% EtOAc/ hexanes); [ ] =20Dα   –0.69o (c = 1.73, CHCl3);  500 MHz 1H 
NMR (CDCl3) δ 7.37–7.29 (m, 5H), 6.15 (dddd, J = 9.5, 5.5, 2.0, 2.0 Hz, 1H), 5.63 (ddd, 
J = 15.5, 1.5, 1.5 Hz, 1H), 5.48 (ddd, J = 16, 5.5, 5.5 Hz, 1H), 4.78 (dd, J = 8.5, 6.5 Hz, 
2H), 4.60 (s, 2H), 4.17 (dd, J = 5.5, 1.5 Hz, 2H), 3.77 (ABq, J = 10.5 Hz, Δv = 23.8 Hz, 
2H), 3.69 (d, J = 1.5 Hz, 2H), 2.90 (dd, J = 17, 2.0 Hz, 1H), 2.81 (q, J = 7.5 Hz, 1H), 
2.75–2.67 (m, 2H), 1.15–1.04 (m, 27 H), 0.92 (s, 9H), 0.08 (s, 6H); 125 MHz 13C NMR 
(CDCl3) δ 169.3, 140.9, 139.8, 137.8, 128.6, 128.1, 128.0, 126.5, 126.4, 95.2, 83.5, 70.0, 
69.8, 65.9, 64.4, 39.8, 36.5, 33.5, 27.3, 26.2, 18.6, 18.1, 12.1, –4.8; 125 MHz DEPT 
(CDCl3) CH3 δ 27.2, 26.2, 18.1, –4.8; CH2 δ 95.2, 70.0, 69.8, 65.9, 64.4, 39.9, 33.5; CH δ 
140.9, 139.8, 128.6, 128.1, 128.0, 126.5, 12.1; C δ 169.3, 137.8, 126.4, 83.5, 26.5, 18.6; 
IR (neat) 2957, 2866, 1761, 1671, 1463, 1367, 1254, 1117, 1049, 882, 837, 777, 684 cm-
1; HRMS (ESI) calcd 683.4139 for C37H64O6NaSi2 (M+Na), found 683.4139. 
Preparation of (R,Z)-5-(((benzyloxy)methoxy)methyl)-
3-((E)-6-hydroxy-3,3-dimethylhex-4-en-1-ylidene)-5-(((triisopropylsilyl)oxy)methyl) 
dihydrofuran-2(3H)-one (2.25): To a 25 mL flask containing enoate 2.24 (133 mg, 0.20 
mmol, 1.0 equiv) was added 3:1:1 AcOH/ THF/ H2O (10 mL). The flask was stoppered 
and stirred in an oil bath at 45 oC for 1 h. Upon cooling to rt, the reaction mixture was 
slowly added to a stirring saturated aqueous NaHCO3 solution (100 mL). The mixture 
was extracted with EtOAc (3 × 15 mL), washed with saturated aqueous NaHCO3 solution 
(50 mL) and brine (50 mL). The organic phase was then dried over Na2SO4, filtered, and 
concentrated. The crude product was purified on a 2 × 10 cm silica gel column, eluting 
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with 25% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 10 –25 were combined 
and concentrated to yield the product (91 mg, 83%) as a colorless oil: Rf = 0.15 (25% 
EtOAc/ hexanes); [ ] =20Dα   –5.4o (c = 0.50, CHCl3);  500 MHz 1H NMR (CDCl3) δ 7.38–
7.29 (m, 5H), 6.14 (dddd, J = 10, 7.5, 5.0, 2.5 Hz, 1H), 5.69 (dd, J = 15.5, 1.5 Hz, 1H), 
5.56 (dt, J = 16, 5.5 Hz, 1H), 4.78 (dd, J = 8.5, 6.0 Hz, 1H), 4.60 (s, 2H), 4.12 (dd, J = 
6.0, 1.0 Hz, 2H), 3.77 (ABq, J = 10.5 Hz, Δv = 21 Hz, 2H), 3.69 (dd, J = 13, 11 Hz, 2H), 
2.91 (dd, J = 16, 2.0 Hz, 1H), 2.85 (dddd, J = 15.5, 8.0, 3.5, 2.0 Hz, 1H), 2.74 (dd, J = 16, 
2.0 Hz, 1H), 2.67 (dddd, J = 15, 9.5, 7.5, 2.0 Hz, 1H), 1.12–1.07 (m, 3H), 1.05 (s, 18 H), 
1.04 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 169.4, 141.8, 140.5, 137.8, 128.7, 128.1, 
128.0, 126.8, 126.1, 95.2, 83.6, 70.0, 69.8, 65.9, 64.1, 39.7, 36.7, 33.5, 27.3, 27.1, 18.1, 
12.1; 125 MHz DEPT (CDCl3) CH3 δ 27.3, 27.1, 18.1; CH2 δ 95.2, 70.0, 69.8, 65.9, 64.1, 
39.7, 33.5; CH δ 141.8, 140.5, 128.7, 128.1, 128.0, 126.1, 12.1; C δ 169.4, 137.8, 126.1, 
83.6, 36.7; IR (neat) 3464, 2943, 2866, 1757, 1684, 1653, 1464, 1383, 1368, 1210, 1170, 
1117, 1046, 973, 882, 801, 734, 682 cm-1; HRMS (ESI) calcd 569.3274 for 
C31H50O6NaSi (M+Na), found 569.3273. 
 Preparation of (2E,6Z)-6-((R)-5-
(((benzyloxy)methoxy)methyl)-2-oxo-5-(((triisopropylsilyl)oxy)methyl)dihydrofura 
n-3(2H)-ylidene)-4,4-dimethylhex-2-enal (2.15): To a solution of alcohol 2.25 (91 mg, 
0.17 mmol, 1.0 equiv) in CH2Cl2 (3.3 mL, 0.05 M) under N2, contained in a 15 mL flask, 
was added DMSO (120 µL, 1.7 mmol, 10 equiv), followed by i-Pr2NEt (210 µL, 1.2 
mmol, 7.0 equiv). After cooling to 0 oC, SO3Pyr (108 mg, 0.68 mmol, 4.0 equiv) was 
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added. The reaction mixture was stirred at 0 oC for 1 h and then quenched with saturated 
aqueous NaHCO3 solution (25 mL). The mixture was extracted with CH2Cl2 (3 × 10 mL), 
dried over Na2SO4, filtered, and concentrated. The product was purified on a 2 × 10 cm 
silica column, eluting with 15% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 8–
20 were combined and concentrated to yield the product (60 mg, 66%) as a colorless oil: 
Rf = 0.38 (25% EtOAc/ hexanes); [ ] =20Dα   –59.4o (c = 1.75, CHCl3);  500 MHz 1H NMR 
(CDCl3) δ 9.53 (d, J = 8.0 Hz, 1H), 7.37–7.30 (m, 5H), 6.81 (d, J = 15.5 Hz, 1H), 6.08–
6.03 (m, 2H), 4.77 (s, 2H), 4.59 (s, 2H), 3.77 (dd, J = 14, 10.5 Hz, 2H), 3.68 (dd, J = 
12.5, 10.5 Hz, 2H), 2.98 (dd, J = 15, 8.0 Hz, 1H), 2.91 (d, J = 16.5 Hz, 1H), 2.81 (dd, J = 
15, 7.5 Hz, 1H), 2.75 (d, J = 16 Hz, 1H), 1.16 (s, 6H), 1.12–1.04 (m, 21H); 125 MHz 13C 
NMR (CDCl3) δ 194.5, 169.2, 166.7, 138.0, 137.8, 130.1, 128.7, 128.3, 128.1, 128.0, 
95.2, 83.9, 70.0, 69.9, 66.0, 38.9, 38.5, 33.4, 26.4, 26.3, 18.1, 12.1; 125 MHz DEPT 
(CDCl3) CH3 δ 26.4, 26.3, 18.1; CH2 δ 95.2, 70.0, 69.9, 66.0, 38.9, 33.4; CH δ 194.5, 
166.7, 138.0, 130.1, 128.7, 128.3, 128.1, 12.1; C δ 169.2, 137.8, 128.0, 83.9, 38.2; IR 
(neat) 2944, 2867, 1757, 1693, 1464, 1369, 1117, 1047, 883, 803, 739 cm-1; HRMS (ESI) 
calcd 567.3118 for C31H48O6NaSi (M+Na), found 567.3116. 






ylidene)-5-(((triisopropylsilyl)oxy)methyl)dihydrofuran-2(3H)-one (2.26): To a 
stirring solution of hydroxyallylsilane 1.42 (66 mg, 0.092 mmol, 1.0 equiv) and aldehyde 
2.15 (60 mg, 0.11 mmol, 1.2 equiv) in Et2O (2.3 mL, 0.04 M) contained in a 10 mL flask 
under N2 at –78 oC was added a solution of TMSOTf in Et2O (1.0 M, 120 µL, 0.12 mmol, 
1.3 equiv). The reaction mixture was stirred at –78 oC for 3 h, and then quenched with i-
Pr2NEt (500 µL). After stirring for 5 min at –78 oC, the solution was added to saturated 
aqueous NaHCO3 solution (25 mL). The mixture was extracted with EtOAc (3 × 10 mL), 
dried over Na2SO4, filtered, and concentrated. The product was purified on a 2 × 10 cm 
silica column, eluting with 10% EtOAc/ hexanes, collecting 5 mL fractions. Product 
containing fractions, 8–22 were combined and concentrated to yield the product (90 mg, 
83%) as a colorless oil: Rf = 0.83 (50% EtOAc/ hexanes); [ ] =20Dα   +1.56o (c = 3.4, CHCl-
3);  500 MHz 
1H NMR (CDCl3) δ 7.71–7.68 (m, 4H), 7.45–7.35 (m, 10H), 7.32–7.29 (m, 
1H), 7.20 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 6.12 (t, J = 7.5 Hz, 1H), 5.63 (d, J 
= 16 Hz, 1H), 5.45 (dd, J = 15.5, 5.5 Hz, 1H), 4.78 (s, 2H), 4.73 (d, J = 11.5 Hz, 2H), 
4.66 (s, 1H), 4.61 (s, 2H), 4.55 (s, 1H), 4.43 (ABq, J = 10.5 Hz, Δv = 35.1 Hz, 2H), 3.98–
3.93 (m, 1H), 3.85–3.83 (m, 1H), 3.80 (s, 3H), 3.78 (ABq, J = 10 Hz, Δv = 20.2 Hz, 2H), 
3.76–3.73 (m, 1H), 3.69 (s, 2H), 3.64–3.61 (m, 1H), 3.59–3.55 (m, 1H), 3.51–3.45 (m, 
1H), 2.90 (d, J = 16 Hz, 1H), 2.81–2.69 (m, 2H), 2.73 (d, J = 16.5 Hz, 1H), 2.30 (d, J = 
23.5 Hz, 1H), 2.27 (d, J = 24 Hz, 1H), 2.18 (t, J = 15.5 Hz, 2H), 2.07–2.01 (m, 3H), 
1.98–1.91 (m, 2H), 1.85–1.73 (m, 2H), 1.70–1.61 (m, 4H), 1.08–1.03 (m, 36H); 125 MHz 
13C NMR (CDCl3) δ 169.3, 159.3, 145.0, 144.3, 140.7, 140.6, 137.8, 135.8, 134.1, 134.0, 
131.2, 129.8, 129.6, 128.6, 128.1, 128.0, 128.0, 127.9, 126.8, 114.0, 109.0, 108.7, 95.2, 
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83.5, 79.2, 75.1, 75.0, 74.8, 72.8, 72.3, 70.0, 69.8, 66.0, 60.6, 55.5, 43.1, 42.6, 41.5, 41.4, 
41.2, 40.4, 39.8, 38.0, 36.6, 33.5, 27.2, 27.1, 27.0, 19.4, 18.1, 12.1; 125 MHz DEPT 
(CDCl3) CH3 δ 55.5, 27.2, 18.1; CH2 δ 109.1, 108.7, 95.2, 72.3, 70.0, 69.8, 66.0, 60.6, 
43.1, 42.6, 41.5, 41.4, 41.3, 40.4, 39.8, 38.1, 33.5; CH δ 140.7, 140.6, 135.8, 129.8, 
129.6, 128.7, 128.1, 128.0, 128.0, 127.9, 114.0, 79.2, 75.1, 75.0, 74.8, 72.8, 12.1; C δ 
169.3, 159.3, 145.0, 144.3, 137.8, 134.1, 134.0, 131.2, 83.5, 36.6, 19.4; IR (neat) 3072, 
2941, 1761, 1613, 1514, 1464, 1428, 1362, 1248, 1110, 846, 730, 703 cm-1; HRMS (ESI) 
calcd 1191.6753 for C71H100O10NaSi2 (M+Na), found 1191.6760. 
	  





dihydrofuran-2(3H)-one (2.25): To a stirring solution of ester 2.26 (59 mg, 0.05 mmol, 
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1.0 equiv) in THF (1.0 mL, 0.05 M) contained in a 10 mL polyethylene vial at 0 oC was 
added a solution of 20% HFPyr in pyridine (1.25 mL, 25 mL/ mmol). The solution was 
stirred at 0 oC for 5 h, after which it was quenched by slowly pipetting it into stirring 
saturated aqueous NaHCO3 solution (30 mL). The mixture was extracted with EtOAc (3 
× 10 mL), dried over Na2SO4, filtered, and concentrated. The crude alcohol was purified 
on a 2 × 10 cm silica gel column, eluting with 30% EtOAc/ hexanes, collecting 5 mL 
fractions. Concentration of fractions 10–36 yielded the product (32 mg, 68%) as a 
colorless oil: Rf = 0.48  (50% EtOAc/ hexanes); [ ] =20Dα  –0.88o (c = 0.57, CHCl3);  500 
MHz 1H NMR (CDCl3) δ 7.37–7.28 (m, 5H), 7.26 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 
Hz, 2H), 6.12 (t, J = 8.0 Hz, 1H), 5.66 (d, J = 16.5 Hz, 1H), 5.45 (dd, J = 15.5, 5.5 Hz, 
1H), 4.77 (s, 2H), 4.74 (m, 2H), 4.69 (s, 1H), 4.60 (s, 2H), 4.60 (s, 1H), 4.48 (q, J = 10 
Hz, 2H), 4.02–3.97 (m, 1H), 3.85–3.80 (m, 1H), 3.80 (s, 3H), 3.76–3.73 (m, 1H), 3.77 
(ABq, J = 10.5 Hz, Δv = 20.9 Hz, 2H), 3.68 (s, 2H), 3.58–3.53 (m, 1H), 3.52–3.43 (m, 
2H), 2.90 (d, J = 17 Hz, 1H), 2.80 (dd, J = 16, 8.0 Hz, 1H), 2.73 (d, J = 19 Hz, 1H), 2.69 
(dd, J = 15.5, 7.5 Hz, 1H), 2.36 (s, 1H), 2.29–2.18 (m, 4H), 2.06–1.92 (m, 6H), 1.80 
(dddd, J = 14.5, 9.0, 8.5, 2.5 Hz, 1H), 1.75–1.62 (m, 4H), 1.10–1.03 (m, 27H); 125 MHz 
13C NMR (CDCl3) δ 169.3, 159.6, 144.7, 144.4, 140.7, 140.6, 137.9, 130.7, 129.7, 129.6, 
128.7, 128.1, 128.0, 126.7, 114.2, 109.0, 108.9, 95.2, 83.6, 79.4, 77.4, 75.5, 75.3, 75.1, 
72.1, 70.1, 69.8, 66.0, 60.5, 55.5, 43.0, 41.8, 41.5, 41.1, 40.5, 39.8, 36.9, 36.6, 33.6, 27.1, 
27.1, 18.1, 12.1; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.1, 27.0, 18.1; CH2 δ 109.0, 
108.9, 95.2, 72.1, 70.0, 69.8, 66.0, 60.5, 43.0, 41.8, 41.5, 41.1, 40.5, 39.8, 36.8, 33.5; CH 
δ 140.7, 140.6, 129.7, 129.6, 128.6, 128.1, 114.1, 79.4, 77.4, 75.5, 75.2, 75.2, 12.1; C δ 
169.3, 159.6, 144.7, 144.4, 137.9, 130.7, 126.7, 83.6, 36.6; IR (neat) 3488, 2942, 1758, 
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1652, 1612, 1514, 1464, 1366, 1248, 1048, 884, 804, 739, 684 cm-1; HRMS (ESI) calcd 





oxy)butanoic acid (2.28): To a stirring solution of alcohol 2.27 (37 mg, 0.04 mmol, 1.0 
equiv) in CH2Cl2 (800 µL, 0.05 M) contained in a 5 mL vial under N2 was added i-Pr2NEt 
(70 µL, 0.40 mmol, 10.0 equiv), followed by DMSO (20 µL, 0.28 mmol, 7.0 equiv). The 
mixture was cooled to 0 oC, and SO3Pyr (26 mg, 0.16 mmol, 4.0 equiv) was added. 
After stirring at 0 oC for 1 h, the reaction mixture was quenched with saturated aqueous 
NaHCO3  solution (25 mL) and extracted with CH2Cl2 (3 × 10 mL). The organic phase 
was then dried over Na2SO4, filtered, and concentrated. The product was purified on a 1 × 
10 cm silica gel column, eluting with 20% EtOAc/ hexanes, collecting 5 mL fractions. 
Fractions 6–14 were concentrated to yield the intermediate aldehyde as a colorless oil 
which was used without further characterization (28 mg, 75%).  
To a stirring solution of the aforementioned aldehyde (28 mg, 0.030 mmol, 1.0 
equiv) in t-BuOH (430 µL, 14.3 mL/ mmol) and 2-methyl-2-butene (430 µL, 14.3 mL/ 
mmol) contained in a 5 mL vial was added an aqueous solution of KH2PO4 (1.25 M, 144 
µL, 0.18 mmol, 6.0 equiv). The rapidly stirred reaction mixture was cooled to –5 oC, and 
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80% NaClO2 (17 mg, 0.15 mmol, 5.0 equiv) was added. The reaction mixture was stirred 
at 0 oC for 1.5 h and then quenched with aqueous pH 4.0 acetate buffer (0.1 M, 25 mL). 
After extraction with EtOAc (3 × 10 mL), the solution was dried over Na2SO4, filtered, 
and concentrated. The resulting product was purified on a 2 × 15 cm silica gel column, 
eluting with 40% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 8–28 were 
combined and concentrated to yield the product as a colorless oil (15 mg, 54%). Rf = 0.48 
(20/ 5/ 0.3 PhCH3/ EtOAc/ AcOH); [ ] =20Dα   +9.4o (c = 0.74, CHCl3);  500 MHz 1H NMR 
(C6D6) δ 7.29 (dd, J = 7.5, 3.0 Hz, 4H), 7.16 (t, J = 7.0 Hz, 2H), 7.07 (t, J = 10 Hz, 1H), 
6.81 (d, J = 8.5 Hz, 2H), 6.00 (t, J = 8.0 Hz, 1H), 5.69 (d, J = 16 Hz, 1H), 5.55 (dd, J = 
16.5, 6.0 Hz, 1H), 4.74 (s, 2H), 4.65 (d, J = 4.0 Hz, 2H), 4.55 (s, 2H), 4.51 (ABq, J = 
11Hz, Δv = 54.2 Hz, 2H), 4.48 (s, 2H), 3.81 (dd, J = 10, 5.5 Hz, 1H), 3.69–3.62 (m, 2H), 
3.67 (d, J = 3.0Hz, 2H), 3.54–3.47 (m, 2H), 3.51 (d, J = 5.5 Hz, 2H), 3.31 (s, 3H), 3.02 
(dd, J = 14.5, 7.5 Hz, 1H), 2.86 (dd, J = 14.5, 7.0 Hz, 1H), 2.69 (dd, J = 16.5, 2.0 Hz, 
1H), 2.50–2.42 (m, 3H), 2.18 (t, J = 14 Hz, 2H), 2.12–2.03 (m, 3H), 1.97–1.76 (m, 5H), 
1.66–1.54 (m, 2H), 1.04–1.00 (m, 27H); 125 MHz 13C NMR (CDCl3) δ 174.5, 169.3, 
159.6, 144.5, 144.3, 140.8, 140.7, 137.8, 130.3, 129.7, 128.7, 128.1, 128.0, 128.0, 126.7, 
114.2, 109.1, 109.0, 95.2, 83.6, 79.3, 75.3, 75.2, 75.0, 72.9, 72.4, 70.1, 69.8, 66.0, 55.5, 
43.0, 42.0, 41.4, 41.3, 41.0, 40.6, 40.0, 39.8, 36.7, 33.6, 27.1, 27.1, 18.1, 12.1; 125 MHz 
DEPT (CDCl3) CH3 δ 55.5, 27.1, 27.0, 18.1; CH2 δ 109.1, 109.0, 95.2, 72.4, 70.0, 69.8, 
66.0, 43.0, 41.9, 41.4, 41.3, 41.0, 40.6, 40.0, 39.8, 33.5; CH δ 140.7, 140.6, 129.7, 128.6, 
128.1, 128.0, 128.0, 114.1, 79.3, 75.2, 75.2, 75.0, 72.9, 12.1; C δ 174.5, 169.3, 159.6, 
144.5, 144.3, 137.8, 130.3, 126.7, 83.6, 36.7; IR (neat) 2943, 2867, 1758, 1712, 1653, 
1613, 1514, 1464, 1367, 1249, 1172, 1112, 1046, 884, 805, 739 cm-1; HRMS (ESI) calcd 
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-8,12-diene-14,19-dione (2.29): To a stirring solution of acid 2.28 (0.037 mmol, 1.0 
equiv) in THF (740 µL, 0.05 M) contained in a 10 mL polyethylene vial at rt was added a 
20% solution of HFPyr in pyridine (925 µL, 25 mmol/ mL). The mixture was stirred at 
rt for 2 days, then quenched by pouring into aqueous pH 4.0 acetate buffer (0.1 M, 25 
mL). The mixture was extracted with EtOAc (3 × 10 mL), dried over Na2SO4, filtered, 
and concentrated. The product was purified on a 1 × 10 cm silica gel column, eluting with 
3% MeOH/ CH2Cl2, collecting 5 mL fractions. Fractions 4–16 were concentrated to yield 
the product as a colorless oil which was used without characterization for the subsequent 
macrolactonization.  
 To a stirring solution of the aforementioned seco-acid in THF (1.2 mL, 0.03 M) 
contained in a 10 mL flask under N2 was added a solution of Et3N in THF (1.0 M, 220 
µL, 0.22 mmol, 6.0 equiv). The reaction mixture was cooled to 0 oC, and a solution of 
2,4,6-trichlorobenzoyl chloride in THF, (1.0 M, 110 µL, 0.11 mmol, 3.0 equiv) was 
added. The reaction mixture was stirred at 0 oC for 5 min and warmed to rt. The reaction 
mixture was then stirred at rt for 3 h. The resulting solution was taken up into PhCH3 (10 
mL) in a 25 mL gas-tight syringe and added over 16 h via syringe pump to a stirring 
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solution of DMAP (90 mg, 0.74 mmol, 20.0 equiv) in PhCH3 (27 mL) contained in a 100 
mL flask under N2 at 40 oC, achieving a final concentration of 0.001 M in substrate. After 
16 h, PhCH3 (1.0 mL) was used to complete the transfer of the reactant. The reaction 
mixture was stirred for an additional h at 40 oC, then cooled to rt, quenched with brine 
(50 mL), and extracted with EtOAc (3 × 10 mL). After drying over Na2SO4, the solution 
was filtered and concentrated. The product was purified on a 1 × 12 cm silica gel column, 
eluting with 15% EtOAc/ hexanes, collecting 5 mL fractions. Fractions 12–24 were 
combined and concentrated to yield the product as a colorless oil (11 mg, 38%). Rf = 0.25 
(25% EtOAc/ hexanes); [ ] =20Dα  + 22.4o (c = 0.42, CHCl3);  500 MHz 1H NMR (CDCl3) δ 
7.36–7.28 (m, 5H), 7.24 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 6.17 (t, J = 8.5 Hz, 
1H), 5.59 (d, J = 17 Hz, 1H), 5.40 (dd, J = 16, 4.0 Hz, 1H), 4.90 (d, J = 6.5 Hz, 1H), 4.78 
(d, J = 6.5 Hz, 1H), 4.72–4.70 (m, 3H), 4.65 (s, 1H), 4.62 (ABq, J = 12 Hz, Δv = 35.9 
Hz, 2H), 4.46 (ABq, J = 11 Hz, Δv = 38.5 Hz, 2H), 4.09 (m, 1H), 4.01 (d, J = 11.5 Hz, 
1H), 3.81 (s, 3H), 3.73–3.71 (m, 1H), 3.69 (q, J = 10.5 Hz, 2H), 3.50–3.41 (m, 2H), 3.36–
3.32 (m, 1H), 2.81–2.74 (m, 3H), 2.62–2.54 (m, 3H), 2.26 (d, J = 13.5 Hz, 2H), 2.21 (d, J 
= 13.5 Hz, 1H), 2.15 (d, J = 13.5 Hz, 1H), 2.01–1.89 (m, 5H), 1.79–1.69 (m, 2H), 1.11 (s, 
3H), 1.06 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 170.7, 168.6, 159.5, 144.6, 144.5, 
141.4, 137.8, 137.8, 130.5, 129.5, 129.0, 128.7, 128.0, 128.0, 125.8, 114.1, 109.0, 108.9, 
94.9, 81.4, 78.5, 77.4, 75.5, 75.4, 73.5, 71.8, 69.9, 65.1, 55.5, 43.7, 42.3, 41.3, 41.3, 41.2, 
41.0, 40.3, 37.9, 34.8, 22.6, 14.3; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 14.3; CH2 δ 
109.0, 108.9, 94.9, 71.8, 69.9, 65.1, 43.6, 42.3, 41.3, 41.3, 41.2, 41.0, 34.8, 22.5; CH δ 
141.4, 137.8, 129.5, 129.0, 128.7, 128.1, 128.0, 114.1, 78.5, 77.5, 75.5, 75.4, 73.5; C δ 
170.7, 168.6, 159.5, 144.6, 144.5, 137.8, 130.5, 125.8, 81.4, 37.9; IR (neat) 3057, 2916, 
	  	  
186	  
1762, 1744, 1707, 1675, 1632, 1576, 1562, 1496, 1446, 1343, 1220, 1077, 1007, 946, 
867, 809, 698 cm-1; HRMS (ESI) calcd 793.3928  for C46H58O10Na (M+Na), found 
793.3939. 
Preparation of Merle 48 
(1R,3S,7R,8E,12Z,16R,21R,23S)-21-hydroxy-16-(hydroxymethyl)-10,10-dimethyl-
5,25-dimethylene-15,18,27,28-tetraoxatetracyclo[21.3.1.13,7.113,16]nonacosa-8,12-
diene-14,19-dione: To a stirring solution of macrolactone 2.29  (9.0 mg, 0.012 mmol, 1.0 
equiv) in CH2Cl2 (1.2 mL, 0.01 M) contained in a 5 mL vial was added H2O (30 µL). 
After cooling to 0 oC, DDQ (27 mg, 0.12 mmol, 10.0 equiv) was added and the reaction 
mixture was stirred at 0 oC for 1 h. The reaction mixture was quenched with saturated 
aqueous NaHCO3 solution (10 mL), then extracted with CH2Cl2 (3 × 5 mL), dried over 
Na2SO4, filtered, and concentrated. The crude alcohol was used without purification for 
the subsequent reaction. 
 To the previously prepared alcohol contained in a 5 mL vial, a solution of  LiBF4 
in 25:1 MeCN/ H2O (0.25 M, 2.0 mL, 45.0 equiv) was added. The vial was flushed with 
N2, capped, and heated at 80 oC overnight. After cooling to rt, the reaction mixture was 
concentrated to dryness and taken up in EtOAc (10 mL). The solution was partitioned 
with brine (25 mL) and subsequently extracted with EtOAc (2 × 10 mL). The combined 
organic phases were dried over Na2SO4, filtered, and concentrated. The crude product 
was purified on a 1 × 11 cm silica gel column, eluting with 35% EtOAc/ pentane, 
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collecting 5 mL fractions. Fractions 20–48 were combined and concentrated to yield the 
macrolide as a colorless oil (3.8 mg, 59% over 2 steps). Rf = 0.36 (50% EtOAc/ hexanes); 
[ ] =20Dα  –27o (c = 0.12, CHCl3);  500 MHz 1H NMR (CDCl3) δ 6.24 (t, J = 8.5 Hz, 1H), 
5.58 (d, J = 16 Hz, 1H), 5.34 (dd, J = 16, 5.5 Hz, 1H), 4.78 (s, 2H), 4.75 (s, 2H), 4.56 (d, 
J = 11.5 Hz, 1H), 4.34 (m, 1H), 4.00 (d, J = 12 Hz, 1H), 3.70–3.63 (m ,4H), 3.44–3.36 
(m, 3H), 3.32 (t, J = 12 Hz, 1H), 2.88 (d, J = 15 Hz, 1H), 2.82 (dd, J = 14, 4.5 Hz, 1H), 
2.59 (d, J = 16 Hz, 1H), 2.45 (dd, J = 9.5, 4.0 Hz, 1H), 2.34 (d, J = 13 Hz, 1H), 2.20–2.14 
(m, 4H), 2.03–1.95 (m, 3H), 1.90 (t, J = 11.5 Hz, 1H), 1.77 (t, J = 14.5 Hz, 1H), 1.64–
1.59 (m, 2H), 1.12 (s, 3H), 1.10 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 170.1, 169.0, 
143.8, 143.6, 141.7, 139.4, 128.3, 126.1, 109.6, 109.4, 82.7, 79.8, 76.1, 75.3, 75.1, 66.0, 
65.7, 62.0, 44.6, 43.8, 42.7, 41.8, 41.6, 41.3, 41.3, 40.3, 38.2, 34.6, 30.3, 25.1; 125 MHz 
DEPT (CDCl3) CH3 δ 30.3, 25.1; CH2 δ 109.6, 109.4, 66.0, 62.0, 44.6, 43.8, 42.7, 41.8, 
41.6, 41.3, 41.3, 40.3, 34.6; CH δ 141.7, 139.4, 128.3, 79.8, 76.1, 75.3, 75.1, 65.7; C δ 
170.1, 169.0, 143.8, 143.6, 126.1, 82.7, 38.2; IR (neat) 3444, 2940, 1743, 1671, 1653, 
1559, 1541, 1437, 1366, 1327, 1281, 1246, 1219, 1161, 1123, 1098, 1072, 1042, 1000, 















Molecular Modeling Methods 
 Molecular modeling studies were conducted by Dr. Megan Peach of the NIH. Her 
methods for these studies are summarized here. 
 
Methods 
 Conformational searching.  The initial structures for Merle 39, Merle 47 , and 
Merle 48 were built based on the crystal structure of bryostatin 143 from the Cambridge 
Compound! Date! Kd-nM-PKCα-! Ki-(nM)! p-value! protein!
Merle-48- 4/28/2015- .28-±-.02- 446.5- 0.91- 25-ng-
4/30/2015- .28-±-.02- 331.1- 0.93- 25-ng-
5/2/2015- .28-±-.02- 310.1- 0.88- 25-ng-
Mean- 362.6- 42.4- SEM-
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Structural Database (reference code BOKKIV) to keep the structure of the A + B rings 
consistent. All searches were performed using mixed torsional/large-scale low-mode 
sampling in MacroModel41 with the OPLS 2005 forcefield44 in octanol implicit solvent. 
During the searches, torsions were varied for 10,000 steps with enhanced sampling, but 
the chiral centers and double bonds were restricted to their crystal conformations. Low 
mode displacements were between 3 and 18 Å. After each step, the resulting structure 
was energy minimized to a gradient convergence of 0.05. The minimized structure was 
then compared to previously stored structures and either kept as a unique conformer or 
rejected as a duplicate, using a 0.75 Å RMSD cutoff to the heavy atoms in the central 
macrolide ring structure. A set of low-energy conformers for each structure, with energies 
with 3 kcal/mol of the global minimum, were passed on to the docking program. 
 Docking.  The crystal structure of the C1b domain of PKCδ45 was prepared for 
docking by adding hydrogen atoms and deleting the phorbol-13-acetate ligand. This was 
saved to a separate file to be used as a template for the similarity constraint (see below). 
Docking was done using the program GOLD, version 5.2.2,42 which uses a genetic 
algorithm to optimize the set of interactions between the ligand and the protein. Default 
settings were used for the genetic algorithm. The binding site was defined as a sphere 
with a 10.0 Ǻ radius, centered on the Nε atom of residue Gln 257. For each conformer, 20 
docking runs were performed, with no early termination, using the GoldScore scoring 
function with an internal ligand energy offset. Free corners of ligand rings were allowed 
to flip above or below the plane of their neighboring atoms during docking, and 
intramolecular hydrogen bonds in the ligand were allowed to form. Torsion angle 
distributions were from the CSD. A template similarity constraint was added to bias the 
	  	  
190	  
conformation of docked ligands toward solutions where the acceptor atoms in the ligand 
were close in space to the acceptor atoms in bound phorbol-13-O-acetate from the crystal 
structure.  
Energy minimization.  A subset of diverse poses with fitness score > 40.0 were 
further refined by energy minimization in MacroModel,2 using the OPLS_2005 forcefield 
and octanol implicit solvent.  All atoms in the C1 domain were held fixed, while ligand 
atoms were free to move, and the complex was minimized using the Polak-Ribiere 
conjugate gradient scheme to a gradient convergence of 0.05.  Hydrogen bonds in the 
docked poses were preserved using distance constraints. 
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1H AND 13C SPECTRA FOR CHAPTER 2 
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